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The amino acid lysine is synthesized via two distinct pathways with the 
-aminoadipate (AAA) pathway being utilized by fungi and certain archaebacteria. The 
first and committed step of this pathway is catalyzed by homocitrate synthase (HCS), 
which transfers an acetyl group from acetyl-Coenzyme A to 2-oxoglutarate (2-OG) to 
yield homocitrate and Coenzyme A. Additionally, HCS plays a role in the regulation of 
the AAA pathway, as it is feedback inhibited by the end product, L-lysine. Due to the 
absence of HCS in humans and its importance in the AAA pathway, this enzyme 
represents a potential target for small molecule inhibitors that may be used as broad-
spectrum antifungal therapies to treat fungal infections, which occur frequently in 
immuno-compromised individuals. To better understand the mechanism of HCS, we 
determined the first crystal structure of a fungal HCS from Schizosaccharomyces pombe, 
along with two different structures of enzyme in complex with 2-OG. The structure 
reveals that 2-OG binds in the active site within the ( / )8 TIM barrel domain via 
hydrogen bonds and coordination to the active site divalent metal ion. Steady state kinetic 
analysis and in vivo growth studies of mutations of residues involved in 2-OG binding or 
implicated in acid-base catalysis impair or abolish activity revealing the roles of these 
amino acids in substrate binding or the catalytic mechanism of HCS. Similar studies were 
completed to elucidate the mechanism of feedback regulation of HCS by L-lysine. The 
structure of an HCS/L-lysine complex illustrates that the inhibitor binds in the same 
binding site as the substrate 2-OG. In vitro and in vivo assays on mutants that interact 
with L-lysine impair feedback inhibition, as do previously identified substitutions of 
residues outside of the active site that render HCS insensitive to L-lysine. Finally, we 
utilized a high-throughput screening (HTS) approach to identify small molecule 
inhibitors of HCS. Collectively, these structural and functional studies elucidate the 
catalytic and regulatory mechanisms of HCS. Furthermore, they provide a framework for 
 xvi 
discovery of inhibitors to HCS either through HTS or structure-based design, which may 
be developed into drugs to treat fungal infections. 
 1 
CHAPTER 1 
HOMOCITRATE SYNTHASE, AN ESSENTIAL ENZYME IN LYSINE 
BIOSYNTHESIS
 
Biosynthesis of L-Lysine 
In complex eukaryotes, including mammals, lysine is an essential amino acid and 
must be obtained through dietary sources (1-3). However, many organisms including 
bacteria, fungi, and plants can synthesize L-lysine from metabolic precursors. Two 
diverse pathways have evolved for the biosynthesis of lysine in these organisms, which is 
unique to lysine among the common twenty amino acids.  The diaminopimelate (DAP) 
pathway belongs to the aspartate family of amino acid biosynthesis and is utilized in most 
bacteria, some lower fungi (zygomycota) and green plants and (4-8). There are four 
variants of this pathway, with most bacteria utilizing the pathway involving succinyl 
intermediates (6, 9). In addition to producing lysine, the DAP pathway is also the source 
of meso-diminopimelic acid, an important component of peptidoglycan which makes up 
the bacterial cell wall (10). Higher fungi (ascomycetes and basidiomycetes), euglenoids 
and certain archaebacteria use the -aminoadipate (AAA) pathway to synthesize lysine, 
which is a member of the glutamate family of amino acid biosynthesis (11-14). There are 
two variants of the AAA pathway with the second half of the pathway diverging in 
archaebacteria and fungi (15). 
 
The AAA Pathway of Lysine Biosynthesis in Fungi 
The AAA pathway has been identified in many fungal species including 
Saccharomyces cerevisiae (16), Schizosaccharomyces pombe (17), Yarrowia (formally 
Saccharomycopsis) lipolytica (18), Neurospora crassa (19), Penicillium chrysogenum 
(20), Pichia guilliermondii (21), Candida maltosa (22), and in the human pathogenic 
fungi Candida albicans, Cryptococcus neoformans and Aspergillus fumigatus (23). 
Biosynthesis of lysine via the AAA pathway in fungi consists of eight enzymatic steps  
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catalyzed by seven enzymes (Scheme 1.1) (14, 24). The first half of the AAA pathway, 
up to the generation -aminoadipic acid, is similar to the tricarboxylic acid cycle,with the 
tricarboxylic acid cycle substrates being only one carbon shorter, and to the reactions 
involved in leucine biosynthesis (25). Studies in S. cerevisiae determined that synthesis 
of the intermediates in the first half of the AAA pathway is catalyzed in the mitochondria 
with the exception of homocitrate formation, which may take place in the nucleus (26, 
27), whereas the second half of the pathway occurs in the cytoplasm (26).  
Homocitrate synthase (HCS) catalyzes the first step in the AAA pathway by 
transferring an acetyl group from Acetyl-CoA (AcCoA) to 2-oxoglutarate (2-OG) to yield 
homocitrate and Coenzyme A (CoA) (Scheme 1.1). A two-step isomerization of 
homocitrate is then carried out by homoaniconitase (HAc) to form homoisocitrate via the 
intermediate cis-homoaconitate. Oxidation of homoisocitrate by homoisocitrate 
dehydrogenase (HIDH) yields the transient intermediate oxaloglutarate, which is then 
decarboxylated to produce 2-oxoadipate. Transamination of 2-oxoadipate by the 
pyridoxal 5’-phosphate-dependent 2-aminoadipate aminotransferase (AAT) using the 
amino donor L-glutamate generates 2-aminoadipate, which is subsequently reduced by 
2-aminoadipate reductase (AAR) to form 2-aminoadipate semialdehyde in a reaction that 
requires both ATP and NADPH. Next, saccharopine reductase (SR) catalyzes the 
condensation of 2-aminoadipate semialdehyde with L-glutamate and the reduction of the 
imine by NADPH to generate saccharopine. Finally, oxidation and hydrolysis at the 
imine catalyzed by saccharopine dehydrogenase (SDH) generates the pathway’s final 
products lysine and 2-OG (14, 24). Enzymes in the AAA pathway of lysine biosynthesis 
are important to study for several reasons.  First, several pathway intermediates as well as 
lysine are used as precursors for other fungal metabolites (24). For example, in P. 
chrysogenum, -aminoadipate is a precursor of the antibiotic penicillin (28). 
Additionally, the AAA pathway biosynthesis enzymes, particularly HCS because it 
catalyzes the initial step in the pathway, are important enzymes to study in part because 
they represent excellent targets for developing inhibitors that may act as anti-fungal 





Scheme 1.1 The AAA pathway of lysine biosynthesis in fungi.  The enzymes that catalyze the steps in the pathway are as follows. 
1. Homocitrate synthase (HCS, EC 4.1.3.21).  2. Homoaconitase (HAc, EC 4.2.1.36).  3. Homoisocitrate dehydrogenase (HIDH, EC 
1.1.1.87). 4. 2-aminoadipate aminotransferase (AAT, EC 2.6.1.39).  5. 2-aminoadipate reductase (AAR, EC 1.2.1.31).  6. 
Saccharopine reductase (SR, EC 1.5.1.10).  7. Saccharopine dehydrogenase (SDH, EC 1.5.1.7). 
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Regulation of the AAA pathway 
The AAA lysine biosynthesis pathway is known to be highly regulated both at the 
levels of enzyme activity and gene expression. The most thoroughly studied example of 
regulation of enzyme activity in this pathway is the control of HCS through feedback 
inhibition by the end product L-lysine (discussed below). Additionally, the expression of 
many AAA pathway enzymes is controlled by two different mechanisms. In S. 
cerevisiae, several amino acid biosynthesis pathways, including the pathway for lysine 
biosynthesis, are regulated by the general control of amino acid biosynthesis. This 
mechanism functions by depressing the transcription of enzymes in several amino acid 
biosynthesis pathways when the organism is starved for one of several amino acids (30, 
31). Experiments using leaky auxotrophic mutations grown on minimal media identified 
HCS, along with enzymes in the second half of the AAA pathway (AAR, SR and SD) 
(Scheme 1.1), as being governed by the general control mechanism (32). Although this 
mechanism has been most extensively studied in S. cerevisiae, it is also known to occur 
in the AAA pathway-utilizing fungus Neurospora crassa (33). In S. cerevisiae, the 
transcription of most of the AAA pathway enzymes, with the exception of HIDH and 
SDH, is also specifically regulated by the transcriptional factor Lys14p in the presence of 
the pathway intermediate 2-aminoadipate semialdehyde (34-36). Lys14p was identified 
as nuclear protein that contains a Zn(II)2Cys6 cluster DNA binding domain.  This domain 
functions to up-regulate transcription by binding to a nonameric core motif that is present 
in the promoter region of the lysine biosynthesis genes, with the exception of HIDH and 
AAT (35-37). Once Lys14p is bound to the promoter, it is believed to be activated by the 
co-inducer 2-aminoadipate semialdehyde to induce gene expression (36).   
In addition to general and specific control of gene expression of the enzymes in 
the AAA pathway, transcription of these genes also appears to be influenced by the end 
product of the pathway, L-lysine. Six of the seven S. cerevisiae AAA pathway enzymes, 
including HCS are susceptible to repression when grown in media supplemented with 
excess lysine (38). However, L-lysine regulation of the five enzymes downstream of HCS 
has been attributed to L-lysine feedback inhibition of HCS. Inhibition of HCS activity 
causes a reduced metabolic flux through the pathway, resulting in a diminished 
production of 2-aminoadipate semialdehyde and inactivation of the transcriptional factor 
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Lys14p (35, 36). These findings implicate feedback inhibition of HCS activity to be vital 




HCS has been characterized both genetically and biochemically in S. cerevisiae, 
which contains two isozymes of this enzyme: Lys20 and Lys21 (11, 14, 24). Biochemical 
studies of HCS from the fungal species P. chrysogenum (39, 40) P. guilliermondii (21), 
Y. lipolytica (18) C. maltosa (22), and from the archaebacteria Thermus thermophilus 
have also been published (15). The protein sequence among fungal HCS is highly 
homologous with many fungal species having 70-91 % identity and T. thermophilus HCS 
sharing 54 % identity to S. cerevisiae HCS (ScHCS) Lys20 (Figure 1.1) (14, 15). 
Although the high sequence homology among HCS suggests that they function with a 
similar catalytic mechanism, HCSs also appear to have properties contingent on the 
species.  
Different subcellular localization of HCS in fungal species has been reported and 
may be species dependent. Early cell fractionation studies demonstrated ScHCS activity 
to be mostly localized in the mitochondria (41). Because most proteins located in the 
mitochondria of S. cerevisiae contain a localization signal that ScHCS Lys20 lacks, it 
was later suggested that 70% of HCS activity is cytosolic with ScHCS Lys20 and Lys21 
being localized to the cytosol and mitochondria, respectively (42). More recent studies 
using monoclonal antibodies and immunofluroescence demonstrate that ScHCSs Lys20 
and Lys21 are mostly localized to the nucleus, with studies utilizing green fluorescent 
protein (GFP) fusions of ScHCS Lys20 and Lys21 proteins confirming a nuclear 
localization (27, 43). The localization of HCS from S. pombe (SpHCS) (encoded by the 
lys4
+ gene) was also examined using SpHCS-GFP fusions and immunoblotting (44). 
SpHCS-GFP fusions were dispersed throughout the cell, whereas SpHCS was found to 
have a non-cytosolic localization when detected by immunoblotting. The GFP fusion 
protein may disturb the subcellular localization of SpHCS resulting in conflicting 
localization patterns between the two techniques. Further studies to determine the exact 






Figure 1.1 Protein sequence alignment of HCS enzymes. Sequences are from various fungi and the archaebacteria T. 
thermophilus. 
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on P. chrysogenum HCS (PcHCS) (encoded by the Lys1 gene) show 75 % of activity to 
be localized in the cytosol with the remaining activity present in the mitochondria (40). 
Studies using a GFP fusion of PcHCS confirm a mostly cytosolic localization of the 
enzyme (39). The cytosolic location of PcHCS my be due to its role in 
penicillinbiosynthesis. The nuclear/non-cytosolic localization ScHCS and SpHCS raises 
the question of whether these enzymes may have a nuclear/non-cytosolic function in 
addition to lysine synthesis. 
The oligomerization of HCS may also vary depending on the species.  HCS was 
originally believed to function as a monomer in T. thermophilus (15), but recently 
released structures of the enzyme reveals that it functions as a homodimer (45). PcHCS 
also functions and as a multi-subunit enzyme, most likely a dimer or trimer (40).  
Although the native subunit composition of ScHCS Lys20 has yet to be determined, 
recombinant ScHCS Lys20 exists as a monomer, dimer, tetramer and higher weight 
aggregates with most of the activity being associated with the lower molecular weight 
species (46). A more complex subunit composition of HCS may have evolved to regulate 
enzymatic activity and thus the metabolic flux through the biosynthetic pathway. 
Although HCS has generally been studied as an enzyme in the AAA lysine 
biosynthesis pathway, it also plays an important biological role in organisms that do not 
utilize this pathway. Diazotrophic bacteria, including the species Azotobacter vinelandii 
HCS (encoded by the NifV gene), produce homocitrate as a constituent of the iron-
molybdenum (FeMo) cofactor in nitrogenase, which is used for nitrogen fixation (47, 48).  
Additionally, a recent study identified HCS (FEN1 gene) in the legume Lotus japonicus, 
which has a symbiotic relationship with rhizobic soil bacteria that lack a HCS gene (49). 
Homocitrate generated by the plant FEN1 gene is subsequently used by the soil bacteria 
to generate nitrogen used by both organisms providing a molecular explanation for the 
necessity of this symbiotic partnership. In summary, the diversity in biological functions 







Activity and Kinetic Mechanism of HCS 
 The activity of HCS purified from cell extracts has been measured from Y. 
lipolytica (18), P. guillermondii (21), C. maltosa (22) and P. chrysogenum (40), whereas 
more recent activity studies have been performed on recombinantly purified HCS from S. 
cerevisiae (50), T. thermophilus (15) and A. vinelandii (47). The large differences in the 
steady state kinetic parameters these HCS enzymes (Table 1.1) may be do to a variety 
of reasons, including how the enzyme was purified and the type of assay used. However, 
the most recent analysis of the activities of recombinant T. thermophilus HCS (TtHCS) 
and ScHCS Lys20 resulted in similar kinetic values (kcat = 63-92 min
-1, KM(2-OG) = 0.044-
0.140 mM and KM(AcCoA) = 32-42 μM) and may represent more accurate measurements of 
HCS activity.  
 In addition to determining the activity of HCS from several species, the kinetic 
mechanism of HCS was also investigated. This mechanism was first studied in Y. 
lipolytica (18). A double reciprocal plot of velocity versus 2-OG concentration at various 
fixed values of AcCoA resulted in intersecting lines suggesting HCS follows a sequential 
mechanism. Limited product inhibition studies were also performed on Y. lipolytica HCS 
using the inhibitor CoA. CoA did not affect the initial velocities at various fixed 2-OG 
concentrations, but was found to be a strong competitive inhibitor of AcCoA, although it 
does not obey Michaelis-Menten kinetics. Together these results suggest that the binding 
of substrates is ordered with 2-OG binding before AcCoA. More resent studies of ScHCS 
Lys20, confirm an ordered sequential mechanism for HCS. Additionally, results from 
more extensive product and dead-end inhibition studies show that HCS obeys a Bi-Bi 
sequential mechanism with 2-OG binding before AcCoA followed by the ordered release 
of CoA before homocitrate with the hydrolysis of the homocitryl-CoA intermediate being 
essentially irreversible (51) (Scheme 1.2). 
 
Enzymes that Catalyze Claisen Condensation Reactions  
 The mechanism of HCS has been proposed to obey a mixed Claisen condensation 
reaction (14). In this type of mechanism, there is a base-catalyzed abstraction of a carbon 
-proton from a ketone or aldehyde to form an enol (or enolate). Next, the carbonyl 
















Table 1.1 Steady state kinetic parameters for HCS from different species. 
Species KM 2-OG (mM) KM AcCoA (μM) kcat (min
-1) 
P. chrysogenum 2.2 sigmoidal N.R. 
Y. lipolytica 1.7 sigmoidal N.R. 
C. maltosa 0.03 33 N.R. 
P. guillermondii 0.02 6 N.R. 
A. vinelandii 2.2 60 N.R. 
T. thermophilus 0.05 32 92 
S. cerevisiae Lys20 0.14 42 63 





































































hydroxy ester (Scheme 1.3) (52). Although this mechanism is reversible, many enzymes 
that proceed via this mechanism, including, HCS (53), -isopropylmalate synthase ( -
IPMS) (54, 55), malate synthase (56, 57), and citrate synthase (58, 59), catalyze the 
irreversible hydrolysis of the resulting -hydroxy ester to produce the final reaction 
product. These enzymes catalyze similar reactions using AcCoA as the acetyl donor 
(Scheme 1.4), however the structures and details of their mechanism are quite different. 
Of the enzymes mentioned above, citrate synthase is the most extensively studied 
and catalyzes the condensation of oxaloacetate and AcCoA to form citrate and CoA as 
the first step in the tricarboxylic acid cycle (Scheme 1.4A). Citrate synthase forms a 
dimer with each monomer consisting of 20 -helices and one small -sheet. Each 
monomer is composed of a large domain and a small domain, with the active site located 
in the cleft between the two domains (Figure 1.2A). In addition, citrate synthase is known 
to adopt two different conformations, a closed form and an open form. The closed form 
appears to be the active form of the enzyme and possesses binding sites for both the 
oxaloacetate and AcCoA substrates (59). The active site of citrate synthase is mostly 
polar with the substrate oxaloacetate forming hydrogen bonds or salt bridge interactions 
to three arginines and two histidines (Figure 1.2B) (60). Based on several binary and 
ternary structures of citrate synthase from Escherichia coli, the first step of the reaction 
has been proposed to occur via a general acid–base catalyzed step to abstract a proton 
from the methyl group of AcCoA. An aspartate residue (Asp375) is thought to function 
as the catalytic base in deprotonation of the methyl group of AcCoA while a histidine 
residue (His274) simultaneously protonates the carbonyl oxygen of the acetyl group to 
form a neutral enol intermediate. The enol intermediate then nucleophilically attacks the 
oxaloacetate to form an alkoxide intermediate that is then protonated by His320, which 
acts as a catalytic acid to form citryl-CoA.  Finally, the resulting citryl-CoA is hydrolyzed 
to form citrate and CoA (58, 59).  
Malate synthase catalyzes the condensation and hydrolysis of glyoxylate and 
AcCoA to form malate and CoA in the glyoxylate pathway (Scheme 1.4B). Although the 
reaction mechanism of malate synthase is analogous to citrate synthase, the structures and 







                                                
 
  










Scheme 1.4 Claisen condensation reactions utilizing AcCoA as the carboxymethyl 
donor. (A) Reaction catalyzed by citrate synthase. (B) Reaction catalyzed by malate 












Figure 1.2 Overall structure and active site of Escherichia coli citrate synthase. (A) 
Ribbon diagram of a monomer of citrate synthase (PDB 5CTS) (58) showing the large 
domain (green) and small domain (blue). Oxaloacetate (OAA) is rendered as sticks with 
yellow carbons.  (B) Stereoview of the active site citrate synthase in a ternary complex 
with oxaloacetate and carboxymethyl-CoA (CM-CoA) (PDB 5CTS) (58). Oxaloacetate 
along with residues in the large and small domain are colored as described in A with 
Arg421  belonging to the neighboring monomer. Only the carboxymethyl tail of 
CM-CoA (purple) is shown for clarity. Hydrogen and salt bridge interactions of active 
site residues to oxaloacetate (yellow) and hydrogen bonds to carboxylate of CM-CoA 
(red) are depicted as dashes. 
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coli malate synthase isoform G in complex with glyoxylate reveals the enzyme functions 
as a Mg(II)-dependent monomer, with a centrally located ( / )8 TIM barrel fold. An 
N-terminal -helical domain flanks the one side of the barrel, while an inserted sheet 
domain folds against the other side of the barrel. Additionally there is an -helical 
C-terminal domain, which forms a plug over C-terminal side of the TIM barrel (Figure 
1.3A). The active site is sandwiched in a cleft between the C-terminal end of the TIM 
barrel and the C-terminal plug. The substrate glyoxylate binds within appropriate 
distancebarrel and the C-terminal plug. The substrate glyoxylate binds within appropriate 
distance to the proposed catalytic base Asp631 and is stabilized through coordinating to 
the magnesium ion and hydrogen bonding to the backbone amides of Phe353 and 
Leu454. The aldehyde oxygen of glyoxylate also forms a hydrogen bond to the 
guanidinium group of Arg338, which is proposed to partner with Asp631 in the 
enolization of AcCoA, analogous to Asp375 and His274 in citrate synthase (Figure 1.3B) 
(57). A ternary complex of malate synthase and mutagenesis studies helped to elucidate 
the details of the mechanism of malate synthase. Although Asp361 in malate synthase is 
essential, a R388K mutation is still active suggesting that it does not participate in proton 
transfer to the carbonyl oxygen of AcCoA (analogous to His274 in citrate synthase) or to 
the alkoxide intermediate (His320 fulfills this role in citrate synthase). Hence, the 
alkoxide intermediate may remain deprotonated during the subsequent catalytic steps 
(56).  
Like malate synthase, -IPMS is also a metal dependent ( / )8 TIM barrel 
enzyme and catalyzes the transfer of the acetyl group of AcCoA to 2-oxoisovalerate 
(2-OIV) to form -isopropylmalate and CoA (Scheme 1.4C). -IPMS shares 39% 
sequence homology with HCS and has been used as a model to provide insights into the 
mechanism and catalytic residues of HCS in lieu of an HCS structure (50). The crystal 
structure of Mycobacterium tuberculosis -IPMS shows that the enzyme exists as a 
domain swapped homodimer with each monomer of consisting of three major domains 
(55) (Figure 1.4A). The N-terminal domain contains an ( / )8 TIM barrel catalytic 
domain with the active site of the enzyme located at the C-terminal end of the TIM 
barrel. The C-terminal domain is a regulatory domain consisting of a novel two-unit 







Figure 1.3 Overall structure and active site of Escherichia coli malate synthase. (A) 
Ribbon diagram of malate synthase (PDB 1D8C) (57) showing the N-terminal domain 
(red), TIM barrel domain (green), -sheet domain (yellow) and C-terminal domain (blue). 
Glyoxylate (GLV) is rendered as sticks with yellow carbons and the Mg(II) ion is 
depicted as a pink sphere.  (B) Stereoview of the active site of malate synthase in a binary 
complex with glyoxylate (PDB 1D8C) (57). Glyoxylate, Mg(II) and residues in the active 
site are colored as described in panel A. Orange and yellow dashes represent coordination 








Figure 1.4 Overall structure and active site of Mycobacterium tuberculosis -
isopropylmalate synthase (A) Ribbon diagram of a monomer of -IPMS (PDB 1SR9) 
(55) depicting the N-terminal TIM barrel domain (green), regulatory domain (yellow) 
along with subdomain I (blue) and subdomain II (red) of the linker domain.  2-OIV is 
rendered as sticks with yellow carbons and the Zn(II) metal ion is depicted as a gray 
sphere.  (B) Active site of -IPMS in a binary complex with 2-OIV (PDB 1SR9) (55). 
The 2-OIV substrate along with the active site residues are colored as described in panel 
A. Orange, yellow and red dashes represent coordination to the Mg(II) ion, hydrogen 
bonding to2-OIV, and hydrogen bonding between predicted active site residues, 
respectively. (C) Stereoview of a modeled ternary complex of -IPMS. The molecule is 
colored as described in panel A with only the acetyl thioester group of AcCoA (purple) 






terminal catalytic domain to the C-terminal regulatory domain. Subdomain I of the linker 
domain is composed of an -helix and two short -strands, while subdomain II consists 
of a three-helix bundle. The two subdomains are separated by a disordered hinge region, 
which allows the two monomers to have different relative orientations in their N- and 
C-terminal domains. 
The active site of -IPMS located at the interior of C-terminal end of the ( / )8 
TIM barrel that consists of a divalent metal cation, Zn(II) in this structure, which has 
octahedral coordination to three protein ligands: Asp81, His285 and His 287, the C1 and 
2-oxo oxygens of the substrate 2-OIV and to a water molecule. 2-IOV is bound within the 
center of the TIM barrel through hydrogen bond interactions with Thr254 and Arg80 
(Figure 1.4B). A ternary complex with 2-OIV and the product CoA could not be solved, 
so the authors chose to model an AcCoA into the active site. The methyl carbon of the 
thioacetyl group of AcCoA was modeled to fit between His379  (the prime ( ) denotes the 
residue is in the neighboring monomer), Glu218 and the C2 carbon of 2-OIV with the 
carbonyl oxygen forming a hydrogen bond to the guanidinium group of Arg80. Based on 
the structure of the modeled -IPMS/2-OIV/AcCoA ternary complex, the authors 
propose a Claisen condensation reaction mechanism with the conserved Glu218 and 
His379  residues in positions to act as the potential bases. Tyr410  may also be important 
in base catalysis as it forms a hydrogen bond with Glu218 and also orients His379  by 
stacking on top of it (55) (Figure 1.4C). Surprisingly, recent kinetic studies on -IPMS 
with mutations at each of these residues, (E218A, H379A or Y410F) did not significantly 
affect the kinetic parameters of the enzyme suggesting that none of these residues are 
critical for activity (61). Further studies are needed to determine which residues in 
-IPMS are necessary for catalysis.  
 
The Catalytic Mechanism of HCS 
Unlike citrate synthase, malate synthase and -IPMS, a structure of HCS has not 
been solved prior to this work, and a model for the catalytic mechanism of this enzyme 
was based on biochemical studies (53). Inductively coupled plasma-high resolution mass 
spectrometry (ICP-HRMS) analysis of metal affinity purified ScHCS Lys20 reveals the 
enzyme to most like be a Zn(II) dependent metalloenzyme. Further experiments 
 19
examining pH dependence of the kinetic parameters, isotope effects and dissociation 
constants for competitive inhibitors provide even more insights into the mechanism of 
HCS. By plotting the log of velocity (V) versus pH at saturating concentration of 
substrates one can determine residues involved in catalysis, whereas plotting the log 
V/KM versus pH at sub-saturating levels of one of the substrates gives insights into 
substrate binding and catalysis. The log V versus pH-rate profile of ScHCS Lys20 has 
slopes of 1 and -1 indicating that one protonated residues and one unprotonated residue 
are required for catalysis. The unprotonated residue had a pK of 6.7 and most like 
functions as a general base to abstract a proton from AcCoA, while the protonated 
residue had a pK of 8.0, and may be the general acid that donates a proton to form 
homocitryl-CoA. The log V/KM(2-OG) versus pH rate profile indicates two protonated 
residues and one unprotonated residues are important for 2-OG binding and/or catalysis.  
One of the protonated residues is potentially the hydrogen bond donor to the 2-oxo group 
of 2-OG and donates a proton during catalysis, and the other protonated residue may 
form a hydrogen bond with the C5-carboxylate of 2-OG. However, the role of the 
unprotonated group in 2-OG binding remains unknown. Analysis of the log V/KM(AcCoA) 
versus pH rate profile shows that two protonated and two unprotonated groups are 
important for AcCoA binding and/or catalysis. Two of these residues are important for 
catalysis as described for the log V pH-rate profile, while the other two groups are 
probably important for AcCoA binding. Additionally, no solvent isotope effect is 
observed, suggesting that the alkoxide remains metal-bound, and subsequently receives a 
proton form the residue acting as the general acid. 
Based on these results, a general acid-base mixed Claisen condensation 
mechanism was proposed for HCS (53) (Scheme 1.5). In this mechanism, 2-OG binds 
first coordinating to an active site metal ion with its C1-carboxlate and 2-oxo atoms, 
while the C5 carbon is stabilized through hydrogen bonding to a protonated residue. 
AcCoA then binds in a position with its thioester group near the C2 carbon of 2-OG and 
the residue that acts as the general base. The general base abstracts a proton from the 
methyl group of AcCoA to generate an enol/enolate, which subsequently attacks the C2 






















from the general acid to form homocitryl-CoA, and subsequent hydrolysis by the 
metal-bound water yields the products CoA and homocitrate.  
 
The Catalytic Base in HCS 
 Since HCS shares a moderate degree of sequence homology with -IPMS, 
mutagenesis and kinetic studies on several conserved residues within the active site of 
these two enzymes were probed for their role in HCS catalysis (50). Alanine and 
conservative mutations of ScHCS Lys20 residues Glu155, His309 and Tyr320 
(corresponding to Glu218, His379, and Tyr410 in -IPMS) (Figure 1.4B) were prepared 
and tested for activity. No detectable activity was observed for H309A and H309N 
mutations, and the E155A and E155Q mutations resulted in >1000 fold reduction in 
activity compared to WT ScHCS Lys20. The presence of imidazole in the H309A mutant 
and formate in the E155A assays increased the activity slightly for these two mutations, 
suggesting the side chains of these residues are important in catalysis. In contrast, an 
Y320F mutation was active, but had a 25-fold decrease in activity compared to WT 
enzyme suggesting that although it is not important for catalysis, it might aid in substrate 
binding and orientation. Based on these findings, a His309-Glu155 catalytic dyad was 
proposed to act as the general base in HCS. However, without an HCS tertiary structure, 
assignment of the residues involved in acid-base catalysis remains speculative. 
 
Role of the Divalent Metal Ion in Catalysis by HCS  
Only a few studies have to the identity of the divalent metal specificity of HCS, 
an essential component needed for activity, have been performed. Although the divalent 
metal in the active site of metal affinity purified ScHCS Lys20 HCS was found to most 
likely be Zn(II) (53), these results may be inaccurate simply due to the fact that the 
enzyme was purified on a divalent metal affinity column (46). Additionally, purified 
ScHCS Lys20 that is inactivated with the metal chelator ethylenediaminetetraacetic acid 
(EDTA) can be reactivated with the addition of either Mn(II) or Zn(II) (53). Recently, the 
metal dependence of TtHCS was also investigated by adding different divalent metal ions 
to EDTA treated enzyme and assaying for activity (45). The addition of Mg(II), Mn(II) 
and Co(II) resulted in the highest activity suggesting to the authors that Mg(II) or Mn(II) 
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may be the biologically relevant divalent cation. Together, these results raise questions 
about the identity of the physiologically relevant metal in HCS, and if the enzyme is 
regulated through a metal switching mechanism similar to the metalloenzymes histone 
deacetylase HDAC8 (62) and the E. coli deacetylase LpxC (63). Studies described in 
Appendix A begin to characterize SpHCS reconstituted with different divalent metals in 
an effort to resolve these types of questions. 
 
Regulation of HCS activity by L-Lysine Feedback Inhibition  
 The activity of many enzymes that function in amino acid biosynthesis pathways 
are regulated by feedback inhibition by the end product or by an intermediate in the 
pathway. The least complex form of feedback inhibition is considered to be the inhibition 
of the first enzyme in the pathway by the final amino acid product (64, 65). This form of 
inhibition is observed for the AAA pathway of lysine biosynthesis in S. cerevisiae (66), 
P. chrysogenum (67), Y. lipolytica (18), and T. thermophilus (15). However, it cannot be 
ruled out that another step in the pathway is also regulated by the end product L-lysine. 
Overexpression of HCS in a P. chrysogenum strain with an inactive AAR gene did not 
lead to an overproduction of the AAR substrate -aminoadipate, suggesting there may be 
another rate-limiting step in this pathway in P. chrysogenum.  
Studies investigating the nature of L-lysine feedback regulation of HCS provide 
evidence for two distinct models of inhibition. In the first model, L-lysine binds 
competitively with the substrate 2-OG in the active site of HCS, despite the lack of 
structural homology between L-lysine and 2-OG. This model is supported by kinetic 
studies in HCS from P. chrysogenum (40), T. thermophilus (15) and S. cerevisiae (68) 
which demonstrate that L-lysine inhibition is competitive with 2-OG. The second model 
of feedback inhibition of HCS is an allosteric model where L-lysine binds in binding 
pocket that is distinct from the active site of the enzyme. Evidence for this model 
includes lysine inhibition studies versus the substrate 2-OG in HCS from Y. lipolytica 
(18). In this species, the inhibition kinetics exhibit non-Michealis-Menten kinetics, 
suggesting an allosteric binding site for L-lysine. Additional evidence that inhibition of 
HCS by L-lysine, comes from studies that isolated HCS lysine overproducing mutants in 
S. cerevisiae (36, 68). Three lysine insensitive point mutants (R276K and S385F in 
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isozyme Lys20 and Q366R in isozyme Lys21) were found to be resistant to 
S-aminoethyl-L-cysteine (AEC), a toxic L-lysine analog. These mutations display a large 
increase in the apparent inhibitor constant (IC50) values compared to WT enzyme, yet 
still maintain HCS activity suggesting 2-OG and lysine do not bind in the same site. 
Determining a structure of an HCS/L-lysine complex resolve this discrepancy by 
providing indisputable evidence for one model over another.  
 
AAA Pathway Enzymes as Antifungal Inhibitor Targets 
Although fungal infections pose little threat in healthy hosts, during the last few 
decades invasive fungal infections have emerged as an increasing cause of morbidity and 
mortality in immuno-compromised individuals, such as transplant recipients, cancer and 
burn patients, and those with acquired immunodeficiencies such as AIDS (29, 69-71). 
Currently, the species Candida, particularly C. albicans, is the most common causes of 
nosocomial fungal infection (72, 73). However, many other fungal pathogens have 
emerged including the genus Cryptococcus, which is the major cause of fungal 
pulmonary infections in AIDS patients (74) and the Aspergillus mold which causes a 
wide range of ailments, with the most severe being invasive pulmonary aspergillosis in 
individuals with weakened immune systems (75).   
 Most of the current therapies to treat invasive fungal infections fall into three 
major categories: polyenes, azoles, and echinocandins (76-78). Amphotericin B is the 
most commonly used polyene and functions by disrupting the fungal membrane. 
Although this agent has a broad fungal specificity, serious side effects, including 
nephrotoxicity and eventual renal failure, are common making this drug less than ideal. 
Azoles function by inhibiting the cytochorme P450-dependend enzyme lanosterol 
demethylase, an enzyme that produces a significant component of the plasma membrane 
in fungi. Members of this family include fluconazole, itraconazole and voriconazole. 
Fluconazole is routinely used as a prophylaxis in bone marrow transplant patients to 
reduce the risk and severity of fungal infections against Candida, but this has led to an 
increase in infections by non-filamentous fungal species including Aspergillus (79). The 
azole drug voriconazole effectively treats Aspergillus infections; however, it interacts 
with many other drugs causing problems for immunodeficient individuals needing 
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multiple medications. The echinocandins are newest class of antifungal agents and 
include caspofungin, anidulafungin and micafungin. Echinocandins are lipopeptides that 
act by specifically inhibiting -1-3-glucan formation, a component of the fungal cell wall. 
The specificity of echinocandins is limited to the Candida and Aspergillus geneses, but 
they are more effective in treating drug-resistant invasive Aspergillus than other classes 
of antifungals. Though significant progress has been made in developing new antifungal 
agents, there is still precedence for the development of additional agents especially those 
that act on novel targets. Many of the current drugs have drawbacks, including severe 
side effects, interactions with other medications (76-78) or can become ineffective 
against resistant fungal species (80). Furthermore, treatment of some fungal infections 
such as aspergillosis with a single agent has a cure rate of only 50% (78) necessitating the 
development of combinatorial therapies and the discovery of novel antifungal agents 
especially against this type of infection.  
The enzymes in the AAA pathway of lysine biosynthesis represent potential 
targets for the development of novel antifungal drugs, in part because they are absent in 
humans. Studies identifying essential genes in A. fumigatus either using a conditional 
promoter replacement method or in silco analysis model identified the AAA pathway 
enzymes HAc, SD and HCS as potential antifungal targets (81, 82). Additionally, a study 
of A. nidulans, the model Aspergillus organism, showed that a mutant lacking the ability 
to synthesize L-lysine (lysA2) had a reduced virulence when infected into murine models 
indicating that lysine levels in the lung are limited, thus making the AAA metabolic 
pathway a promising novel target for the development of antifungal targets (83). 
Although the AAA pathway enzymes have long been proposed to be targets for the 
control of pathogenic yeast (23), only recently have studies been published on the design 
of inhibitors to enzymes in this pathway. The rational design of carboxyaryl-substituted 
D-malic acids as analogs to 2-(R)-homocitrate or (2R, 3S)-homoisocitrate, the substrates 
of HAc, were shown to inhibit growth of A. ndulans by 50% at 3 mM compound, 
however this a very high level compared to the 1 uM of amphotericin B need to cause the 
same level of inhibition (84). Additionally, a study to design and test inhibitor 
compounds against HIDH found the molecule thiahomoisocitrate to be a strong inhibitor 
(Ki of 97 nM) on HIDH from S. cerevisiae (85). However, studies are still needed to 
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further develop these potential inhibitors as antifungal agents and to unearth potent 
inhibitors against other enzymes in the AAA pathway, especially against HCS, which 
catalyzes the first and committed step in this pathway. 
  
Objectives of This Work 
Since the initial purification of HCS, many genetic and biochemical studies have 
been performed to elucidate the mechanism and regulation of this enzyme. For example, 
HCS was found to be regulated at both the levels of gene expression and enzyme activity.  
Additionally, over the past decade both the kinetic and general chemical mechanism have 
been described for this enzyme. However, many questions addressing the specifics of the 
mechanism of regulation of HCS remain unanswered partly due to a lack of a structure of 
a member of the HCS family. In this work, we address the details of the mechanism and 
regulation of HCS by using a variety of biochemical approaches including structural 
studies and in vivo and in vitro functional assays (Chapters 2, 3). Furthermore, a HCS 
fluorescent activity assay was developed and used in high-throughput screening (HTS) to 
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CHAPTER 2 
CRYSTAL STRUCTURE AND FUNCTIONAL ANALYSIS OF HOMOCITRATE 
SYNTHASE
 
Many organisms can synthesize lysine utilizing one of two distinct biosynthetic 
pathways.  In plants and most bacteria lysine is synthesized via the DAP pathway (1-3). 
Yeast, and most fungi, including the human pathogens Cryptococcus neoformans, 
Candida albicans and Aspergillus fumigatus, and some archaebacteria, including 
Thermus thermophilus utilize the AAA pathway to synthesize lysine (4-7). Because HCS 
is unique to fungi, and absence in mammals, these enzymes represent an excellent target 
for screening and developing small molecule inhibitors that may have potential clinical 
value as broad-spectrum anti-fungal therapeutics, particularly for immuno-compromised 
individuals, such as AIDS and cancer patients and transplant recipients, who are at higher 
risk of developing invasive fungal infections. 
The AAA lysine biosynthetic pathway in fungi and yeast consists of eight 
enzymatic steps with HCS catalyzing the first and committed step in this pathway by 
transferring an acetyl group from AcCoA to 2-OG to form homocitrate and CoA (5, 8). 
The kinetic mechanism of ScHCS Lys20 was determined to be a sequential Bi-Bi 
reaction with 2-OG binding before AcCoA followed by the release of CoA before 
homocitrate (9). The reaction mechanism of HCS has been proposed to follow a general 
acid base mixed Claisen condensation reaction (10), which is the same mechanism used 
by citrate synthase (11), malate synthase (12, 13) and -IPMS (14). Based on the 
structure of -IPMS, mutagenesis and kinetic studies of ScHCS Lys20 have provided 
evidence that a glutamate-histidine catalytic dyad is responsible for the deprotonation of 
the AcCoA acetyl group (15).   However, without a structure of a HCS, the residues that 
act as the general acid and general base are not definitively known.  
Here we describe the first crystal structures of a fungal HCS along with two 
distinct binary complexes with the substrate 2-OG. In one of the 2-OG binary complexes, 
a lid motif covers the entrance to the active site, gating access for substrate binding. 
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Steady state kinetic assays and in vivo yeast growth assays on WT SpHCS and active site 
allow us to elucidate the contribution these residues play in substrate binding and 
catalysis. Together these results yield new insights into the mechanism of HCS, which 
provides a platform for identifying anti-fungal modulators of HCS. 
 
MATERIALS AND METHODS 
 
Materials 
DNA primers used for cloning were purchased from Invitrogen, whereas primers 
used for mutagenesis were obtained from Integrated DNA Technologies. The pLp2211 
vector containing lys4+ under the control of the S. cerevisiae HCS LYS20 promoter was 
constructed in the laboratory of Lorraine Pillus at the University of California San Diego. 
Tobacco Etch Virus (TEV) protease was purified on Talon resin essentially as described 
(16), but was further purified by eluting with a 100 mM to 1 M NaCl gradient on a 
SP-sepharose ion exchange column (Amersham Biosciences) at pH 8.0. Peak fractions 
were concentrated to 1 mg/mL ( 280nm = 31970M
-1cm-1) and glycerol was added to 10% 
(v/v).  Aliquots were flash frozen and stored at -80 oC. Amino acids and 
L-selenomethionine used in the selenomethionine minimal media were purchased from 
Sigma. The polyethylene glycol (PEG) 400, sodium phosphate monobasic and potassium 
phosphate dibasic used in crystallization screens were purchased from sigma at the 
highest quality available, while the magnesium acetate was supplied as a 1 M solution 
from Hampton Research. Thiostar [10-(2,5-dihydro-2, 5-di-oxo-1H-pyrrol-1-yl)-9-
methoxy-3-oxo-, methyl ester 3H-naphthol(2,1-b) pyran-S-carboxylic acid] dye was 
purchased from Luminos LLC and prepared by dissolving in dimethyl sulfoxide 
(DMSO). The concentration of the dye was determined by measuring its absorbance at 
381 nM and using an extinction coefficient of 15,100 M-1 cm-1. AcCoA trilithium salt was 
purchased from Sigma. Commercially available AcCoA is contaminated with a small 
percentage of CoA, which causes high background in the HCS fluorescent assay. 
Therefore, purchased AcCoA (25 mg) was treated with 50 μL acetic anhydride (Fluka) 
for 10 minutes at room temperature, brought up to 1 mL with 100 mM HEPES, pH 7.5 
and the concentration was measured ( 260nm = 15,400 M
-1 cm-1). Aliquots were flash 
frozen and stored at -80 oC until use. 2-OG disodium salt was purchased from Fluka and 
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was stored as a 1 M stock at -20 oC. CoA trilithium salt was purchased from Sigma and 
stocks were made up in water and the concentration was determined ( 260nm = 15,400 M
-1 
cm-1) before flash freezing and storing at -80 oC. All other materials used were of the 
highest grade available. 
 
Cloning of SpHCS 
 Full length HCS encoded by the lys4+ gene was amplified from 
Schizosaccharomyces pombe genomic clone SPBC1105.02c (Sanger Institute) using the 
polymerase chain reaction and the following primers: 5’-GCAGGTAAGATGGTAGGA 
TCCATGTCTGTGTCCGAAGCAA-3’ and 5’-CTGGCTCATCCGCTCGAGGAATTCT 
TAAGCAGACGCTTCTTTGG-3’. The PCR reaction was catalyzed using Platinum Pfx 
DNA Polymerase (Invitrogen) and the resulting DNA fragment was purified using 
agarose gel electrophoresis on a 1% agarose gel and a rapid gel extraction kit (Marligen). 
The SpHCS DNA and a parallel expression vector pHIS2 (17), which contains an 
N-terminal 6xHIS tag and TEV protease cleavage site, were each digested for 1 hour at 
37 oC with the restriction enzymes BamH1 and EcoR1. The digested SpHCS DNA and 
pHIS2 vector were PCR purified (Marligen) and ligated using T4 DNA ligase. Ligation 
product was transformed into calcium competent Escherichia coli DH5  cells, which 
were grown overnight at 37o C on Luria-Broth (LB) agar plates containing 100 μg/mL 
ampicillin (AMP). Plasmid DNA from resulting colonies was purified using a QIAprep 
Spin Miniprep kit (Qiagen) and dideoxynucleotide sequencing was performed 
(University of Michigan DNA Sequencing Core) to confirm the sequence of the lys4+ 
gene. 
 
Mutagenesis of SpHCS Active Site Residues 
Active site mutants of SpHCS/pHIS2 and SpHCS/pLp2211 were made using site-
directed mutagenesis following a modified QuikchangeTM mutagenesis kit protocol 
(Stratagene). Complimentary sets of primers containing the mutations were designed 
(Table 2.1) and PCR reactions (50 μL) were set up with 10 or 20 ng vector/SPHCS DNA, 






Table 2.1 Primers used for SpHCS site directed mutagenesis. 
Mutation Primer 
R43A 5 -CCATTATTGAGTCTACTCTTGCTGAAGGTGAGCAATTCGC-3 a 
 
R43K 5 -CCATTATTGAGTCTACTCTTAAGGAAGGTGAGCAATTCGC-3  
 
R43Q 5 -CCATTATTGAGTCTACTCTTCAGGAAGGTGAGCAATTCGC-3  
 
Q47A 5 -CTACTCTTCGTGAAGGTGAGGCATTCGCAAACGCTTTTTTCG-3  
 
E74A 5 -CTTTGGTGTCGATTACATTGCATTGACTTCTCCCGTGGC-3  
 
E74Q 5 -CTTTGGTGTCGATTACATTCAATTGACTTCTCCCGTGGC-3  
 
H103A 5 -GGCTTAAAGTGTAAAATTTTAACTGCTATTCGCTGTCATATGG-3  
 
R163A 5 -GCAAGGGTATTGAAGTCGCCTTTTCATCTGAGGATTCTTTCCG-3  
 
R163K 5 -GCAAGGGTATTGAAGTCAAGTTTTCATCTGAGGATTCTTTCCG-3  
 
R163Q 5 -GCAAGGGTATTGAAGTCCAGTTTTCATCTGAGGATTCTTTCCG-3  
 
S165A 5 -GCAAGGGTATTGAAGTCCGCTTTGCATCTGAGGATTCTTTCCG-3  
 
E167A 5 -GAAGTCCGCTTTTCATCTGCGGATTCTTTCCGTTCTGATC-3  
 
E167Q 5 -GAAGTCCGCTTTTCATCTCAGGATTCTTTCCGTTCTGATC-3  
 
T197A 5 -CCGTGTTGGTATTGCTGACGCCGTTGGTTGCGCTACTCCTCGCC-3  
 
T197S 5 -CCGTGTTGGTATTGCTGACTCCGTTGGTTGCGCTACTCCTCGCC-3  
 
T197V 5 -CCGTGTTGGTATTGCTGACGTCGTTGGTTGCGCTACTCCTCGCC-3  
 
H321A 5 -GCTTTTACCCATAAGGCTGGTATCGCTGCTAAAGCTATTCTCGC-3  
 
Y332A 5 -CGCTAACCCTTCTACAGCTGAAATTCTTAAGCCCGAGG-3  
 
Y333F 5 -CGCTAACCCTTCTACATTTGAAATTCTTAAGCCCGAGG-3  
aForward primer is listed with reverse primer being the reverse complement of the 






and 2.5 U pfuUltraTM HF DNA polymerase (Stratagene). The reactions were cycled for 
30 seconds at 95 oC followed by 16 rounds of 30 seconds at 95 oC, 1 minute at 55 oC and 
9 minutes at 68 oC in a thermocycler. The resulting amplifications were digested with 
20 U Dpn 1 (Invitrogen) for 1 hour at 37 oC and 1 μL of the digest was transformed into 
E. coli DH5  cells. The cells were plated on LB agar plates containing 100 μg/mL AMP 
and grown overnight at 37 oC. DNA from the resulting colonies was isolated utilizing a 
QIAprep Spin Miniprep kit (Qiagen) and the mutated sequences were verified by 
dideoxynucleotide sequencing (University of Michigan DNA Sequencing Core). 
 
Expression of SpHCS 
SpHCS/pHIS2 plasmid was transformed into E. coli Rosetta2 (DE3) cells (EMD  
Biosciences) and grown overnight at 37 oC on LB agar plates containing 100 μg/mL 
AMP and 50 μg/mL chloramphenicol (CHLOR). Several colonies were transferred and 
grown in a starter culture of 2X-YT media supplemented with 100 μg/mL AMP and 
50 μg/mL CHLOR overnight at 37 oC. SpHCS was over expressed by inoculating the 
starter culture into twelve flasks of 500 mL 2X YT media supplemented with 100 μg/mL 
AMP and 50 μg/mL CHLOR. The cells were grown at 37 oC to an OD600 of 0.3 and the 
temperature was reduced to 18 oC. Once the shaker reached 18 oC, protein was 
overexpressed by adding 0.1 mM isopropyl -D-1-thiogalactopyranoside (IPTG) and 
growing the cells overnight. Harvested cells were resuspended in lysis buffer consisting 
of 50 mM sodium phosphate pH 7.0, 500 mM NaCl, 5mM -mercaptoethanol ( -me) and 
stored at -20 oC.   
 
Purification of SpHCS for Crystallization 
All purification steps were performed at 4 oC unless otherwise stated. Cell pellets 
were thawed and lysed by adding 5 mg lysozyme and rocking at room temperature for 
1 hour followed by a flash freeze and thaw cycle. The cells were sonicated after the 
addition of 30 mL lysis buffer and the insoluble material was separated from the soluble 
enzyme by centrifugation at 15,000 rpm for 20 minutes in a Sorvall SS-34 rotor. The 
soluble enzyme was loaded onto a Talon (Clontech) Co(II) immobilized metal affinity 
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chromatography (IMAC) column pre-equilibrated in lysis buffer and eluted with a linear 
gradient of 0-500 mM imidazole. Fractions containing SpHCS were pooled and the 
6xHIS tag was removed by TEV protease during dialysis in a 10,000 MW cut-off bag 
(Pierce) overnight against 50 mM sodium phosphate, pH 8.0, 150 mM NaCl and 5 mM 
-me. The NaCl and imidazole concentrations in the dialyzed protein were brought up to 
500 mM and 40 mM respectively and the TEV protease and undigested SpHCS were 
removed by batch binding to 5 mL Talon resin for 1 hour. Unbound SpHCS was 
concentrated to 2 mL using an 30k Amicon Ultra centrifugal Filter Device (Millipore) 
and was further purified by loading onto a Superdex 200 (GE healthcare) gel filtration 
column and isocratically eluted with 25 mM Tris, pH 9.0, 50 mM NaCl, 1 mM 
tris(2-carboxyethyl)phosphine (TCEP). In some cases for crystallization, SpHCS was 
treated with 10mM EDTA prior to gel filtration to remove the bound divalent metal.  
Peak fractions were judged to be essentially pure by SDS-PAGE and were concentrated 
to 40-80 mg/mL as measured by absorbance at 280 nM using the calculated extinction 
coefficient of 28350 M-1 cm-1. Concentrated SpHCS was flash frozen and stored at 
-80 oC. 
 
Purification of SpHCS and SpHCS Mutants for Kinetic Studies 
A Zn(II) charged IMAC sepharose 6 Fast flow (GE Healthcare) resin was used in 
the first steps of the purification of SpHCS and SpHCS mutants used in kinetic studies. 
With the exception of the IMAC resin, the purification was performed identically as 
described for crystallization. 
  
Inductively Coupled Plasma-High Resolution Mass Spectroscopy  
 WT SpHCS from two different purifications on Zn(II) charged IMAC sepharose 
along with WT SpHCS from a Talon Co(II) IMAC purification treated with EDTA were 
diluted to 20 μM in 50 mM HEPES, pH 7.5. Metal content was analyzed using a 
ThermoFisher Finnigan Element Inductively Coupled Plasma-High Resolution Mass 
Spectrometer (ICP-HRMS; University of Michigan, Department of Geology) with the 




Preparation of Selenomethionyl-Incorporated SpHCS 
Selenomethionyl-SpHCS (SeMet-SpHCS) was prepared following a modified 
protocol of Doubolié (18, 19). Selenomethionine minimal media (10 L) was prepared by 
cooling 5 L of autoclaved MilliQ water to 60 oC and adding 0.4 g tyrosine and 5.0 g of 
each of the following bases: adenine, guanosine, thymine and uracil (TyB media). The 
TyB media was cooled to room temperature and divided into two 6 L flasks and the 
following was added to each flask:  100 mL of 50x amino acid mix (all amino acids at 
0.2 mg /mL except for tyrosine, glutamine and methionine), 100 mL 50% glycerol, 
50 mL 20% glucose, 10 mL glutamine (20 mg/mL), 6.25 mL trace metal ion mix 
(5g FeCl2•4 H2O, 184 mg CaCl2•2 H2O, 64 mg H3BO3, 40 mg MnCl2•4 H2O, 18 mg 
CoCl2•6 H2O, 4 mg CuCl2•2 H2O, 340 mg ZnCl2 and 605 mg Na2MoO4•2 H2O dissolved 
in 8 mL concentrated HCl and brought up to 500 mL with water), 5.0 mL 1M MgSo4, 
2.5 ml 1M CaCl2, and 2.0 ml thiamine (5 mg/mL), 1 L autoclaved selenomethionine salts 
(5 mg/mL NH4SO4, 22.5 mg/mL KH2PO4, 52.5 mg/mL K2PO4 and 2.5 mg/mL 
Na3Citrate), 1.25 L autoclaved water and 200 mg L-selenomethionine. SpHCS/pHIS2 
plasmid was transformed into the methionine auxotroph E. coli B843 (DE3) cell line and 
a starter culture of the cells was grown overnight in LB media supplemented with 
100 mg/mL AMP and 50 mg/mL CHLOR. The selenomethionine minimal media with 
100 mg/mL AMP and 50mg/mL CHLOR was inoculated with a 1/100 dilution of the 
starter culture and SeMet-SpHCS was overexpressed and purified identically to wild type 
enzyme used for crystallization. 
 
Crystallization of SpHCS  
To identify initial conditions that produced crystals of SpHCS, several 
commercially available sparse matrix crystallization screens were utilized including the 
Index HT Screen (Hampton Research), Wizard I and II Screen (Emerald BioSystems) 
Structure Screen 1 and 2 (Molecular Dimensions) and JCSG+ Suite Screen (Qiagen 
formally Nextal). Crystallization was carried out in 96 well protein sitting drop 
crystallization plates (Greiner Bio-One) by adding 70 uL of the crystallization solution to 
the reservoir well and 2 μL a 1:1 ratio of the protein mixture (20-24 mg/mL SpHCS, 
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1-2 mM CoA, 1-50 mM 2-OG) to crystallization solution to the crystallization wells. The 
trays were immediately sealed, incubated at 20 oC or 24 oC and observed daily for crystal 
formation. 
SpHCS protein crystals formed in several initial conditions, a few of which were 
optimized to obtain the largest and sharpest looking crystals. To identify optimized 
crystallization conditions, the hanging drop vapor diffusion method was employed using 
24 well VDX plates (Hampton Research).  A 2 μL drop of a 1:1 ratio of protein mixture 
to crystallization condition was dispensed onto cover slides, which were sealed over each 
reservoir containing 500 μL of the crystallization condition. SpHCS-free enzyme protein 
crystals formed in 100 mM HEPES, pH 6.8-7.2, 200 mM Mg acetate, 16-25% (v/v) 
PEG 400 at 24 oC using 24 mg/ mL native SpHCS or SeMet-SpHCS, 1 mM CoA and 
1 mM 2-OG. To obtain crystals of SpHCS in complex with the substrate 2-OG, a 
phosphate condition was optimized. Crystals of the SpHCS open loop complex with 
2-OG were obtained in 1.3-1.6 M Na/KPO4 (pH 5.4-6.4) at 24 
oC using 20 mg/mL EDTA 
treated SpHCS, 1 mM Zn(II), 2 mM CoA and 50 mM 2-oxoglutarate while crystals of the 
SpHCS closed loop complex with 2-OG were obtained in 1.2-1.8 M Na/KPO4, pH 5.6-6.8 
at 24o C using 24 mg/mL SpHCS, 2 mM CoA and 50 mM 2-OG. Optimized crystals were 
harvested, cryo-protected in the crystallization condition containing 20% glycerol and 
flash frozen in liquid nitrogen. 
 
Phase Determination and Data Collection 
To determine the phases needed for SpHCS structure determination, the selenomethionyl 
single wavelength anomalous dispersion (SAD) technique was used (20). Data was 
collected at the phi and inverse phi angles on a single SeMet-SpHCS crystal at the 
experimentally determined selenium peak (0.97913 Å) using the 23-ID-B beamline of 
General Medicine Cancer Institutes-Collaborative Access Team (GM/CA-CAT) at the 
Advanced Source Synchatron (Table 2.2). The data was then processed and scaled using 
HKL2000 (21). The program SOLVE/RESOLVE (22) located 8/9 initial Se sites in a 
P6222 space group and the program autoSHARP (23) was used to refine the heavy atom 
sites, calculate and refine SAD phases, perform density modification and build a partial 









Table 2.2 Data collection and refinement statistics. 





closed lid [Zn(II)] 
WT SpHCS/2OG 
open lid [Co(II)] 
Data Collection     
Beamline 23-ID-B 23-ID-B 21-ID-G 21-ID-G 
Space group P6222 P62  P62 P62 
Cell dimensions a=b, c (Å) 136.9, 120.9 136.0, 122.1 133.7, 125.9 133.8, 125.7 
Wavelength (Å) 0.97913 0.97930 0.97856 0.97872 
Resolution (Å) 40.0-2.70 (2.80-2.70)a 50.0-2.24 (2.33-2.24) 40.0-2.67 (2.78-2.67) 40.0-2.72 (2.82-2.72) 
Rmerge (%) 7.9 (32.5) 6.0 (54.0) 6.0 (51.2) 5.6 (49.5) 
I/ I 48.3 (15.4) 28.1 (3.67) 35.4 (4.54) 22.2 (2.54) 
Reflections     
  Total 657,489 446,827 343,456 125,123 
  Unique 18,936 60,860 36,145 33,176 
Redundancy 34.7 (31.7) 7.3 (7.0) 9.5 (8.8) 3.8 (3.7) 
Completeness (%) 100.0 (100.0) 99.4 (99.7) 100.0 (100.0) 96.4 (98.5) 
Phasing power 2.789    
Sites found/total 8/9    
F.O.M.b 0.4727/0.8464    
Refinement     
Resolution range (Å)  29.45-2.24 39.4-2.67 39.41-2.72 
No. of reflections   60,728 36,061 31,491 
No. of atoms  6064 6324 5935 
 Protein atoms  5788 6149 5794 
  Metals/ligand atoms  4/-- 4/20 4/20 
  Water atoms  272 151 117 
Rwork/Rfree
c  19.1/22.1 16.5/20.7 17.9/21.9 
Average B-factors (Å2)     
  Overall  54.5 54.5 63.3 
  Protein  55.1 55.7 66.2 
  Metals/Ligand  54.9/-- 38.6/57.8 51.1/78.7 
  Water  59.0 56.3 63.5 
R.m.s. deviations     
  Bond length (Å)  0.012 0.013 0.013 
  Bond angles (o)  1.294 1.436 1.472  
MolProbity score  1.93d  2.09e  2.28f  
Ramachandran favored (%)  96.69 96.20 96.43 
Ramachandran allowed (%)  3.31 3.80 3.57 
Ramachandran outliers (%)  0.00 0.00 0.00 
aValues in parentheses are for the highest-resolution shell. 
bBefore and after density modification in SHARP. 
cRwork =  Fo  - Fc  /   Fo ; Rfree
 =   T Fo  - Fc  /  T Fo , where T is a randomly chosen set of reflections consisting of 5% 
of the total reflections. 
d89th percentile for 1.99-2.49 Å structures. 
e97th percentile for 2.42-2.92 Å structures. 








SeMet-SpHCS crystal at the 23-ID-B beamline. The detector distance was set to 225 mm 
and 120 degrees of data were collect at 0.5o of oscillation with an exposure time of 3 
seconds at a wavelength of 0.97930 Å. 
Data sets for SpHCS in complex with the substrate 2-OG were collected at the 
21-ID-G beamline of Life Sciences-Collaborative Access Team (LS-CAT). The open 
loop complex (120o of data at 0.5o oscillation) was collect at a wavelength of 0.9782 Å 
with a detector distance of 320 mm and an exposure time of 3 seconds. Data (150o at 0.5o 
oscillation) for the closed loop complex 150o of data at 0.5o oscillation collected for the 
closed loop complex at a wavelength of 0.97856 Å with a detector distance of 300 mm 
and an exposure time of 9 seconds. Both the 2-OG open and closed data sets were 
processed and scaled in HKL2000 (21).  
 
Model Building and Refinement 
The partial model built by autoSHARP (23) using the SAD phases and data from 
the SeMet-SpHCS crystal was completed by alternating between refinement using CNS 
(24, 25) and manual building in the program Coot (26). The initial model consisted of a 
monomer in which the main chain of 350 out of 418 residues was built. This model was 
then used for molecular replacement with the high resolution SeMet SpHCS data set in 
MOLREP (27)  with the programs Coot (26) and REFMAC (28) used for model building 
and refinement, respectively. The R-factors remained high during refinement in the 
higher symmetry space group P6222 because the crystallographic two-fold axis is forced 
to coincide with the pseudo-symmetry of the molecular two-fold axis of the dimer, 
masking subtle differences between the two monomers. This problem was resolved by 
refining in the lower space group P62 in which the entire homodimer was refined, 
allowing for minor variations in the conformation of each monomer. In later stages of 
refinement, residues with alternative conformations were modeled, TLS refinement (29) 
was applied and water molecules were added. The SpHCS 2-OG complexes were built 
and refined similarly to the high resolution SeMet SpHCS data set. The final SeMet-
SpHCS structure has Rworking and Rfree values of 19.1% and 22.1% respectively, while the 
final Rwork and Rfree values for the 2-OG open lid and the 2-OG closed lid structures were 
17.9% and 21.9% and 16.5% and 20.7% respectively (Table 2.2). No residues in any of 
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the structures were found in the disallowed regions of the Ramachandran plot as 
determined by MolProbity (30). Simulated annealing omits maps for 2-OG were 
calculated in CNS (24, 25). 
 
Kinetic Studies Using a Fluorescent HCS Assay 
 The fluorescence assay used to determine the steady state kinetic parameters of 
SpHCS and SpHCS mutants was adapted from previous work (31). Instead of using the 
fluorescent dye CPM [7-diethylamino-3-(4-maleimidylphenyl)-4-methylcoumarin], 
ThioStar was used (32) (Scheme 2.1). HCS assays were carried out in triplicate at room 
temperature in 100mM HEPES, pH 7.5 with potassium hydroxide. Before adding to the 
reaction mixture, AcCoA stocks were diluted 2:1 in 1 M HEPES, pH 7.5 to bring the pH 
of the solution to 5. To determine KM and kcat values for AcCoA, the 2-OG concentration 
was held at a saturating concentration of 5 mM to 200 mM, and the AcCoA concentration 
was varied from 0-400 μM. To determine KM and kcat values for 2-OG, the AcCoA 
concentration was held at a saturating concentration of 200 μM or 400 μM and the 2-OG 
concentration was varied from 0-200 mM. The enzyme concentration used in the assays 
was 10-100 nM. Assays were initiated with the addition of enzyme into a 220 μL reaction 
mixture and 50 μL aliquots were quenched at 0, 1, 2 and 3 minutes in 50 μL DMSO 
dispensed into individual wells of a black round bottom 96-well polypropylene plate 
(Corning). After completing the assay, 100 μL of 25 μM ThioStar was added to each well 
and allowed to react in the dark for 10 min. The plate was then read on a Genios Pro 
(Tecan) using emission and excitation filters at 400 nM and 510 nM at 25 oC with a gain 
setting of 30. Standard curves were measured in duplicate with each assay using 0-10 μM 
CoA in 100 mM HEPES, pH 7.5. Additionally, to correct for the increased fluorescence 
of the ThioStar dye with increasing concentrations of 2-OG over 2 mM, CoA standard 
curves were performed at every 2-OG concentration above 2 mM used in each assay. 
 Fluorescence acetyltransferase data was analyzed in Excel (Microsoft) by first 
converting fluorescence values to CoA concentrations by using the CoA standard curves. 
Initial velocities ( o) were determined by fitting a least squares linear fit to CoA 
concentration versus time for each substrate concentration assay.  Initial velocities were 




Scheme 2.1 HCS fluorescence assay. The CoA-SH generated in the HCS reactions is quantified by reacting with the sulfhydryl-
sensitive fluorophore Thiostar, which produces a thiol adduct that fluoresces strongly at 513 nM when excited at 384 nM. 
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equation (Eq. 1) in SigmaPlot (Systat Software) or Prism (GraphPad Software) to 
determine KM and kcat values. 
Eq 1: vo = kcat[Et][S]/([S] + KM) 
 
Circular Dichroism Spectroscopy of Inactive SpHCS Mutants 
 To confirm proper folding of the inactive SpHCS mutants circular dichroism was 
measured using a J-715 spectropolarimeter (Jasco) at room temperature in a 1 mm 
pathlength cell.  Enzyme was diluted to 0.1 mg/mL in 50 mM sodium phosphate, pH 7.5 
and scans were taken at 100 nm/ second at a bandwidth of 1 nM and response time of 
1 second. Each spectrum represents the average of 20 consecutive scans, which were 
corrected for baseline and converted to mean residue ellipiticity. 
 
In vivo Cell Growth Assay for HCS Activity 
Yeast strain LPY 11411 (MATa ade2-1 can1-100 his3-11,15 leu2-3,112 trp1 
ura3-1 rDNA::ADE2CAN1 lys20 ::KanMX  lys21 ::NATMX4) was transformed using 
lithium acetate method with empty 2 m URA3 vector pRS202 (pLP1402), pRS202 
containing LYS20 (pLP1412), pRS426 containing lys4+ under the control of the 
S. cerevisiae LYS20 promoter (pLP2211), or pLP2211 containing point mutations of 
lys4
+. Yeast cells were grown on synthetic complete medium lacking uracil or uracil and 
lysine according to standard procedures (33). Western blot analysis demonstrated that the 





Purification and Structure Determination of SpHCS 
 We observed SpHCS structures bound to two different divalent metals. Analysis 
of synchatron radiation x-ray fluorescence scans detected Co(II) in the SeMet derivatized 
crystals, which was most likely incorporated into the protein from the Co(II) IMAC 
purification steps. The structures of the Zn(II) bound SpHCS/2-OG closed lid complex 
and the Co(II) bound SpHCS/2-OG open lid complex were solved by treating the Co(II) 
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IMAC purified enzyme with EDTA prior to gel filtration followed by the addition of 
2 mM Zn(II) or Co(II), respectively during crystallization. Additionally, because HCS 
has been reported to be a Zn(II) dependent enzymes, SpHCS and its mutants were 
purified on a Zn(II) IMAC column for kinetic analysis. Both the EDTA treated Co(II) 
IMAC and Zn(II) IMAC purified SpHCS appeared to elute as a dimer at ~110 kDa on a 
superdex 200 gel filtration column and were judged to be essentially pure by SDS-PAGE 
(Figure 2.1). To verify the metal content of WT SpHCS used in crystallization trials and 
kinetic studies, we analyzed the enzyme using ICP-HRMS. SpHCS purified on a Zn(II) 
IMAC column had a Zn(II) content of 87 ± 5 %, whereas SpHCS purified on a Co(II) 
IMAC column and treated with EDTA retained only 8.4  ± 0.4  % Co(II). 
The crystal structure of full-length (residues 1-418) SpHCS was solved by 
selenomethionine SAD phasing to 2.7 Å resolution in space group P6222 (Table 2.2). The 
partially refined model of the SpHCS monomer was used in molecular replacement to 
determine the high resolution (2.24 Å) SeMet-SpHCS structure (PDB 3IVS). During 
refinement of this structure, the R-factors remained high, and it was discovered that 
SpHCS is not a perfect homodimer. Refinement in the lower symmetry space group P62 
let us refine each monomer separately, which allowed for small differences in amino acid 
conformations between the two monomers. The SeMet-SpHCS dimer was then used as a 
molecular replacement model to solve the 2-OG bound complex structures. While 
screening for crystals of the SpHCS/2-OG complex, we discovered two different 
conformations (open and closed) of the lid motif (residues 320-333) that functions to gate 
access to the active site of SpHCS. In the closed lid complex (2.67 Å) (PDB 3IVT), clear 
electron density is seen for the lid motif, which obstructs the entrance of the active site. In 
contrast, electron density for the lid motif is missing in the open lid complex (2.72 Å) 
(PDB 3IVU) leaving the active site solvent exposed.    
 
Crystal Structure of SpHCS 
 SpHCS forms a domain-swapped (34) homodimer within the asymmetric unit of 
space group P62 with a 46.7 kDa monomer being composed of two domains: an 
N-terminal catalytic domain and a C-terminal domain of mixed -helical and -sheet 














Figure 2.1 Purification of SpHCS. (A) Superdex 200 gel filtration chromatogram of 
SpHCS purified on a Zn(II) IMAC column (solid lined) and Co(II) Talon column 
followed by treatment with EDTA (dashed line). Molecular weight values for gel 
filtration standards are also depicted and demonstrate that SpHCS appears to elute as a 
dimer. (B) SDS-PAGE gels of the peak fractions from the Superdex 200 purifications of 
SpHCS (Zn(II) on the top and Co(II) treated with EDTA on the bottom). SpHCS migrates 
at approximately 50 kDa corresponding with the calculated molecular weight of the 











Figure 2.2  Crystal structure of SpHCS. (A) Ribbon diagram of the SpHCS homodimer bound to 2-OG (closed lid motif) with the 
N-terminal domain, C-terminal subdomain I, and C-terminal subdomain II of monomer A depicted in red, orange, and yellow, 
respectively, and of monomer B depicted in green, blue, and violet, respectively. The Zn(II) atom is modeled as a dark gray sphere 
and the bound 2-OG is rendered as sticks with yellow carbon atoms. (B) Ribbon diagram of the secondary structure of a monomer of 
SpHCS in complex with 2-OG with the secondary structure assigned following standard nomenclature for TIM barrel enzymes. The 
secondary structure is colored to distinguish between the N-terminal domain, C-terminal subdomain I, and C-terminal subdomain II. 
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extension (residues 1-34), with electron density only being present in the SpHCS/2-OG 
complexes and a canonical ( / )8 TIM barrel (residues 35-300). The N-terminal 
extension is composed of a short -strand ( 0) followed by a 310 helix (3101) in the 
SpHCS/2-OG complexes, however the extension preceding the 310 helix is disordered in 
the free enzyme. Within the canonical ( / )8 TIM barrel are additional secondary 
structural elements. Several short 310 helices (3102-3104) are present throughout the /  
fold. Additionally, a 310 helix followed by -sheet hairpin ( 4.1 and 4.1) forms between 
4 and 4 in the SpHCS/2-OG complexes, whereas in the SpHCS free enzyme, this 
region remains disordered (see below). At the C-terminus of the N-terminal domain, two 
-helices ( 9 and 10) pack against helices 8 and 1 of the TIM barrel, respectively. 
 The C-terminal domain consists of two subdomains (Figure 2.2B).  Subdomain I 
(residues 301-350) is of mixed topology and is composed of a short anti-parallel -sheet 
( 9- 10) followed by a second parallel -sheet ( 11- 12), with the two -strands 
separated by three 310 helices (3105-3107). In the SpHCS free enzyme and closed lid 2-OG 
complex, 3105 and 3106 form the lid motif that prevents access to the active within the 
TIM barrel. Subdomain II (residues 351-405) forms a three-helix bundle ( 11- 13), with 
the residues following 13 (406-418) being disordered in all of the SpHCS structures. 
Both the N-terminal catalytic domain and C-terminal domain contribute to the 
dimer interface and act to stabilize the domain swapped homodimer (Figure 2.2A), which 
is assumed to be the biological unit based on the structure and elution size during 
purification (Figure 2.1). Dimerization buries an extensive area of ~5900 Å2 per 
monomer, representing ~41 % of the total monomer surface. A large percentage of the 
total buried surface area is formed by the dimerization of the TIM barrel domains through 
interactions between 6- 10 helices of each monomer (Figure 2.2). The remainder of the 
interaction between the two monomers is formed by domain swapping of the N-terminal 
extension and the C-terminal domain. In the SpHCS/2-OG complexes, 0 in the 
N-terminal extension forms an anti-parallel -sheet with 4.1 of the -harpin between 4 
and 4, whereas these regions are disordered in the SpHCS free enzyme. 
 The C-terminal domain also plays an important role in stabilizing the domain-
swapped homodimer. Deletion of this region (residues 301-418) results in insoluble 
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protein, demonstrating the importance of this domain in maintaining the quaternary 
structure of SpHCS (data not shown). Both subdomain I and II of the C-terminal domain 
participate in dimerization. The two -sheets along with the 3105 and 3106 helices in that 
make up the lid motif that make up subdomain I contact the neighboring monomer 
(Figure 2.2). However, in the open SpHCS/2-OG helices 3105 and 3106 are disordered, 
and this interaction is absent. The three helix bundle in subdomain II also contributes to 
the dimer interface with 12 and 13 packing against their counterparts in the adjacent 
monomer. 
 
Structural Comparison of SpHCS and -IPMS 
 After determining the structure of SpHCS, we sought to identify structural 
homologs of the enzyme by searching the Protein Data Bank using the 3D structure 
comparison server Dali (35). Using a full length SpHCS monomer, many structural 
matches were identified by Dali. However most of the structures were matches simply 
because of the commonality of the TIM barrel protein fold. The TIM barrel enzymes 
3-hydroxy-3-methylglutaryl-CoA lyase (36), the aldolase-dehydrogenase DmpG/DmpF 
(37), and M. tuberculosis -IPMS (14) shared the highest homology with SpHCS. The 
latter enzyme was identified as the top hit (Z-score 31.1), consistent with the predicted 
structural homology between SpHCS and -IPMS and the analogous reactions catalyzed 
by these enzymes. The TIM barrel domains of -IPMS (residues 73-357) and SpHCS 
(residues 36-298) align extremely well with a root mean square deviation (R.M.S.D.) in 
the main chain positions of 1.38 Å (Figure 2.3).  The active site residues that coordinate 
to the divalent metal and that are involved in substrate binding and catalysis are also 
structurally homologous between the two enzymes (see below). There are a few 
differences in the fold of the TIM barrel between the enzymes nevertheless; SpHCS has a 
310-helix following 2 and -hairpin, which are both absent in -IPMS.   
In contrast to the TIM barrel catalytic domain, the C-terminal domain of SpHCS 
shares limited homology to the linker domain of -IPMS. Subdomain I of SpHCS and 
-IPMS are structurally similar with the exception of helices 3105 and 3106 of SpHCS 











Figure 2.3 SpHCS superimposed with M. tuberculosis -IMPS. A monomer of 
SpHCS (blue) in complex with 2-OG and overlaid with a monomer of -IPMS (gold) 
bound to 2-OIV. Coordination of the Zn(II) metal site in SpHCS and in -IPMS is 
depicted as dashed orange and blue lines, respectively, while 2-OG and 2-OIV are 









subdomain II of SpHCS and -IPMS are both composed of three helix-bundles, they are 
oriented differently in space relative to the TIM barrel. However, the largest difference 
between the two structures in the presence of a  fold regulatory domain at the 
C-terminus of -IPMS that is absence in SpHCS. In -IPMS, the regulatory module 
functions to allosterically bind the feedback inhibitor leucine. In SpHCS, feedback 
inhibition by lysine has been reported to be competitive versus the substrate 2-OG, 
suggesting that lysine binds within the active site (38, 39). Lack of this regulatory domain 
in SpHCS indicates that the two enzymes may utilize distinct regulatory mechanisms for 
feedback inhibition (see Chapter 3). 
 
Active Site and 2-OG Binding 
 The active site of SpHCS is located at the C-terminal end of each ( / )8 in the 
interior of the TIM barrel (Figure 2.2B) and is identifiable by the presence of a divalent 
metal. In the structures reported here, the divalent metal cation is either Co(II) or Zn(II), 
(Table 2.2) which coordinates in an octahedral geometry to the side chains of Glu44, 
His224 and His226 is SpHCS, to the C1 carboxylate and the 2-oxo carbonyl of 2-OG; 
and to a water molecule (Figure 2.4A). 2-OG is further stabilized through a network of 
hydrogen bonds and salt bridge interactions with the protein.  The C1 carboxylate of 
2-OG hydrogen bonds to the hydroxyl group of Thr197 while the 2-oxo group forms a 
hydrogen bond with the guanidinium group of Arg43. The C5 carboxylate group of 2-OG 
also engages in several hydrogen bonds with the side chains of residues His103, Arg163 
and Ser165 of SpHCS.  The active sites and substrate binding orientation of SpHCS and 
-IPMS are analogous, with the exception of the hydrophobic interaction the methyl 
groups of 2-OIV with Leu143 within the TIM barrel (Figure 2.4).  
 Upon 2-OG binding, a conformational change takes place within the catalytic 
domain of SpHCS.  Superimposition of the active sites of the SpHCS free enzyme and 
2-OG closed complex shows that the carboxylate groups of Asp123 and Glu222 rotate 
away from the center of the barrel to make room for the C5 carboxylate of 2-OG while 
Arg43, His103, Arg163 and Ser165 rotate inwards to form hydrogen bonds or salt bridge 
interactions with the substrate (Figure 2.5). This reorientation appears to coincide with 






Figure 2.4 Active sites of SpHCS and -IPMS. (A) Active site of SpHCS (closed lid conformation; blue carbon atoms) in complex 
with 2-OG (yellow carbons) and Zn(II) (blue). Orange and yellow dashes represent coordination of the Zn(II) ion and hydrogen 
bonding to 2-OG, respectively. (B) Active site of -IPMS (gold carbons) in complex with 2-OIV (magenta carbons) and Zn(II) 

















Figure 2.5 Stereoview of the active site of SpHCs 2-OG closed lid complex and 
SpHCS free enzyme. The SpHCS 2-OG closed lid complex (rendered as in figure 2.4) 
overlaid with the SpHCS apoenzyme (gray carbons). The Zn(II) ion and water molecules 
are represented as gray and red spheres, respectively.  Electron density of the Fo-Fc 
simulated annealing omit map (contoured at 2.5 ) corresponding to the 2-OG in the 


















the catalytic domains of the free enzyme and 2-OG complex are modest with a R.M.S.D 
value of 1.25 Å for all aligned atoms, structural changes do occur in the linker between 
4 and 4. This region is disordered in the free enzyme, however upon 2-OG binding, 
the linker becomes ordered and forms the 3104 helix and the 4.1- 4.2 hairpin.  
Additionally, the first turn of helix 4 is unwound and the helix is pushed outward to 
accommodate the formation of the -haripin. The formation of this region contributes to 
the ordering of the N-terminal extension with 0 in the N-terminal extension forming a 
-sheet with the -hairpin (Figure 2.6).   
 
Kinetic Analysis of 2-OG Binding Mutants 
To investigate the structural basis for the changes that occur upon 2-OG binding, 
we analyzed the residues involved in 2-OG binding. Steady state kinetic analysis of 
Zn(II)-bound SpHCS yielded a kcat value of ~300 per min and KM values for AcCoA and 
2-OG of 10.7 ± 0.6 μM and 0.159 ± 0.015 mM, respectively (Figure 2.7 and Table 2.3). 
These values are comparable to those reported for other HCSs, including ScHCS Lys20 
and TtHCS (kcat = 63-92 min
-1, KM(2-OG) = 0.044-0.140 mM and KM (AcCoA) = 32-42 μM) 
(15, 40). We next measured the steady state kinetic parameters of conservative and 
alanine mutations of the active site residues that interact with the 2-OG (Figure 2.4). In 
addition, to demonstrate proper folding of inactive SpHCS mutants, circular dichroism 
spectra were taken of WT and inactive mutants (Figure 2.8). The spectra of the inactive 
SpHCS mutants were nearly superimposible with WT SpHCS illustrating that the loss of 
activity of these mutants is not due to misfolding. 
Mutation of Thr97, which forms a hydrogen bond to the C1-carboxylate of 2-OG, 
to serine, resulted in a modest decrease in the catalytic efficiency (as defined by kcat/KM) 
compared to WT SpHCS due to a minor decrease in the turnover number. In contrast, a 
T197A substitution exhibited a 25 fold decrease in the kcat value, whereas the T197V 
mutation abolished activity (Table 2.3).  These results illustrate that the hydrogen bond 
between the Thr197 hydroxyl group and the C1-carboxylate group of 2-OG contributes to 
catalysis. Interactions between the 2-oxo carbonyl group of 2-OG are also important for 










Figure 2.6 Superimposition of SpHCS 2-OG closed lid complex and SpHCS free 
enzyme. SpHCS 2-OG closed lid complex is denoted in blue with the corresponding 
monomer in the SpHCS apoenzyme in gray. The secondary structural elements that 



















Figure 2.7 In vitro activity of SpHCS.  (A and B) Michaelis-Menten plot of the initial 
velocity versus AcCoA concentration with 2-OG held at 5 mM(A) and 2-OG 
concentration with AcCoA held at 200 mM (B) for the formation of homocitrate 
catalyzed by WT SpHCS. Data points are the average of triplicate measurements, and the 




















Table 2.3  Kinetic analysis of WT SpHCS and its active site mutants. 










 μM min-1 min-1 μM1 mM min-1 min-1 mM-1 
WT 10.7 ± 0.6a 299 ± 7 28.0 ± 1.7 0.159 ± 0.015 308 ± 4 1940 ± 190 
R43A N.A. N.A. N.A. N.A. N.A. N.A. 
R43K N.A. N.A. N.A. N.A. N.A. N.A. 
R43Q N.A. N.A. N.A. N.A. N.A. N.A. 
Q47A 57.6 ± 12.6 35.0 ± 0.1 0.608 ± 0.133 4.94 ± 1.28 33.5 ± 0.08 6.78 ± 1.76 
E74A N.A. N.A. N.A. N.A. N.A. N.A. 
E74Q 30.7 ± 3.0 44.5 ±1.4 1.45 ± 0.15 0.791 ± 0.081 46.7 ± 1.7 59.0 ± 6.3 
H103A 35.2 ± 5.7 20.0 ± 0.9 0.568 ± 0.096 3.56 ± 0.61 18.2 ± 0.7 5.11 ± 0.35 
R163A N.A. N.A. N.A. N.A. N.A. N.A. 
R163K 146 ± 28b 33.9 ± 2.8b 0.232 ± 0.048 24.4 ± 4.3 26.1 ± 1.4c 1.07 ± 0.20c 
R163Q N.A. N.A. N.A. N.A. N.A. N.A. 
S165A 18.6 ± 2.3 158 ± 5.8 8.5 ± 1.0 0.536 ± 0.070 160 ± 6 298 ± 40 
E167A N.A. N.A. N.A. N.A. N.A. N.A. 
E167Q N.A. N.A. N.A. N.A. N.A. N.A. 
T197A 7.44 ± 0.35 10.7 ± 0.1 1.44 ± 0.07 0.341 ± 0.083 11.9 ± 0.7 34.9 ± 8.7 
T197S 6.00 ± 0.59 124 ± 3 20.6 ± 2.1 0.229 ± 0.034 137 ± 4 597 ± 91 
T197V N.A. N.A. N.A. N.A. N.A. N.A. 
Y332A N.A. N.A. N.A. N.A. N.A. N.A. 
Y332F 40.0 ± 4.6 23.5 ± 0.8 0.59 ± 0.07 0.461 ± 0.070 20.7 ± 0.79 44.9 ± 6.9 
N.A. No detectable activity measured using 100 nM mutant assayed with 200 μM AcCoA and 50 mM 2-OG. 
aErrors are reported as the error in curve fitting. 
bValues are approximate because the mutant is inhibited at AcCoA concentrations above 400 μM so saturation could 
not be achieved. 






















































abolished activity suggesting the hydrogen bond between the 2-oxo atom of 2-OG and 
the guanidinium group of Arg43 is critical for catalysis. 
 Residues that interact with the C5 carboxylate group of 2-OG are also essential 
for substrate binding (Figure 2.4). Mutagenesis of Arg163 to alaine of glutamaine 
completely arrested activity, whereas H103A and R163K substitutions severally impaired 
catalytic efficiency. Mutation of His103 to alanine resulted in a reduced kcat/KM >370 fold 
compared to WT SpHCS by increasing KM value for 2-OG (>20 fold) and reducing the 
turnover rate (>16 fold), while the R163K substitution caused a 200 fold reduction in 
catalytic efficiency by raising the KM of 2-OG by 150 fold.  Unexpectedly, the R163K 
mutation also increased the KM for AcCoA by ~13 fold. This could be caused by the 
severely diminished affinity for 2-OG, which binds before AcCoA in the ordered Bi-Bi 
reaction mechanism (9). In contrast, an alanine mutation of Ser165 resulted in a modest 
decrease in the catalytic efficiency compared to WT SpHCS (Table 2.3). Together, these 
results illustrate that the residues that interact with the C5 carboxylate group of 2-OG are 
vital for proper substrate binding within the active site. 
 
In Vivo Analysis of 2-OG Binding Mutants 
To evaluate the effects these SpHCS mutations in vivo yeast growth assays were 
performed. For these studies, the two genes encoding the ScHCS homologs LYS20 and 
LYS21 were deleted in S. cerevisiae to generate a lys20  lys21  double deletion strain. 
This strain exhibits lysine auxotrophy, but displays robust growth on lysine-
supplemented media (Figure 2.9).  Next, we tested if expression of SpHCS encoded by 
lys4
+, which is >80 % identical to ScCHS Lys20 and Lys21 (Figure 2.10), could rescue 
lysine auxotrophy by transforming the double deletion strain with a vector of the lys4+ 
gene under the control of the LYS20 promoter. Transformants expressing either LYS20 or 
lys4
+ were able to restore growth on media lacking lysine, whereas those transformed 
with vector alone were inviable on lys- media, demonstrating that lys4+ complements the 
loss of ScHCS Lys20 and Lys21 (Figure 2.9). Finally we determined whether SpHCS 
2-OG binding mutants had the ability to complement growth on lysine deficient media. 
As controls, we first demonstrated that the 2-OG binding mutants expressed at 


























     
 
      
Figure 2.10 Sequence alignment of HCSs with the secondary structure of SpHCS 2-OG closed lid complex.  The secondary 
structure of the TIM barrel, C-terminal subdomain I and C-terminal subdomain II are depicted in red, orange and yellow 
respectively.  Residues involved in metal coordination, 2-OG binding, and binding to the acetyl oxygen atom of AcCoA are 
highlighted in red and yellow and blue respectively while residues that act as the catalytic acid and base along with the lid loop motif 
are highlighted in magenta and light blue respectively. 
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mutants behave in a recessive manner when co-expressed in WT cells (data not shown).  
All of the 2-OG binding mutations, with the exception of the SpHCS conservative T197S 
mutant, and to a lesser extent the S165A mutant failed to grow on lysine deficient media 
(Figure 2.9). These results are in agreement with our in vitro kinetic studies where the 
T197S and S165A mutants only exhibited a three-fold and seven-fold reductions in 
catalytic efficiency, respectively compared to WT SpHCS (Table 2). In contrast, the other 
2-OG binding mutants had more severe defects in catalytic efficiency and failed to 
restore growth on media lacking lysine. 
 
Putative Functions of the Lid Motif 
 An interesting finding that arose during our studies of the SpHCS structures is the 
presence of a lid motif that encloses over the active site of the enzyme. The lid motif is a 
conserved feature of fungal HCSs (Figure 2.10) but is absent in the structurally related -
IPMS. The lid motif is made up of the 3105-3106 helices in subdomain I of the C-terminal 
domain, and when closed participates in domain-swapping by completely burying the 
substrate 2-OG in the active site of the neighboring monomer.  In contrast, the motif is 
disordered in the SpHCS/2-OG open lid complex, which leaves the active site solvent 
exposed permitting free exchange of the substrate 2-OG and water molecules (Figure 
2.11A). Alignment of the active sites of the open and closed 2-OG SpHCS complexes 
shows that the lid’s disorder does not cause large changes in the residues that coordinate 
2-OG (Figure 2.11B). This is consistent with the observation that the lid motif does not 
form direct contacts with 2-OG. Instead several water molecules are lodged between 
2-OG and the lid motif, which are presumably trapped during lid closure.   
Comparison of the lid loop motif in the open and closed structures reveals that the 
lid closure is maintained by a network of hydrogen bonds in the neighboring monomer 
with the hydroxyl group of Y332  along with the backbone amide nitrogens of Leu326  
and Ala327  (the ( ) denotes residues in the lid motif of the neighboring monomer) 
forming interactions with Glu167 (Figure 2.12A). In the open lid complex residues 
323 -329  in the lid motif are disordered, resulting in the loss of the hydrogen bond 




Figure 2.11 The SpHCS/2-OG open lid complex. (A) Structural superimposition of the SpHCS/2-OG complexes with the open lid 
motif (monomer A is green and monomer B is pale green) and the closed lid motif (monomer A is blue and monomer B is cyan). The 
2-OG and Zn(II) ion of the closed lid structure are depicted in yellow carbons and gray, respectively. (B) Stereoview of the active 
site of SpHCS/2-OG open lid complex (green carbon atoms with 2-OG rendered with orange carbons) overlaid with the SpHCS/2-
OG closed lid complex (blue carbons). Electron density for the Fo-Fc simulated annealing omit map (contoured at 2.0 ) 
corresponding to the 2-OG in the open lid complex is shown in cyan. The orange and yellow dashes represent coordination of the 
Zn(II) ion and hydrogen bonding to 2-OG, respectively. 
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Figure 2.12 The lid motif of SpHCS (A, B) Comparisons of the active site and lid motif of the SpHCS/2-OG open and closed lid 
complexes. Monomer A (blue carbons) and B (cyan carbons) of the closed lid complex are depicted with the Zn(II) ion (gray) and 2-
OG (yellow carbons) (A), whereas  monomer A (green carbons) and B (light green carbons) of the open lid complex are illustrated 
with the Co(II) ion (pink) and 2-OG (orange carbons) (D). Dashed lines denoted the coordination of the metal ion (orange), hydrogen 
bonding to 2-OG (yellow), and hydrogen bonding within the lid motif (red). Residues in the lid motif that lack interpretable side 
chain electron density are modeled as alanines, while the side chain of Tyr332 in the open lid complex (B) is modeled with an 
occupancy of 0.5. (C) Model of a ternary complex of SpHCS bound to 2-OG (orange carbons) and AcCoA (violet carbons).  The lid 
motif of the SpHCS/2-OG closed lid complex (cyan) is superimposed on the gray surface of the SpHCS/2-OG open lid complex. 
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open complex is only partially ordered and is modeled with occupancy of 0.5. The 
hydroxyl group of Tyr332  still maintains its hydrogen bind with the side chain of 
Glu167, but these residues adopt an alternative conformation over the 2-OG binding site 
presumably orienting the carboxyl group of Glu167 for base catalysis of the acetyl group 
of AcCoA (Figure 2.12B) (see below). 
 In addition to gating access to 2-OG, the lid motif may also function to regulate 
AcCoA binding to SpHCS. We were unsuccessful in obtaining an SpHCS ternary 
complex with 2-OG and either CoA or acetonyl-CoA or with the inactive E167Q mutant 
with 2-OG and AcCoA, therefore we modeled a SpHCS Michaelis complex with 2-OG 
and AcCoA based on the superimposition of the coordinates of the 2-OG open complex 
and the previously reported model of the -IPMS/2-OIV/AcCoA ternary complex (14). 
The model shows a groove in the enzyme’s surface adjacent to the active site where the 
pantetheine arm of AcCoA could bind (Figure 2.12C). Superimposition of the AcCoA-
bound model with the closed SpHCS/2-OG complex reveals that the lid motif occupies 
the same space as the modeled AcCoA, implying that the lid motif must be inherently 
flexible to accommodate AcCoA binding. Together, these findings imply that the lid 
motif serves as the gatekeeper to regulate substrate binding to SpHCS. 
 
Catalytic Reaction Mechanism 
 The catalytic mechanism of HCS has been proposed to proceed via a mixed 
Claisen condensation reaction (10) (Scheme 2.2). In this reaction mechanism, there is 
first an ordered binding of the substrate 2-OG followed by AcCoA, which is consistent 
with kinetic studies of ScHCS Lys20, and the spatial arrangement of the substrates in the 
modeled ternary complex. A general base then abstracts a proton from the methyl group 
of AcCoA to generate an enol (or enolate). The enol/enolate nucleophile then attacks the 
C2 carbonyl carbon of 2-OG to form the alkoxide of homocitryl-CoA, which is 
protonated by a catalytic acid to generate homocitryl-CoA. The water molecule bound to 
the active site divalent metal ion has been proposed to subsequently hydrolyzes the 
thioester bond homocitryl-CoA yielding the products CoA and homocitrate. A similar 
reaction mechanism is thought to occur for -IPMS (14). 
















Scheme 2.2 Catalytic mechanism of SpHCS. The 2-OG and AcCoA substrates are 


















The SpHCS/2-OG/AcCoA ternary complex model gives insights into the residues 
implicated in homocitrate synthesis (Figure 2.12). The AcCoA is arranged in the active  
site so that its acetyl group is located near the C2 carbon of 2-OG where nucleophilic 
attack by the enolate occurs.  Many residues that are conserved in HCS (Figure 2.10) and 
that are structurally analogous in -IPMS surround the AcCoA acetyl group, implicating 
them in catalysis. In the SpHCS/2-OG/AcCoA ternary model, the carbonyl oxygen of the 
acetyl group of AcCoA is within hydrogen bond distance to the amide side chain of 
Gln47 and to the guaidinium group of Arg43, which also hydrogen bonds to 2-OG. A 
similar model of AcCoA binding has been proposed for -IPMS where the positively 
charged side chain for the corresponding Arg80 stabilized both AcCoA and 2-OIV (14). 
The hydrogen bonds to Gln47 and Arg43 in SpHCS also stabilize the enol tautomer of 
AcCoA, promoting nucleophilic attack of the C2 atom of 2-OG. In the modeled complex, 
the methyl group of AcCoA is located ~3 Å from the carboxylate group of Glu167, which 
is proposed to function as the catalytic base that deprotonates the methyl group of 
AcCoA. The orientation of the side chain of Glu167 is stabilized by hydrogen bonding to 
the hydroxyl group of Tyr332  in the adjacent monomer. This glutamate-tyrosine dyad is 
conserved in HCSs (Figure 2.10) and in -IPMS (residues E218-Y410 ) (Figure 2.4B) 
and has been proposed to position the glutamate’s carboxylate group for base catalysis in 
both enzymes (14, 15). Following enolization of AcCoA, the enol/enolate nucleophile 
attacks the C2 carbonyl carbon of 2-OG to form homocitryl-CoA through the formation 
of a carbon-carbon bond (Scheme 2.3 and Figure 2.13).  The C2 center becomes 
electrophilic due to the polarization of the 2-oxo atom of 2-OG through its coordination 
to the metal ion and hydrogen bond to the guanidinium cation of Arg43. In the SpHCS 
structures, the conformation of the Arg43 side chain is maintained through a hydrogen 
bond to Gln47 and salt-bridge interaction with Glu74 (Figure 2.13). Arg43 and Glu74 of 
SpHCS are conserved in HCSs (Figure 2.10) and structurally invariant in -IPMS, 
suggesting a role for them in catalysis.  
 
In Vitro and In Vivo Activity of Residues Implicated in Catalysis 

















Figure 2.13 SpHCS ternary complex model. Stereoview of the active site of the 
modeled SpHCS ternary complex with 2-OG and the panetheine arm of AcCoA rendered 
as in Figure 2.11C. Dashed lines represent coordination of the Zn(II) ion (orange), 
hydrogen bonding to 2-OG (yellow), hydrogen bonding to the putative catalytic residues 
(blue) and the direction of the nucleophilic attack from the enolate tautomer of AcCoA to 

















the in vitro and in vivo activities of conservative and alanine catalytic mutations (Table 
2.3 and Figure 2.14). First, we examined the effects of mutations of the putative catalytic 
base Glu167, and the adjacent Tyr332  in SpHCS (Figure 2.13). Both alanine and 
glutamine substitutions of Glu167 abolish activity in vitro, which is consistent with the 
idea that this residue acts as the catalytic base in enolization of AcCoA. This also agrees 
with the >1000 fold decrease in kcat reported for alanine and glutamine mutations of the 
corresponding residues Glu155 in ScHCS Lys20 (15). Mutation of Tyr332 , which forms 
a hydrogen bond with Glu167, also disrupted activity. No detectable activity was 
observed for the Y332A mutation while the turnover rate of the Y332F mutation was 
reduced by ~13 fold with only modest increases in the KM values for each substrate 
compared to WT SpHCS. In vivo plate growth assays using the S. cerevisiae lys20  
lys21  deletion strain demonstrated that both the SpHCS Glu167 and Tyr332  mutations 
were unable to rescue growth on lys- media (Figure 2.14), consistent with the in vitro 
kinetic defects of these mutants. 
 We also examined the effects mutations of Arg43, Gln47 and Glu74 had on 
homocitrate production. As discussed previously, Arg43 mutations to alanine, glutamine 
and lysine abolished activity in vitro and in vivo (Table 2.3 and Figure 2.9), 
demonstrating that the guanidinium group of Arg43 is vital for catalysis. Substitutions of 
Gln47 and Glu74, which hydrogen bond to Arg43 also reduced enzymatic activity 
(Figure 2.14). An alanine substitution of Glu74 in SpHCS abrogated activity in vitro, 
while the E74Q mutation resulted in a moderate decrease in the turnover and slight 
increase in the KM values for 2-OG and AcCoA in comparison to WT enzyme (Table 
2.3). An alanine mutation of Q47 resulted in even more elevated (5 fold for AcCoA and 
30 fold for 2-OG) KM values. Substitution of the Gln47 side chain may have resulted in 
increased KM values by weakening hydrogen bonding to the acetyl group of AcCoA in 
the ternary complex and by perturbing the orientation of Arg43 which hydrogen bonds to 
2-OG. Like the SpHCS Glu167 and Tyr332 mutants the Arg43, Gln47 and Glu74 
mutations failed to grow on lysine deficient media when transformed into the double 
deletion strain (Figure 2.9 and 2.14), demonstrating the importance of these residues in 































Residues Implicated in Base Catalysis 
 The structures of SpHCS presented here yield new insights into the basis of 
substrate binding and catalytic mechanism of HCSs. Additionally, our results highlight 
the similarities and differences between HCSs and other enzymes that catalyze mixed 
Claisen condensation reactions including -IMPS, MS and CS. Recent studies have 
proposed that a glutamate-histidine dyad in -IPMS (Glu218-His279 ) and ScHCS Lys20 
(Glu155-His309 ) participates in base abstraction of the methyl group of AcCoA (14, 15).  
In -IPMS, the side chains of Glu218 and His-279  are close enough to deprotonate the 
acetyl group of AcCoA in the modeled IPMS/2-OIV/AcCoA ternary complex (14). A 
similar role has been proposed for Glu115-His309  in ScHCS Lys20 (15). However, the 
structure of SpHCS reveals that His321  (corresponding to His309  in ScHCS) is located 
in helix 3105 within the lid motif (Figure 2.10), which is disordered in one or the two 
monomers of the 2-OG open complex used to make the ternary model.  In monomer B of 
the 2-OG open complex, clear electron density is seen for His321 , however the side 
chain of this residue is located ~13 Å away from the Glu-167 carboxylate group. Similar 
distances between these two residues are also observed in the free enzyme and the 
SpHCS/2-OG open lid complex. Although this distance is too large to form a histidine-
glutamate dyad, upon AcCoA binding it is possible that a conformational change in the 
lid motif could take place that would bring the side chains of residues Glu167 and 
His321  close enough to act in base catalysis. Consistent with this model, a H321A 
mutation decreased the activity by more than 200-fold compared to WT SpHCS (data not 
shown) in agreement with His309 mutations that affect the activity of ScHCS Lys20 (15). 
Alternatively, mutations of residues within the lid motif, such as His321  and Tyr332 , 
might disrupt substrate binding by altering local dynamics in the conformation of the lid 
motif without directly affecting the chemical steps in catalysis. Further studies are needed 
to determine whether a histidine-glutamate dyad participates in base catalysis in HCS. 
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Residue Implicated in Acid Catalysis 
 There is a general consensus that the conserved glutamate residue is involved in 
base catalysis in HCS and -IPMS (14, 15), however the identity of the catalytic acid in 
the reaction mechanisms of these enzymes remains unknown (Scheme 2.2). Our 
structural and biochemical studies suggest that Arg43 may fulfill this role by protonating 
the alkoxide of homocitryl-CoA. Although it is unusual for an arginine guanididium 
cation to act as a proton donor due to its high pKA value, several lines of evidence 
support the role for Arg43 in acid catalysis. First, there are no other ionizable residues or 
solvent molecules in the active site of the ternary complex model that are located within a 
distance to the 2-oxo atom of 2-OG to function as catalytic acid, unless a large 
conformation change occurs within the TIM barrel upon AcCoA binding (Figure 2.13). 
Additionally, Arg43 is invariant in the HCS family (Figure 2.10) and mutation of this 
residue completely abolishes activity (Table 2), illustrating the importance of this residue 
in substrate binding and/or catalysis. Third, the pKA value of an alkoxide ion is greater 
than 12.5, favoring protonation by the guanidinium group of Arg43 (aqueous pKA = 
12.5).  Fourth, a recent review has described a role for arginine in acid-base catalysis for 
several enzyme reaction mechanisms (41). For example, in soluble fumarate reductase, an 
arginine residue (Arg402) has been reported to protonate fumarate to form succinate 
during flavin-dependent reduction (42). Finally, the close proximity of the divalent metal 
ion to the Arg43 guanidinium group (~5 Å) may contribute to reducing the residue’s pKA 
value promoting acid catalysis. Collectively, these observations suggest a role for Arg43 
as the proton donor, however it is also possible that an acid-catalyzed step is not required 
in the reaction mechanism of HCS. Instead, the alkoxide intermediate may remain 
deprotonated during the subsequent steps in catalysis, similar to the mechanism of E. coli 
malate synthase in which the arginine residue (Arg338) that hydrogen bonds to aldehyde 
oxygen of glycoxylate was shown not to participate in proton transfer (Figure 1.3) (12, 
13). Future studies are needed to determine whether the reaction mechanism of HCS 
occurs via an acid-catalyzed step, and if so, whether the structurally conserved arginine 
acts as the catalytic acid in protonation of the alkoxide intermediate. 
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Comparison of HCS with -IPMS and Citrate Synthase 
 Although the HCS and -IPMS are structurally similar and catalyze analogous 
reactions, the mechanisms by which their activities are regulated are distinct. Among the 
most noticeable differences are the relative accessibilities of their active sites. In -IPMS, 
the entrance of the TIM barrel is solvent-exposed, suggesting that the enzyme can 
accommodate the binding of the substrates 2-OIV and AcCoA within its active site 
(Figure 2.3). In contrast, the entrance of the TIM barrel in SpHCS is effectively blocked 
by the flexible lid motif that gates access of 2-OG to the active site and competes with 
AcCoA binding to the enzyme (Figure 2.11B and 2.11C).  The closed lid conformation is 
stabilized by hydrogen bonding to the carboxylate group of Glu167, illustrating its dual 
roles in catalysis and in regulating substrate access to the active site. The intrinsic 
flexibility of the lid motif may serve a regulatory function by interacting with factors that 
control its open or closed states, thus governing the rate of homocitrate synthesis and the 
metabolic flux through the AAA pathway. 
In contrast, the structural similarities along with the details of the catalytic 
mechanisms of HCS and -IPMS are distinct from those of citrate synthase, which 
catalyzes the Claisen condensation of oxaloacetate and AcCoA to yield citrate and CoA. 
Citrate synthase functions as a homodimer with each monomer composed of two domains 
that are predominately -helical, whereas HCS and -IPMS adopt a TIM barrel fold (14, 
43, 44). The active site of citrate synthase is located between the two domains of the each 
monomer with arginine and histidine residues forming hydrogen bonds and salt bridge 
interactions with the substrate oxaloacetate. This substrate binding mode is different from 
HCS in which 2-OG is bound within the TIM barrel through coordination to the divalent 
metal center and through basic and polar amino acids (Figure 2.4A). Furthermore, there 
are differences in the residues involved in acid-base catalysis in the Claisen 
condensations reactions catalyzed for each enzyme. In citrate synthase an aspartate 
residue (Asp375) functions the catalytic base in deprotonation of AcCoA to initiate the 
condensation reaction and a histidine residue (His320) acts as the catalytic acid to 
protonate the alkoxide intermediate of citryl-CoA (Figure 1.2) (11, 44). In contrast, our 
structural and functional studies of SpHCS suggest that Glu167 functions as the catalytic 
acid, whereas Arg43 may participate in acid catalysis. Additionally, there are major 
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differences in the conformational changes that occur upon substrate binding in citrate 
synthase and HCS. Citrate synthase can exist in an open and closed form with the binding 
of oxaloacetate inducing closure of the enzyme which then stimulation AcCoA binding 
and catalysis (43, 44). In HCS, a large-scale conformational change upon substrate 
binding does not take place. Instead the lid motif in HCS appears to function as a flexible 
gate that regulates substrate binding (Figure 2.11), and conformational changes in the 
TIM barrel are localized to the 4- 4 region where a -haripin forms upon 2-OG binding 
(Figure 2.6).  In summary, the structure and catalytic mechanisms of citrate synthase and 
HCS are quite different providing evidence for the molecular evolution of two different 
mechanisms for the catalysis of Claisen condensation reactions using two closely related 
2-oxo acid substrates. 
 
HCS as an Antifungal Target  
 The enzymes in the AAA pathway have been proposed as potential targets for 
antifungal inhibitors. HCS, in particular, represents an excellent target for inhibition 
because it catalyzes the first and committed step in the pathway, and also functions in 
controlling the metabolic flux through the pathway as it is feedback inhibited by L-lysine 
(8). The loss of activity exhibited by the majority of the lys4+ mutants in vivo further 
emphasizes the importance of HCS in maintaining fungal viability in lysine deficient 
conditions (Figure 2.8 and 2.14). Our structural and functional characterization of SpHCS 
provides a platform for developing selective inhibitors to HCS. The enzyme active site 
has a conserved divalent metal ion and a number of polar and charged residues with 
which small molecules may interact. Additionally, to maximize interactions with the 
active site and surrounding surface, bi-substrate analog inhibitors that mimic homocitryl-
CoA could be synthesized. However, efforts to rationally design inhibitors must account 
for the flexibility of the active site residues that bind 2-OG as well as the movement of 
the lid motif that regulates access to the active site. Small molecules that are rationally 
designed or identified in high-throughput screening may take advantage of the 
conformational flexibility of HCS to discover potent inhibitors that may act as lead 
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STRUCTURAL BASIS FOR L-LYSINE FEEDBACK INHIBITON OF 
HOMOCITRATE SYNTHASE
  
The AAA pathway in S. cerevisiae is highly regulated at both the levels of gene 
expression and enzyme activity (1). Regulation of enzyme activity is mediated 
predominantly through feedback inhibition of HCS by L-lysine, thus limiting the 
metabolic flux through the pathway.  This pathway is also regulated transcriptionally by 
two different mechanisms. Along with other amino biosynthesis pathways, enzymes in 
the second half of the AAA pathway respond to the general control of amino acid 
biosynthesis (2). Additionally, expression of several AAA pathway enzymes is 
specifically regulated by the transcriptional activator Lys14p in the presence of the 
pathway intermediate -aminoadipate semialdehyde (3). Conversely, six of the seven 
S. cerevisiae AAA pathway enzymes, including HCS were shown to be repressed by the 
end product L-lysine (4). However, L-lysine regulation of the five enzymes downstream 
of HCS has been attributed to a diminished production of -aminoadipate semialdehyde 
and inactivation of Lys14p due to a reduced metabolic flux caused specifically by lysine 
feedback inhibition of HCS (5, 6). This implicates feedback inhibition of HCS to be vital 
in the control of lysine biosynthesis at both the biochemical and transcriptional levels. 
 Lysine feedback inhibition of HCS has been observed in many fungal species that 
utilize the AAA pathway. Based on these studies two opposing models of inhibition have 
been proposed. Kinetic studies in ScHCS (7), PcHCS (8) and TtHCS (9) have 
demonstrated that L-lysine inhibition is competitive with the substrate 2-OG, suggesting 
that the amino acid binds within the enzyme’s active site. However, this model leads to a 
contradiction in understanding how both 2-OG, a dicarboxylic acid, and lysine, a basic 
amino acid can both be accommodated within the same site. Feedback inhibition of HCS 
by L-lysine has also been proposed to be allosteric with L-lysine inhibition of Y. lipolytica 
HCS exhibiting allosteric kinetics (10). Further evidence for an allosteric model arises 
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from studies in which ScHCS point mutants were found to be insensitive to lysine yet 
still maintain HCS activity suggesting 2-OG and lysine may not bind in the same site (6). 
Due to data supporting both these models, the mechanism of feedback inhibition of HCS 
has remained unresolved.  
 To elucidate the molecular basis for feedback regulation of HCS, we have 
determined the structure of SpHCS in a binary complex L-lysine and compare it to he 
structures of the free enzyme and binary complex with the substrate 2-OG (Chapter 2). 
The structure of SpHCS/L-lysine complex reveals that the inhibitor binds within the 
2-OG binding site at the center of the TIM barrel domain, in agreement with steady state 
kinetic analysis illustrating that the amino acid is a competitive inhibitor of 2-OG.  
Differential recognition of 2-OG and L-lysine is accomplished through a switch position 
within the active site in which acidic residues interact with the -ammonium group of 
L-lysine and basic residues coordinate the C5 carboxylate group of 2-OG. Steady state 
kinetic yeast growth assays of SpHCS mutants demonstrate that the acidic residues in the 
switch position are essential for L-lysine feedback inhibition in implicated in vitro and in 
vivo. Additionally, SpHCS mutations homologous to those reported for the L-lysine 
insensitive mutant in ScHCS also displayed a reduced sensitivity to L-lysine. Taken 
together these studies allow us to elucidate the mechanism of regulation of HCS by 
L-lysine feedback inhibition.  
 
MATERIALS AND METHODS 
 
Materials 
 DNA primers used for mutagenesis were synthesized by Integrated DNA 
Technologies. The sodium phosphate monobasic and potassium phosphate dibasic used 
in crystallization screens were purchased from Sigma at the highest quality available. 
Reagents used in the fluorescent HCS assay including the ThioStar dye (Luminos LLC), 
along with AcCoA and CoA purchased from Sigma were prepared as described in 
Chapter 2, whereas the L-lysine acetate, D-lysine and s-aminoethyl-L-cysteine (AEC) 
hydrochloride used in the inhibition studies were obtained at the highest grade from 
Sigma. All other materials used were of the highest grade available.  
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Mutagenesis and Purification of SpHCS Lysine Binding Mutants 
Mutants of SpHCS/pHIS2 and SpHCS/pLp2211 involved in feedback inhibition 
by lysine were made by designing complementary sets of primers (Table 3.1) and using 
site-directed mutagenesis following a modified QuikchangeTM mutagenesis kit protocol 
(Stratagene) as described in Chapter 2. Lysine binding mutants were overexpressed and 
purified identically to SpHCS purified for kinetic studies (Chapter 2) using a Zn(II) 
charged IMAC Sepharose  High Performance resin (GE Healthcare) column for the 
affinity purification.  
 
Crystallization of SpHCS in Complex with Lysine 
SpHCS enzyme used in crystallization trails was purified on Talon (Clontech) 
Co(II) affinity resin column as described in Chapter 2. The sodium and potassium 
phosphate condition used to crystallize SpHCS in complex with 2-OG (Chapter 2) was 
optimized and used to produce crystals of SpHCS in complex with L-lysine using the 
hanging drop vapor diffusion technique as described in Chapter 2. SpHCS crystals in 
complex with lysine were obtained in 1.2-1.5 M sodium and potassium phosphate (pH 
5.8-6.8) at 24 oC using 20 mg/mL EDTA treated SpHCS, 1 mM Zn(II) and 100 mM –
L-lysine. SpHCS/L-lysine crystals were harvested, cryo-protected in the crystallization 
condition containing 20% glycerol and flash frozen in liquid nitrogen. 
 
Data Collection, Model Building and Refinement 
 A data set of SpHCS in complex with the feedback inhibitor L-lysine to 2.38 Å 
(Table 3.2) was collected at the 21-ID-G beamline of LS-CAT at a wavelength of 
0.97856 Å and a detector distance of 300 mm. 150o of data was collect at an oscillation of 
0.5o with an exposure time of 4 s per frame. The data set was processed and scaled in 
HKL2000 (11) and the structure was solved using the high resolution (2.24 Å) SeMet-
SpHCS structure (PDB 3IVS) as a model for molecular replacement in MOLREP (12). 
Model building and refinement was performed similarly to the SpHCS 2-OG complexes 
(Chapter 2) using the programs Coot (13) and REFMAC (14). The final SpHCS/lysine 
structure had Rwork and Rfree values of 16.9% and 20.3%, respectively (Table 3.2). 



















Table 3.1 Primers used for SpHCS mutagenesis of residues involved in L-lysine 
feedback inhibition 
Mutation Primer 
D123N 5 - GAGACTGGAGTTGATGGTGTTAATGTTGTTATCGGAACTTCTC-3 a 
 
E222Q 5 -TCTCTTGTGATATTCAATGTCATTTTCACAATGACACTGGTATGGCTATTG-3  
 
R288K 5 -CCCACAAATACAAGCTTAACCAGTTAAAGGAGCTTGAAAACCTTGTCGC-3  
 
Q364R 5 -GCCATCAAATCTCGTGCTGAGCGGCTTAACCTTCATCTTACTGATGCC-3  
 
aForward primer is listed with reverse primer being the reverse complement of the 






















Table 3.2 Data collection and refinement statistics. 
 WT SpHCS/L-lysine complex 
(Zn(II)) 
 Data Collection  
 Beamline 21-ID-G 
 Space group P62 
 Cell dimensions a=b,c (Å) 135.6, 122.9 
 Wavelength (Å) 0.97856 
 Resolution (Å) 40.0-2.38 (2.48-2.38)a 
 Rmerge (%) 5.7 (47.2) 
 I/ I 35.7 (3.02) 
 Reflections  
   Total 455,828 
   Unique 50,397 
 Redundancy 9.0 (6.7) 
 Completeness (%) 98.0 (89.1) 
 Refinement  
 Resolution range (Å) 38.7-2.38 
 No. of reflections  47,811 
 No. of atoms 6107 
   Protein atoms 5799 
   Metals/ligand atoms 4/20 
   Water atoms 284 
 Rwork/Rfree
b 17.0/20.4 
 Average B-factors (Å2)  
   Overall 53.6 
   Protein 54.6 
   Metals/Ligand 35.9/50.0 
   Water 55.3 
Root mean square deviation  
   Bond length (Å) 0.013 
   Bond angles (o) 1.402 
MolProbity score 2.11c  
Ramachandran favored (%) 96.03 
Ramachandran allowed (%) 3.97 
Ramachandran outliers (%) 0.00 
aValues in parentheses are for the highest-resolution shell. 
bRwork =  Fo  - Fc  /   Fo ; Rfree
 =   T Fo  - Fc  /  T Fo , where T is  
a randomly chosen set of reflections consisting of 5% of the total. 





plot as determined by MolProbity (15). Simulated annealing omits maps were calculated 
in CNS (16, 17). 
 
Steady State Kinetics and Lysine Inhibition Studies 
The fluorescence HCS assay was used to determine the steady state kinetic 
parameters for WT and mutant SpHCS enzymes as described in Chapter 2. Briefly, HCS 
assays were carried out in triplicate at room temperature in 100mM HEPES, pH 7.5 using 
10 nM enzyme and variable concentrations of 2-OG and AcCoA. To correct for the 
increased fluorescence of the ThioStar dye (Luminos) with increasing concentrations of 
2-OG over 2 mM, CoA ( 260nm = 15,400 M
-1 cm-1) standard curves were performed at 
every 2-OG concentration over 2 mM that was used in each assay. The KM and kcat values 
for HCS mutants were determined by fitting the data to the Michaelis-Menten non-linear 
regression using Prism (GraphPad Software). 
The fluorescence HCS assay was also used to determine the inhibition pattern and 
equilibrium inhibition constant (Ki) value of L-lysine versus the substrates 2-OG and 
AcCoA for WT SpHCS. Additionally, the Ki values for L-lysine versus 2-OG were 
determined for HCS mutants implicated in lysine binding. Initial velocities were 
measured in triplicate at varying concentrations of the substrate 2-OG (0.66-2.0 mM or 
0-100 mM for the E222Q mutant) at various fixed concentrations of L-lysine (0-50 μM 
for WT enzyme or 0-10mM for the lysine binding mutants) with AcCoA held constant  
(100 μM or 200 μM for the E222Q) mutant. Inhibition of WT SpHCS by D-lysine (up to 
2 mM) was also tested using a similar protocol. To determine the inhibition pattern and 
Ki value of L-lysine versus the substrate AcCoA for WT SpHCS, initial velocities were 
measured in triplicate at varying concentrations of the substrate AcCoA (0-100 μM) at 
various fixed concentrations of L-lysine (0-100 μM) with the 2-OG concentration held at 
a saturating concentration of 2 mM. To correct for the increased fluorescence due to 
lysine concentrations over 1mM, CoA standard curves were performed at every 
combination of L-lysine and 2-OG concentrations used in each assays. 
Data was analyzed using the program Prism (GraphPad Software). Double 
reciprocal plots of the 2-OG concentrations versus initial velocities for each lysine 
concentration and Lineweaver-Burk lines using KM and Vmax values calculated from 
 87
Michaelis-Menten fits to the untransformed data were plotted to determine the pattern of 
inhibition. To determine Ki values for L-lysine versus the substrate 2-OG, data sets were 
fit to the non-linear Michaelis-Menten regressions for a competitive inhibitor (Eq. 1). 
Data for lysine inhibition versus the substrate AcCoA was fit to the regression for a 
mixed inhibitor (Eq. 2), where Ki and Ki  represent the equilibrium constants for 
competitive and uncompetitive inhibition, respectively. 
Eq 1: o = kcat[Et][S]/([S] + KM(1+[I]/Ki)) 
Eq.2: o = kcat[Et][S]/(KM(1+ [I]/Ki) + [S](1+[I]/Ki )) 
 
In Vivo Cell Growth Assays 
In vivo viability of the lys4+ lysine mutants in the absence of L-lysine was 
determined as previously described (Chapter 2). Cells were assayed for growth on 
synthetic complete medium lacking lysine (lys-) and uracil (ura-) to maintain selection of 
the vector, WT, or mutant lys4+ plasmids. Where indicated, plates contained AEC. 
Protein immunoblot analysis showed that the steady state levels of the mutant proteins 




Crystal Structure of SpHCS Bound to L-lysine 
The crystal structure of full length SpHCS (residues 1-418) bound to the feedback 
inhibitor lysine was determined by molecular replacement to 2.38 Å using SeMet-SPHCS 
(PDB 3IVS) (Chapter 2) as a model (Table 3.1).  Unlike the free SpHCS structure, the 
L-lysine bound structure contains the divalent metal Zn(II) in the active site, which was 
achieved by removing the Co(II) from the Talon purified enzyme with EDTA and adding 
2mM Zn(II) during crystallization. The overall structure of the SpHCS/lysine complex is 
highly similar to the Co(II)-bound free SpHCS structure with a R.M.S.D. of 0.66 Å for all 
aligned atoms. (Figure 3.1A), whereas an alignment with the Zn(II)-bound SpHCS/2-OG 
complex reveals that the L-lysine bound structure lacks the 4.1- 4.2 hairpin motif and 
domain-swapped N-terminal extension present in the substrate complexes (Figure 3.1B). 






Figure 3.1 Structure of SpHCS in complex with L-lysine and comparison with the 
free enzyme. (A) Ribbon diagram of the overall structure of SpHCS in complex with 
L-lysine (pink with L-lysine rendered in green) overlaid with free enzyme (gray). (B) 
Overall structure of SpHCS L-lysine complex (colored as described in A) superimposed 
with SpHCS 2-OG closed lid complex (blue with 2-OG rendered in yellow). (C) 
Stereoview of the active site of SpHCS L-lysine complex (pink carbons) overlaid with 
SpHCS free enzyme (gray carbons). Electron density of the simulated annealing Fo-Fc 
omit map (contoured at 2.5 Å) corresponding to the L-lysine is shown in cyan, while 
green and blue dashes represent coordination to the Zn(II) ion and hydrogen bonding to 
L-lysine, respectively (D) Stereoview of the active site of the free SpHCS enzyme (gray 
carbons). Coordination to the active site Co(II) ion (pink) is represented by green dashes, 
while coordination to the Mg(II) ion (orange) and hydrogen bonds with the protein and 
solvent molecules are shown as blue and red dashes, respectively. 
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substrate binding in the neighboring monomer, adopts a closed conformation as in the 
free enzyme and closed SpHCS/2-OG structures (Chapter 2). 
Inspection of the electron density maps of the active site of SpHCS revealed 
density corresponding to a bound L-lysine molecule, which was subsequently confirmed 
in a simulated annealing Fo-Fc omit map (Figure 3.1C). An alignment of the coordinates 
of the SpHCS free enzyme and L-lysine complex reveals that the residues within the 
active site are virtually superimposable with the exception of Arg43 that adopts an 
alternative side chain conformation to accommodate inhibitor binding (see below). In the 
free enzyme structure, a Mg(II) ion occupies the area of the -ammonium group of 
L-lysine and is bound to Glu222 and five water molecules in an octahedral coordination, 
suggesting that this pocket can function as a general cation binding site (Figure 3.1D). 
An alignment of the L-lysine and 2-OG complexes illustrates that the substrate 
and inhibitor are nearly superimposable, providing structural evidence that L-lysine is a 
competitive inhibitor of 2-OG (Figure 3.2A). Surprisingly, the substrate and inhibitor 
have similar binding conformations despite their lack of structural and chemical 
homology. Coordination of the carboxylate groups and -amine of L-lysine to the active 
site metal coincides with the coordination of the C1 carboxylate and 2-oxo moiety of 
2-OG, respectively In addition, the carboxylate of L-lysine hydrogen bonds to the 
hydroxyl group of Thr197, analogous to its interactions with the C1 carboxylate of 2-OG. 
The L-lysine side chain adopts an extended all-trans conformation that spans the diameter 
of the TIM barrel’s interior, positioning its -ammonium group for the salt-bridge 
interactions with the carboxylate groups of Asp123 and Glu222 and water mediated 
interactions with Glu74 and Asp258 (Figure 3.2B). The Asp123 and Glu222 residues are 
located in the barrel’s interior adjacent to Arg163 and Ser165 that hydrogen bond to the 
C5 carboxylate of 2-OG and assist in orienting the side chain of Arg163 for hydrogen 
bonding to the substrate (Figure 3.2C). 
A superimposition of the structures of the lysine and 2-OG closed complexes 
provides insights into the flexibility of the active site in accommodating the binding of 
the inhibitor and substrate (Figure 3.2A). This flexibility arises through conformational 




Figure 3.2 The switch position in SpHCS mediates differential ligand recognition. 
(A) Stereoview of the active site of the SpHCS L-lysine complex (pink carbons) 
superimposed with the SpHCS 2-OG closed lid complex (blue carbons). Orange and 
yellow dashes represent coordination to the Zn(II) ion and hydrogen bonding to 2-OG 
respectively in the 2-OG closed loop complex, whereas coordination to the Zn(II) ion and 
hydrogen bonding to L-lysine are depicted as described in Figure 1C. Residues 
composing the switch position are labeled in red. (B) Stereoview of the active site of the 
SpHCS/L-lysine complex (pink carbons with L-lysine shown with green carbons). 
Coordination to the Zn(II) ion (gray) is shown as green dashes while potential hydrogen 
bonds to the inhibitor lysine and are represented by blue dashes.  Hydrogen bonds within 
the protein and to solvent molecules are displayed as red dashes. (C) Stereoview of the 
active site of the SpHCS/2-OG complex (blue carbons with 2-OG shown with yellow 
carbons). Coordination to the Zn(II) ion (gray), hydrogen bonds to 2-OG, and interactions 
between the protein and solvent are as depicted as in panel B.  For clarity, only certain 




The residues, His103, Asp123, Arg163 and Glu222 have roles in distinguishing 
between 2-OG and lysine. These four residues line the interior wall of the TIM barrel 
opposite the metal ion active site in a location that we refer to as the switch position. In 
the SpHCS/2-OG complex, the basic residues His103 and Arg163 rotate towards the 
substrate to form hydrogen bonds or salt bridge interactions with the C5 carboxylate of 
2-OG (Figure 3.2B). Previous studies have shown that these residues are important in 
vitro and in vivo for homocitrate production (Chapter 2). In the L-lysine SpHCS complex, 
these basic residues are orientated away from the inhibitor and the acid residues Asp123 
and Glu222 reorient to form salt bridge interactions with the lysine -ammonium group 
(Figure 3.2B). Alignment of the SpHCS free enzyme and the ligand bound complexes of 
SpHCS reveals that the conformational changes in the residues that make up the switch 
position appear to be coordinated due to their close proximity and to the salt bridge 
interactions between Arg163 and Glu222 that is maintained in each of the structures 
(Figure 3.2). The arrangement of the switch position in the 2-OG complex may also 
explain the ordering of the adjacent -hairpin motif that is disordered in the structures of 
the free enzyme and L-lysine complex (Figure 3.1A and 3.1B). Analysis of the crystal 
packing in the three structures reveals that the -hairpin motif is solvent exposed in the 
various structures and crystal contacts do not contribute to the ordering of this region. 
Thus, rearrangements in the switch region residues appear to coincide with the ordering 
of this region in the 2-OG bound structure. 
Along with conformational changes within the active site, rearrangements in the 
lid motif are also observed in the SpHCS free enzyme and ligand-bound complexes. In 
the free enzyme, Arg43 forms a bifurcated hydrogen bond between its guanidinium group 
and the carbonyl oxygen of Ala324  (the  denotes a residue from the adjacent monomer) 
(Figure 3.3A), which maintains the closed lid state.  However, the binding of the inhibitor 
L-lysine causes a conformational change in the side chain of Arg43 resulting in a direct 
and a water-mediated hydrogen bond to the carbonyl oxygen of Ala324 . This 
conformational change and altered hydrogen bonding pattern results in the lid motif 
shifting a small distance away from the TIM barrel active site as compared to the free 
enzyme. A third lid motif conformation is seen in the 2-OG complex with the 
















Figure 3.3 Conformational variations in the lid motif among SpHCS structures. (A) 
Superimposition of the active site and lid motif in the SpHCS/L-lysine complex (pink 
with L-lysine shown in green carbons and water molecules represented as green spheres) 
and SpHCS free enzyme (gray with water molecules shown as red spheres). Coordination 
to the Zn(II) ion (gray) in the SpHCS/L-lysine complex and in free SpHCS is depicted as 
green and orange dashes, respectively. Hydrogen bonds within the SpHCS/L-lysine 
complex are shown as blue dashes, whereas they are illustrated as red dashes in the 
structure of the free enzyme. (B) Overlay of the lid motif and active site of the 
SpHCS/L-lysine complex (colored as described in A) and the SpHCS/2-OG complex 
(blue with 2-OG shown in yellow carbons and water molecules represented as yellow 
spheres).  Coordination to the Zn(II) ion and hydrogen bonds in the SpHCS/L-lysine 
complex are colored as depicted in panel A, while in the SpHCS/2-OG complex, these 











substrate (Figure 3.3B).  This arrangement breaks the hydrogen bonding between Arg43 
and Ala324  allowing the lid motif to shift further away from the active site. These 
observations imply that the conformation adopted by the lid motif is sensitive to the 
ligand bound within the active site of the enzyme.  
 
Kinetic Analysis of L-lysine Inhibition of HCS  
The structure of the SpHCS/L-lysine complex provides structural evidence that 
L-lysine binds within the active site and is a competitive inhibitor with 2-OG. To confirm 
this finding, we analyzing the double reciprocal plots of velocity versus substrate 
concentration for both 2-OG and AcCoA. The inhibition patterns indicated that L-lysine 
was a competitive inhibitor with 2-OG and a mixed inhibitor with AcCoA (Figure 3.4). 
These inhibition pattern are in corroboration with the Bi-Bi sequential mechanism of 
HCS in which 2-OG binds before AcCoA (18) and are also in agreement with our 
structural studies which indicate that L-lysine and 2-OG bind within the same site (Figure 
3.2A). L-lysine competitively inhibited the binding of 2-OG with a Ki value of 3.56 ± 
0.66 μM (Figure 3.4. and Table 3.3). This value is in agreement with Ki values for HCS 
regulation by lysine in T. thermophilus (Ki = 9.4 μM) (9) and P. chrysogenum (Ki  = 
8 μM) (8). We also investigated the inhibition equilibrium constants for L-lysine 
inhibition a with respect to AcCoA and measured Ki and Ki  values of 63.2 ± 9.1 μM and 
191 ± 60 μM, respectively. Finally, we probed the stereospecificity of lysine inhibition of 
HCS by both D- and L-lysine. Unlike L-lysine, D-lysine did not inhibit SpHCS activity at 
concentration up to 2 mM (data not shown) demonstrating that HCS specifically 
recognizes L-lysine. Taken together, the kinetic inhibition pattern of L-lysine versus both 
substrates along with the structure of SpHCS with L-lysine bound in the same active site 
pocket as the substrate 2-OG provides strong evidence that L-lysine regulates the activity 
of SpHCS through active-site inhibition.  
 
In Vitro and In Vivo Analysis of L-lysine Interacting Residues 
 After examining the biochemical basis for inhibition, we sought to investigate the 
functions of the L-lysine-interacting residues in SpHCS. To understand the biochemical 


















Figure 3.4 Kinetic mechanism of L-lysine inhibition of SpHCS. (A) Double reciprocal 
plots of initial velocity versus 2-OG concentration at different concentrations of L-lysine 
and a fixed saturating concentration (100 mM) of AcCoA. (B) Double reciprocal plots of 
initial velocity versus AcCoA concentration at different concentrations of L-lysine and a 
fixed saturating concentration (2 mM) of 2-OG. Data points are the average of triplicate 
measurements, and the error bars represent one standard deviation, with the lines 
representing Lineweaver-Burk fits using the Vmax and KM values derived from Michaelis-















                                                     
 
aSteady state kinetic parameters for WT SpHCS are previously reported (Chapter 2). 
bErrors are reported as the error in curve fitting. 
 
Table 3.3  Kinetic analysis and lysine inhibition studies of WT SpHCS and mutants implicated in lysine inhibition 
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first determined the steady state kinetic parameters for conservative mutations of the 
switch region residues Asp123 and Glu222, which form salt bridges to the -ammonium 
group of L-lysine. Mutagenesis of Asp123 to asparagine (D123N) results in almost WT 
activity (kcat = 70% WT) with less than a 2-fold affect on the KM values for both AcCoA 
and 2-OG (Table 3.3). The E222Q substitution also had a turnover number comparable to 
the WT enzyme, but exhibited an increased KM
 values for 2-OG  (60 fold), presumably 
due to the disruption in a salt bridge interaction between its carboxylate group and the 
guanidinium group of Arg163, an important residue involved in 2-OG binding (Chapter 
2).  
We next determined the effect these SpHCS mutations had on L-lysine binding. 
Double reciprocal plots of initial velocity versus the substrate 2-OG revealed that L-lysine 
inhibition of the E222Q mutant was severely compromised (Ki = 44.4 mM), whereas the 
D123N mutation completely abolished lysine inhibition up to a concentration of 100 mM 
(Table 3.3). With intracellular concentrations of lysine in S. cerevisiae ranging from 1-10 
mM (19, 20), the high Ki values measured for these mutants suggests that the salt bridge 
interactions of the -amine of lysine to both Asp123 and Glu222 are essential for 
feedback inhibition of SpHCS by L-lysine and may render mutations of these residues 
insensitive to feedback regulation in vivo. 
  To evaluate this possibility, we examined the growth of these mutants in a 
S. cerevisiae lys20  lys21  double deletion strain that was previously generated (Chapter 
2). The lys20  lys21  deletion strain exhibits lysine auxotrophy; yet thrives when lysine 
is present in the media. We transformed the double deletion strain with a plasmid 
consisting of the LYS20 promoter followed by the mutant lys4+ genes to see if they could 
support growth in lysine-deficient media. The D123N and E222Q mutants were both able 
to complement the lysine auxotrophy of the double deletion strain (Fig. 3.5). However, 
the E222Q displayed a weaker growth phenotype, most likely due to its increased KM 
value for 2-OG (Table 3.3) that decreased its catalytic efficiency (defined as kcat/KM).  We 
next tested the response of the D123N and E222Q mutations to lysine inhibition in vivo 
using AEC, a toxic analog that was previously used to identify ScHCS mutants that are 




















Figure 3.5 Effects of mutations of lysine binding residues in vivo. HCS null strain was 
transformed with empty vector, wild-type lys4+, and lys4 mutants engineered at positions 
D123N, E222Q, R288K and Q364N  (pLP 2387-pLP2390, respectively). Growth was 
compared on medium containing lysine (ura-, to select for the plasmids), on medium 
lacking lysine to evaluate HCS function (ura- lys-) and on medium (ura- lys-) containing 
AEC, a toxic lysine analog, at the indicated concentrations. Cell cultures were grown 
under permissive conditions (ura-), normalized to an A600 of 1, and serially diluted five-
















into protein, as an AEC-resistant mutant results in altered lysyl-tRNA synthase activity 
(21). As expected, the lys20  lys21  strain transformed with WT SpHCS exhibited weak 
growth at 5 μg/mL AEC that was completely abolished at 50 μg/mL AEC (Figure 3.5). 
Similar to the WT enzyme, the E222Q mutation could not overcome AEC toxicity at 
either concentration primarily due to its defect in catalytic efficiency due to its high KM 
value for 2-OG (Table 3.3) and reduced growth phenotype on ura- lys- media (Figure 
3.5). Conversely, the D123N mutation displayed strong resistance to AEC at 
concentrations up to 50 μg/mL (Figure 3.5), in agreement with the complete insensitivity 
of this mutation to L-lysine inhibition in vitro (Table 3.3). These findings also suggest 
that the D123N mutation overproduced lysine in vivo, enabling yeast to survive the 
toxicity of AEC. Together, our in vitro and in vivo data demonstrate that the salt bridge 
interactions between the L-lysine e-ammonium group and the Asp123 and Glu222 
carboxylate groups in the switch position are critical to feedback regulation. 
  
Location and Function of the Reported L-lysine Insensitive Mutants 
In addition to investigating the roles of Asp123 and Glu222 in L-lysine inhibition, 
we probed the role of lysine-overproducing mutants previously identified in the ScHCS 
isozymes Lys20 and Lys21. Three point mutations including R276K and S385F in 
ScHCS Lys20 and Q366R in ScHCS Lys21 were identified to be insensitive to lysine by 
selecting for resistance to AEC, a toxic analog to lysine (6). A sequence alignment of the 
C-terminal domains of SpHCS and ScHCS illustrates that Arg276 in ScHCS Lys20 and 
Q366 in ScHCS Lys21 are conserved in the SpHCS (homologous to residues Arg288 
and Gln364), whereas Ser385 of ScHCS Lys20 is not conserved in SpHCS and was not 
included in our studies (Figure 3.6).  
Investigation of the SpHCS crystal structures reveals that these residues are 
located over 25 Å away from the TIM barrel active site domain where L-lysine binds. 
Arg288 resides in 10 in the enzyme’s N-terminal domain and adopts different 
conformations in the free enzyme and ligand bound complexes. In the SpHCS/L-lysine 
complex, the arginine side chain extends towards the end of 13 of the same monomer 
forming hydrogen bonds to the backbone carbonyl groups of Leu399 and Tyr402 (Figure 


















Figure 3.6 Sequence alignment of the C-terminal domain of SpHCS and ScHCS 
Lys20 and Lys21. The secondary structure of the TIM barrel (pink), and C-terminal 
subdomain I and II (violet) of the SpHCS/L-lysine complex is depicted above the 
alignment. Residues implicated in L-lysine binding (ref) that are conserved (green) and 























Figure 3.7 Structural locations of the L-lysine insensitive mutations. (A) Ribbon 
diagram of the N-terminal TIM barrel active site domain (pink) and C-terminal domain 
(violet) of an SpHCS monomer in complex with L-lysine.  Arg288 and Gln364, along 
with their interacting partners are depicted as sticks with hydrogen bonds depicted as 
green dashes.  (B) Ribbon diagram of the N-terminal TIM barrel active site domain 
(gray) and C-terminal domain (teal) of a monomer of the SpHCS free enzyme. Arg288 
and Gln364, along with their interacting partners are depicted as sticks with hydrogen 
bonds depicted in orange (C) Ribbon diagram of an SpHCS/L-lysine dimer depicting the 
location of Arg288 and Gln364 (rendered as spheres). The N-and C-terminal domain of 
monomer A is as described in panel (A), whereas they are shown in yellow and blue, 
respectively in monomer B. L-lysine (green) and the active site Zn(II) (grey) metal ion are 




the L-lysine complex (data not shown). However in the free enzyme, Arg288 adopts two 
different conformations. One conformation is similar to the ligand bound enzyme, and the 
alternate conformation is orientated to form a hydrogen bond with the side chain of 
Asp396 in 13. In contrast, Glu364 is located in the same position in these three 
structures. It resides in 11 of the C-terminal subdomain II and forms hydrogen bonds 
with the backbone carbonyl groups of Phe314 and Arg344 in parallel -strands 11 and 
12 and with the guanidinium group of Arg361 (Figure 3.7B). Notably, the Arg288 and 
Gln364 in each monomer are located at opposite faces in the SpHCS homodimer (Figure 
3.7C) and only form interactions within their own SpHCS monomer (Figure 3.7A and 
3.7B), implying that these residues do not form a surface that may bind L-lysine, nor do 
they directly participate in interactions or conformational changes at the subunit interface 
of the dimer. 
To assess the effects of the R288K and Q364R point mutation in feedback 
regulation, we assayed their activity in vitro and in vivo (Figure 3.4 and Table 3.3). The 
R288K and Q364R mutations exhibit near WT KM values for both AcCoA and 2-OG 
with 65% and 55% the turnover rate when compared to WT, respectively (Table 3.3). In 
agreement with the effects of the corresponding ScHCS mutants (6), the SpHCS R288K 
and Q364R mutations impaired L-lysine inhibition by values of  ~150 and ~300 fold, 
respectively compared to the Ki for competitive inhibition against 2-OG for the WT 
enzyme. Although these mutants exhibited a substantial decrease in the sensitivity to 
feedback regulation, their Ki values are >45-fold lower that those determined for the 
D123N and E222Q mutants. This difference may be due to the fact that the latter mutants 
form direct interactions with L-lysine (Figure 3.2B and Table 3.2), whereas the R288K 
and Q364R mutants appear to decrease lysine sensitivity by an indirect mechanism given 
their distances from the active site. 
Additionally, we examined the effects of the SpHCS R288K and Q364R 
mutations in vivo. Both mutations complemented the lysine auxotrophy of the 
S. cerevisiae deletion strain (Figure 3.5). In agreement with previous studies by Feller et 
al (6), both the R288K and Q364R mutants displayed reduced sensitivity to AEC 
compared to WT SpHCS and the E222Q mutation (Figure 3.5).  However, their 
resistance to AEC was not as strong as that of the D123N mutation, consistent with the 
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kinetic data demonstrating that this mutation abolished feedback inhibition (Table 3.3). 
In summary, the L-lysine insensitivity of the SpHCS R288K and Q364R mutants 





L-lysine Feedback Inhibition of HCS is Competitive with 2-OG 
Feedback inhibition of HCS is an important mechanism by which the metabolic 
flux in the AAA pathway is regulated in vivo. Taken together, our structural and 
functional studies demonstrate L-lysine regulates the activity of SpHCS through 
competitive inhibition with the substrate 2-OG, in agreement with previous studies of 
HCS from P. chrysogenum (8), T. thermophilus (9) and S. cerevisiae (7). The flexibility 
of the enzyme’s active site allows differential recognition of 2-OG and L-lysine. This 
recognition is achieved through conformational changes of the acidic and basic residues 
in the switch position that form salt bridge interactions and hydrogen bonds to the 
-ammonium group of L-lysine or the C5 carboxylate group of 2-OG, respectively 
(Figure 3.2). In contrast to the conformal changes between the L-lysine and 2-OG bound 
complexes, the structures of the SpHCS free enzyme and L-lysine complex are quite 
similar, especially within the active site (Figure 3.1). This structural similarity implies 
that the free enzyme may be predisposed to feedback inhibition by L-lysine, providing a 
molecular explanation for the high affinity of binding of the inhibitor towards the enzyme 
(Table 3.3). Our findings also show that the salt-bridge interactions between the 
-ammonium group of L-lysine and the carboxylate groups of Asp123 and Glu222 are 
vital for tight binding, as conservative mutations of these residues completely abolish 
inhibitor binding in vitro and are resistant to AEC in vivo (Table 3.3 and Figure 3.5). 
While this work was under review, coordinates were released for the structure of a 
TtHCS/L-lysine complex, which also displays competitive binding of L-lysine and 2-OG 
(22) similar to SpHCS. In summary, our results, along with the T. thermophilus structure, 
provide strong evidence for a competitive model for feedback inhibition of HCS.  
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Role of the C-terminal L-lysine Insensitive Mutants 
  Although our results are inconsistent with an allosteric model of inhibition, they 
do not exclude the possibility of the involvement of residues outside the active site in 
feedback regulation. Although located in the C-terminal domain ~25 Å away from the 
active site, the SpHCS R288K and Q364R mutations caused a reduced sensitivity to 
L-lysine feedback inhibition in vitro and in vivo (Table 3.3 and Figure 3.5). Because these 
residues are not involved in stabilization of the dimer interface (Figure 3.7C), it is likely 
that these residues alter the local conformational dynamics of the enzyme by disrupting 
hydrogen bonding within the C-terminal domain. These disruptions may affect the 
equilibrium between the conformation of the free enzyme and L-lysine complex versus 
the 2-OG complex (Figure 3.1 and 3.2), affecting the binding of L-lysine that 
preferentially recognizes the conformation adopted by the free enzyme (Figure 3.1). 
Alternatively, HCS may exhibit half-site reactivity between its two active sites in the 
homodimer in which L-lysine inhibition of one subunit induces an allosteric signal that 
results in inhibition of the other subunit. This type of inhibition may not exhibit allosteric 
kinetics as shown in other homodimeric enzymes, such as prostaglandin endoperoxide 
H synthases (23-25). Further studies are needed to determine if HCS functions in a 
similar manner. 
 
Comparison of the Regulatory Mechanisms of HCS and -IPMS 
A comparison of SpHCS and the related enzyme Mycobacterium tuberculosis 
-IPMS provides insights into the evolution of regulatory mechanisms of these two 
enzymes. -IPMS catalyzes a mixed Claisen condensation in the first step in leucine 
biosynthesis by condensing AcCoA and 2-OIV to form -isopropylmalate, similar to 
homocitrate production by HCS (26, 27). The catalytic domains of HCS and -IPMS are 
structurally similar TIM barrel folds, and the active site residues involved in metal 
coordination, substrate binding and catalysis are mostly conserved in the two enzymes. 
Both enzymes are subjected to feedback inhibition, however their mechanisms are 
distinct. Unlike SpHCS, -IPMS possess a C-terminal regulatory domain that functions 
to allosterically bind the feedback inhibitor L-leucine (27). This regulatory domain 
consists of two similar  folds, with L-leucine binding in a hydrophobic pocket 
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formed at the interface of the fold that is located ~50 Å away active site of -IPMS. 
Upon leucine binding, a loop region that folds over the amino acid becomes more 
ordered, however the structure of the active site remaining unchanged compared to the 
-IPMS/2-OIV complex. Kinetic studies demonstrate that L-leucine exhibits slow-onset 
noncompetitive inhibition versus the substrate 2-OIV (28). In contrast, L-lysine exhibits 
rapid competitive inhibition with 2-OG as demonstrated by our structural and functional 
studies. These differences may reflect distinct physiological requirements for controlling 
the metabolic flux of the leucine and lysine biosynthetic pathways by feedback 
regulation. 
 
Insights into Designing HCS Inhibitors for Use as Antifungals 
HCS has been proposed as a novel target for antifungal drug design due to its 
presence in pathogenic fungal species such as A. fumigatus, C. albicans and 
C. neoformans (29). Our structural and functional characterization of the SpHCS/L-lysine 
complex yield important insights in designing inhibitors. Notably, our results show that 
small molecule competitive regulators, like L-lysine, inhibit HCS activity effectively in 
vitro and in vivo (Table 3.3 and Figure 3.5). The flexibility of the residues in the switch 
position (Figure 3.2) may provide opportunities to identify or design small molecule 
inhibitors that specifically target conformations adopted by the HCS active site.  This 
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HIGH-THROUGHPUT SCREENING FOR SMALL MOLECULE INHIBITORS 
OF HOMOCITRATE SYNTHASE 
 
 Over the last few decades, invasive fungal infections have emerged as a threat to 
human health. Although these types of infections pose little risk to healthy individuals, 
they occur frequently and have a high rate of morbidity and mortality in those with 
compromised immune systems, such as burn patients, recent transplant recipients, 
individuals undergoing cancer treatments, and those with immunodeficiencies such as 
HIV and AIDS (1-4). Recently, considerable advances have been made in discovering 
new fungicides and novel antifungal targets, however current treatments remain 
unsatisfactory (5-8). For example, existing treatments for infections caused by 
Aspergillus have a cure rate of only 50% (8). In addition, many of the present antifungal 
treatments have additional shortcomings including serious side effects, numerous drug-
drug interactions, or ineffectiveness against resistant infections (5-8).  For these reasons, 
further development of new therapies is needed, especially against novel antifungal 
targets. 
 One potential target for the development of new fungal drugs is the AAA pathway 
of lysine biosynthesis that is utilized in fungi, including the pathogenic species 
C. albicans, C. neoformans and A. fumigatus (9). Recent studies in A. fumigatus, 
determined the AAA pathway enzymes HAc, SD and HCS to be essential genes and thus 
possible antifungal targets (10, 11). Although prior work has examined rationally 
designed inhibitors of HIDH and HAc, the second and third enzyme in this biosynthetic 
pathway (12, 13), there is still a precedence to further identify and characterize inhibitors 
to other enzymes in this pathway. In this work, we chose to identify inhibitors of HCS, a 
divalent metal dependent enzyme that catalyzes the first and committed step in the AAA 
pathway by condensing 2-OG and AcCoA to form homocitrate. Additionally, HCS plays 
a critical role in the metabolic flux through the pathway due to its feedback inhibition by 
the end product L-lysine (14-16). Because of its importance in the AAA pathway, and its 
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absence in human hosts, HCS represents an attractive target for the development of novel 
antifungals. 
 Here we identify inhibitors to SpHCS utilizing an in vitro high-throughput 
screening (HTS) technique. The fluorescent HCS assay (Chapter 2) was optimized for 
use in a 384-well plate format and the University of Michigan’s Center for Chemical 
Genomics (CCG) library of ~50,000 compounds was screened for their ability to inhibit 
SpHCS. The initial hits from the first stage of HTS were subjected to confirmation 
screens and counter screens to eliminate compounds that displayed fluorescence-
quenching properties or acted as metal chelators. After completion of the second phase of 
screening, 341 potential inhibitors remained. We plan to further test these molecules 
using an in vivo yeast growth assay and will confirm the potency of the compound that 
inhibit growth by dose response curves. We envision that this approach will yield small 
molecule HCS inhibitors that can be potentially optimized as lead compounds in the 
development of new antifungal drugs or as molecular probes to study HCS function in 
vivo. 
 
MATERIALS AND METHODS 
 
Materials 
 The Zn(II)-bound WT SpHCS used in all of the HTS assays.  Enzyme from two 
different 1 L cell pellets were purified by Zn(II) IMAC, and were pooled and purified on 
a size exclusion column as described in Chapter 2. Nunc brand black 384-well 
polypropylene microliter plates (Thermo Fisher Scientific) were used for all HTS 
experiments. A 1 M solution of HEPES buffer (99.5% purity Sigma) was prepared and 
brought to pH 7.5 with a 5 M solution of potassium hydroxide (Acros Organics) for use 
in the HTS assays. The 2-OG disodium salt, AcCoA and CoA trilithium salts and 
Thiostar fluorescent reporter reagent were prepared as described in Chapter 2. MnCl 
tetrahydrate (Acros Organics) was prepared as a 0.2 M stock for use in the secondary 
HTS, and anhydrous DMSO (Fluka or Acros Organics) was used in all of the HTS 
assays.  
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 The library compounds used in the HTS were obtained from the CCG. The library 
consists of 53,906 compounds from several commercially available screens including a 
~16,000 Hit-finder compound collection from Maybridge Chemical, a ~3200 library from 
Chembridge, the FDA approved MS Spectrum library that contains 2000 compounds and 
a >20,000 compound library from ChemDiv. A screen of natural products generated in 
the lab of David Sherman (University of Michigan) was also included in the CCG’s 
library.   
 
Miniaturization of the HCS Fluorescent Assay  
The HCS fluorescent assay (Chapter 2) was optimized for use in 384-well format 
for HTS to test for small molecule inhibitors to SpHCS. Briefly, this assays detects HCS 
activity by reacting CoA-SH with a thiol-sensitive dye ThioStar to form a fluorescent 
ThioStar-CoA adduct (see Scheme 2.1) and was used to determine the steady state kinetic 
parameters and L-lysine inhibition kinetics of WT SpHCS and mutations involved in both 
catalysis and regulation (Chapters 2 and 3). Controls were performed on Zn(II) purified 
WT SpHCS using the conditions of the standard HCS fluorescent assay (Chapter 2) to 
determine if it would be amenable for HTS. First, the stability of the enzyme at room 
temperature was determined by incubating SpHCS (40 nM) at room temperature for 0-60 
min and assaying for activity at saturating substrates.  Next, the effect of DMSO on HCS 
activity was measured using 10 nM WT SpHCS, saturating concentrations of substrates 
(2 mM 2-OG and 200 μM AcCoA) and 0-2.5% DMSO. Finally, the linearity of the 
reaction over time at half KM values for both substrates was examined by measuring HCS 
activity at various time points up to 20 min using 5.0 or 7.0 nM WT SpHCS, 5.3 μM 
AcCoA and 80 μM 2-OG. 
 
The HCS High-throughput Screening Protocol 
The HCS HTS assay was conducted by adding 20 μl of 100mM HEPES pH 7.5 
and 160 μM 2-OG into black polypropylene 384 well microplates (Corning) using an 
8-tip multidrop dispenser (Thermo Labsystems). Inhibitor compounds (0.2 μl of 
1.2-2 mM stocks) from the CCG’s library were added to columns 3-22 of the 384 well 
plates using the pin-tool application on a Biomek FX (Beckman) liquid handling robot.  
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At the same time, DMSO was added to the negative (columns 1-2) and positive controls 
(columns 23-24). A mixture of 100 mM HEPES pH 7.5 and 10.7 μM AcCoA was 
dispensed into the positive control columns and the assay was initiated with the addition 
of 20 μl of a mixture of 100 mM HEPES, pH 7.5, 10 nM SpHCS and 10.7 μM AcCoA 
(columns 1-22) using the 8-tip multidrop dispenser yielding final concentrations of 
reagents 100 mM HEPES pH 7.5, 80 μM 2-OG, 5.35 μM AcCoA and 5nM SpHCS. The 
reactions were incubated at room temperature for 20 min and the reaction was stopped 
with the addition of the reporter reagent (40 μl of 25μM ThioStar in DMSO) to every 
well using the 8-tip multidrop dispenser. The plates were covered and after a 10 min 
incubation the fluorescence of the ThioStar-CoA adduct was measured at 460 nm using 
an excitation wavelength of 380 nm using a PHERAstar (BMG Labs) plate reader.  
  
Counter Screen to Detect ThioStar-CoA Quenching Molecules 
 A counter screen was performed in triplicate on confirmed hits to ensure that they 
were not false positives due to quenching of the fluorescence ThioStar-CoA conjugate. 
This screen was conducted as described for the HTS assay with the following exceptions.  
Instead of adding a mixture of 100 mM HEPES, pH 7.5, 10 nM SpHCS and 10.7 μM 
AcCoA to columns 1-22 to initiate the reaction, a solution of 20 μl containing 1 μM CoA 
(100 mM HEPES, pH 7.5, 1 μM CoA and 10.7 μM AcCoA) was added to mimic the 
approximate concentration of CoA generated in the negative control reactions. The 
reporter reagent (40 μl of 25μM ThioStar in DMSO) was immediately added, and the 
plates were covered and allowed to incubate at room temperature for 10 min before the 
fluorescence of the ThioStar-CoA adduct was measured.  
  
Secondary Screen to Eliminate Metal Chelators 
 Analysis of the compound hits revealed that some of them might have metal 
binding groups. Because the final compound concentration (6-10 μM) is much higher that 
the enzyme concentration (5 nM) in the HTS assays, compounds that can bind metals 
may indirectly inhibit HCS by chelating the active site metal. Previous results (Appendix 
A) illustrate that the active site of SpHCS does not coordinate the metal Mn(II), which 
was therefore chosen for use in the secondary screen. Control experiments using the 
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assay conditions of the standard fluorescent HCS assay (Chapter 2) were run in the 
presence of 0-20 μM Mn(II) and in the presence of 20 μM Mn(II) and 0-20 μM EDTA to 
examine the activity of the WT SpHCS enzyme in these conditions. To eliminate small 
molecule metal chelators, a secondary HTS screen was performed in triplicate as 
described for the HTS with the exception that a mixture of 100 mM HEPES, 160 μM 
2-OG and 20 μM MnCl was added in the initial step.  
 
HTS Data Analysis 
The HTS assay was validated by analyzing the statistics of the positive and 
negative control reactions, where a positive control indicates complete inhibition and a 
negative control represents no inhibition. Negative control reactions were performed in 
half of a 384-well plate using the HTS assay protocol in the absence of inhibitor 
compounds and the positive controls (SpHCS was omitted in the reactions) was set up 
identically in the other half of the 384-well plate. The resulting data was then analyzed by 
calculating the signal to noise ratio, the Z-factor (Z´) (Eq. 1) (17) and the coefficient of 
variation (CV) (Eq. 2). 
Eq 1: Z´ = 1-((3SDpositive + 3SDnegative)/(Meannegative – Meanpositive)) 
Eq 2: CV = SDnegative / Meannegative 
Active molecules from the initial screen were determined using two different sets 
of criteria. Standard deviations of both the negative and sample fluorescent values 
calculated in the CCG’s M-screen database. Percent effect values per plate were also 
computed, with the average of the negative and positive controls were set at 0% and 
100% effective, respectively. Compounds with a standard deviation (SD) > 3 and 
samples with a percent effect to  30.0% were defined as active. Promiscuous 
compounds were defined as having a SD > 3.0 in 10 or more previous screens. 
Confirmation of the active hits was determined by calculating the median and maximum 
value for each compound (n=3) using the statistical analysis software JMP (SAS Institute 
INC.). Confirmed compounds had a median value (% by plate)  30.0%, whereas general 
promiscuity in this assay was defined as having  30.0% activity 10 or more previous 
screens. To eliminate possible fluorescence quenchers and metal chelators, the percent 
effect values of the median fluorescent value were calculated by plate for these screens. 
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Compounds that had values  30.0% were discarded as quenches in the ThioStar-CoA 
counter screen, whereas compounds that displayed values < 30.0% were rejected as likely 




Development and Validation of the HCS Fluorescent Assay for HTS 
To determine the feasibility of the fluorescent HCS assay for HTS screening of 
small molecule inhibitors, we conducted a series of control experiments using the 
standard assay conditions (Chapter 2). First, we verified that SpHCS is stable for at least 
1 hour at room temperature (data not shown). Next, we assayed SpHCS in the presence of 
DMSO, because the small molecule inhibitors will be added to the assay in DMSO at a 
final volume of 0.5%. Control assays found that the addition of DMSO to the assay had 
no effect up to 2.0% (Figure 5.1A). Finally, we established that 5 to 7 nM of SpHCS 
produced a linear velocity up to 20 min in conditions at half substrate KM values (80 μM 
2-OG and 5.53 μM AcCoA) (Chapter 2) (Figure 4.1B). This result was confirmed using 
the HTS assay protocol (Table 4.1), where up to 10 nM SpHCS displayed linearity over 
20 min (Figure 4.1C). Although 10 nM SpHCS exhibited linearity to 20 min using the 
HTS protocol, we chose to use a final concentration of 5 nM in the assay because it limits 
AcCoA consumption to 10% of the initial substrate concentration.  
 After optimizing the HCS fluorescent assay in vitro HTS, we validated the assay 
protocol (Table 4.1) by determining Z´, CV and signal to control ratio values by 
performing an equal number of positive and negative control reactions in a single 
384-well microplate with the positive controls defined as complete inhibition (SpHCS 
was omitted from the reaction) and negative controls defined as no inhibition (DMSO 
control reactions). Analysis of the data yields a Z´ and CV values of 0.7, representing an 
excellent assay where there is a large separation between the sample signal variation and 
the control signal variation (17). A CV value of 8.5 % and signal to noise ratio of 11.7 are 


















Figure 4.1 Optimization of the fluorescent HCS assay for in vitro HTS. (A) Fraction 
of activity relative to no DMSO for WT SpHCS in the presence of increasing 
concentrations of DMSO. Data represents the average of two replicates. (B) Linearity of 
WT SpHCS in the standard assay conditions (Chapter 2). Linear regressions were fit to 
the data points that were measured in duplicate. (C) Linearity of WT SpHCS using the 
conditions for the optimized HTS assay (Table 5.1).  Linear regressions were fit to the 









                                 
 
Table 4.1 Homocitrate synthase HTS assay protocol. 
 116 
HTS Primary and Confirmation Screens of CCG’s Compound Library 
 After confirming the reproducibility of the HCS HTS fluorescent assay, we 
screened the CCG’s 53,906 compound library for small molecule inhibitors of HCS. Each 
test compound was assayed at a single concentration ranging from 6-10 μM with positive 
and negative controls (n=32) being included in each plate for analysis of the inhibition 
and to detect any irregularities in the assay (Table 4.1). The scatter plot screening the MS 
Spectrum 2000 Library (Figure 4.2) is shown as a representation of the HTS results. The 
Z´ value was calculated by plate and falls with the range of 0.7-0.9 demonstrating the 
quality of these assays. Following screening of the entire CCG library, a total of 4083 hit 
compounds were identified as actives by having a SD  3 or a percent effectiveness 
 30.0 % (Table 4.2). Additional triage was completed to exclude promiscuous 
compounds, cytotoxic molecules and those containing maleimide groups, which would 
compete with ThioStar reporter agent for conjugation to CoA. We also eliminated any 
positive hits that were natural products do to the limited characterization and availability 
of these compounds. After triage, a total of 1399 compounds were selected for 
confirmation assays that were performed in triplicate for each molecule. An analysis of 
data from this screen confirmed 595 actives, defined as having a median percent effect 
value (% by plate) 30.0%.  Molecules from this set that exhibited general promiscuity or 
were large compounds with a topological polar surface area value exceeding 140 Å2 were 
also eliminated (Table 4.2). The number of positive hits remaining after confirmation 
screening was 514, representing ~1% of the total number of compounds assayed.  
   
ThioStar-CoA Quenching Counter Screen 
 Inspection of the chemical structures of the positive hits in the HTS confirmation 
revealed that several of the compounds have large conjugated aromatic systems that may 
act to quench the ThioStar-CoA adduct formed in the HCS assay. To eliminate false 
positives due to fluorescence quenching, we conducted an HTS counter screen on 496 of 
the confirmed actives (eighteen of the confirmed compounds were not screened due to 
availability concerns) (Table 4.2) by including 1 μM CoA to the initiation step in the 
assay in place of the SpHCS enzyme (Table 4.1). This concentration of CoA was used to 
mimic the approximate amount of CoA generated in the negative control reactions. 
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Figure 4.2 Representation of the HTS screening results using the MS Spectrum 2000 
compound library. The x-axis corresponds to the compounds screened (green squares) 
and the positive (red squares) and negative control assays (blue squares).  The left y-axis 
represents percent effectiveness per plate, whereas the right y-axis reports the Z´ value 
for each plate (purple line).  The red line represents 3 SD as calculated from the negative 

















                           
 
Table 4.2 Results of HTS for inhibitors of HCS. 
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Analysis of the ThioStar-CoA counter screen data resulted in the elimination of 54 likely 
quenchers as defined as having a median percent effect of 30.0% (Table 4.2).     
 
Metal Chelator Secondary Screen 
Several of the small molecule hits contain heterocyclic rings systems or multiple 
polar groups, which may function to bind metals. Because HCS requires a divalent metal 
ion for catalysis and exhibits little activity after removal of the active site metal 
(Appendix A), it was necessary to eliminate false positives due to metal chelation. Our 
previous results indicated that SpHCS does not bind the metal Mn(II) (Appendix A), 
therefore we chose to use this metal in the secondary screen. Before completion of the 
HTS secondary screen, we first determined the activity of SpHCS in the presence of up to 
50 μM MnCl2 and if the addition of the metal could effectively block inhibition by the 
metal chelator EDTA. Our results indicated that the addition of 20 μM MnCl2 (twice the 
inhibitor concentration in the HTS assay) caused a modest (~17%) decrease in activity 
compared to SpHCS assayed with no Mn(II) (Figure 4.3A). Additionally, we found that 
the addition of Mn(II) effectively blocked metal chelation by EDTA at concentrations 
equal to or less than half the concentration of Mn(II) (Figure 4.3B). To eliminate 
potential metal chelators, the secondary screen was performed on 496 of the confirmed 
actives using the HTS assay protocol (Table 4.1) with the exception that 20 μM MnCl2 
was added to the initial step of the assay. Analysis of the data resulted in the exclusion of 
81 likely chelators, which exhibited a median percent effect of < 30.0% leaving a total of 
361 inhibitor compounds for additional follow up (Table 4.2).  
 
Characteristics of the Compounds which Inhibit HCS 
An analysis of the remaining confirmed hits revealed several classes of 
structurally related compounds, with one of these classes including 20 members that 
contain an 8-hydroxyquinoline functional group (Figure 4.4), which is a known chelator 
that can bind a variety of biologically relevant divalent metals (18). Therefore, these 
compounds will be excluded in further studies leaving a total 341 to be assayed in follow 

















Figure 4.3 HCS control assays for the HTS secondary screen to eliminate metal 
chelators. (A) The fraction of activity (relative to 0 μM MnCl2) for WT SpHCS in the 
presence of increasing concentrations of MnCl2. Data are the average of duplicate 
measurements. (B) The fraction of activity (relative to 0 μM EDTA) for WT SpHCS in 
the presence of 20 μM MnCl2 and increasing concentrations of EDTA. Measurements 
























Figure 4.4 Compounds containing an 8-hydroxyquinoline moiety. (A) Structure of 8-




Mn(II) counter screen, perhaps because they have a low affinity for Mn(II). The 
remaining hits included compounds that could be categorized into two structurally similar 
classes. Class 1 includes 23 compounds (~7% for the total hits) that contain a core three-
member ring scaffold with various substitutions on the piperidine and phenol rings 
(Figure 4.5), whereas Class 2 is made up of 5 members containing a conserved five-
member ring scaffold (Figure 4.6). The remaining small molecule inhibitors exhibit 
greater structural divergence and could not be assigned to a structurally related class. In 
summary, a diverse set of small molecule inhibitors of SpHCS were detected through 
HTS including a large set of compounds containing an core three-ring scaffold, which 




HCS is a potential target for antifungal drug design because it is absent in 
humans, catalyzes the first step in the AAA biosynthetic pathway and controls the 
metabolic flux of the pathway through L-lysine feedback inhibition. (14-16). In this work, 
we describe the development of a HTS assay for small molecule inhibitors of SpHCS that 
was used to effectively screen the CCG’s 53,906 compound library. Following 
conformation screening, 514 inhibitors displayed inhibition towards HCS. These 
compounds were further reduced to 361 by performing a ThioStar-CoA counter screen 
and a metal chelation secondary screen. Although the secondary screen removed many 
compounds containing groups that might act as metal binders, a family of compounds 
containing the metal binding 8-hydroxyquinoline group escaped elimination (Figure 4.4). 
This group has been reported to bind Mn(II) at pH 7.0, at a 10:1 ratio of reagent to metal 
(18), however its binding affinity may to be low to effectively chelate Mn(II) under the 
conditions of the HTS assay. Alternatively, the substituents attached to the 
8-hydroxyquinoline group may decrease the ability of these compounds to chelate all 
metals resulting in inhibition of SpHCS via an alternative mechanism. Nonetheless, these 
compounds will be removed from future assays to avoid the possibility that they 
inactivate SpHCS through chelation of the active site metal. A subset of the 341 








Figure 4.5 Class 1 structurally related compound hits. (A) Conserved scaffold of 
compounds from Class 1, where R1 –R5 denote substituent groups. (B) Examples of 






















Figure 4.6 Class 2 structurally related compound hits. Conserved 5-member ring 













might represent novel HCS inhibitors. However, additional studies are still needed to 
finalize the characterization of these remaining inhibitors. To complete these studies we 
plan to first screen these compounds in vivo for their ability to inhibit the growth of yeast. 
A counter screen will also be performed to identify compounds that are not specific to 
SpHCS in vivo, but are generally cytotoxic. Finally, the potency of the in vivo inhibitors 
will then be tested in vitro and in vivo by performing dose response curves. We are 
optimistic that these additional screens will result in identifying a handful of potent small 
molecule inhibitors to SpHCS that can be used as lead compounds in developing 
antifungal drugs. 
In addition, our results provide proof-of concept for this HTS strategy that can 
also be applied to discover inhibitors of HCS from fungal pathogens, including 
C. albicans, C. neoformans and A. fumigatus (9). Indeed, the CCG has recently expanded 
their compound library to ~150,000 small molecule compounds that can be screened for 
their ability to inhibit HCS from these pathogenic species, using the HTS protocol 
outlined here. A comparison of inhibitors for each of these species will establish whether 
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SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS
 
Significant progress has been made over the past few decades in understanding the 
fundamental biochemistry of HCS. Specifically, work on HCS Lys20 from S. cerevisiae 
has provided insights into the kinetic and catalytic mechanism of this enzyme (1-3). 
Additionally, kinetic studies on ScHCS, PcHCS and TtHCS show that L-lysine feedback 
regulation is kinetically competitive with the substrate 2-OG (4-7). However, prior to this 
work the mechanism by which L-lysine is recognized remained unknown. The work 
presented here focuses on using structural and biochemical studies to elucidate the 
mechanistic details of catalysis and regulation of HCS. In addition, these studies have 
furnished the basis to develop a HTS assay to identify small molecule inhibitors to this 
enzyme, which may serve as lead compounds in the development of antifungal drugs. 
 
Substrate Binding and Catalytic Mechanism of HCS 
 While a general acid-base Claisen condensation chemical mechanism has been 
proposed for HCS (3), the mechanistic details, including the residues that may act as the 
catalytic acid and base, remained speculative in part due to a lack of a structure of a HCS 
enzyme. In Chapter 2, the structures of SpHCS and two different SpHCS/2-OG 
complexes are described. Because these are the first HCS structures to be reported, they 
provide invaluable insights into the identity of the residues involved in substrate 
recognition and catalysis. The structures illustrate that HCS forms a homodimer that is 
stabilized by domain swapping between the N and C-terminal domains of each monomer. 
The N-terminal catalytic domain is composed of a ( / )8 TIM barrel fold in which 2-OG 
binds via hydrogen bonds and coordination to the active site divalent metal ion. 
Biochemical studies performed in Chapter 2 reveal that nearly all of the tested 2-OG 
binding mutations either impaired or abolished activity, illustrating that interactions to 
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both the C1 and C5 carboxylate groups of 2-OG are vital for proper substrate binding 
within the active site.  
The structural studies on HCS described in Chapter 2 also provide some 
unexpected findings. For example, in the free enzyme structure and one of the 2-OG 
complexes, a lid motif in the C-terminal domain covers the entrance of the active of the 
neighboring monomer, whereas in the second 2-OG complex the lid motif is disordered. 
When closed, the lid motif forms two 310 helices that completely occlude 2-OG and 
AcCoA binding, implying that it regulates substrate access to the active site through its 
apparent plasticity. The flexibility of this conserved region (Figure 2.10) is also observed 
in the TtHCS structures (6). The lid motif in the TtHCS/L-lysine complex has a similar 
location to the lid motif seen in the closed SpHCS/2-OG and L-lysine complexes (Figure 
6.1A, 6.1B and 6.1C), however an alternative conformation in this motif is observed in 
the TtHCS/2-OG complexes. Instead of forming a 310 helix that occludes the entrance to 
the active site of the neighboring monomer, the lid motif rearranges into a longer -helix 
followed by a 310 helix that does not cover the active site of the neighboring monomer 
(Figure 6.1D).  
Additionally, this conformational change causes a rearrangement of residues 
implicated in base catalysis. Based on the sequence homology to -IPMS, mutagenesis 
and biochemical studies on conserved ScHCS Lys20 active site residues suggested that a 
glutamate-histidine dyad acts as the general base in deprotonation of the methyl group of 
AcCoA to form an enol (or enolate) (2, 8). Although our structural and biochemical 
studies of SpHCS support a role for the glutamate residue (Glu167) in catalysis, the 
corresponding histidine (His321 ), which is located in the lid motif, is located too far 
away from Glu167 to form a functional catalytic dyad. However, it is possible that upon 
AcCoA binding a conformational change could take place to bring the histidine residue 
within a distance to act in base catalysis. Indeed, the recently published structures TtHCS 
illustrates that the lid motif adopts a conformation that orients the histidine so that it may 
function as the glutamate-histidine dyad (Glu137-His292 ) in base catalysis (6) (Figure 
6.1D). The conservation of this dyad in -IPMS and TtHCS but not in SpHCS may either 
indicate that the structure of SpHCS is not in a catalytically active form, or there may be 










Figure 6.1 Arrangements of the lid motif in SpHCS and TtHCS. (A, B) SpHCS in 
complex with L-lysine (orange) (A) and 2-OG (yellow) (B). Monomer A and B are 
colored blue and green respectively, whereas the Zn(II) metal ions (grey) are shown as 
spheres. In theses structures the lid motif forms the two 310 helices. (C) TtHCS/L-lysine 
complex (PDB 3A9I) with monomer A, monomer B and L-lysine colored as described in 
panel (A). The Co(II) ion is depicted as a pink sphere. (D) TtHCS (monomer A and B 
colored blue and green, respectively) in complex with 2-OG (yellow) (PDB 2ZTJ).  In 







studies are needed to determine if a similar arrangement of the lid motif, and thus the 
movement of the histidine residue implicated in catalysis occurs in SpHCS and other 
fungal HCS homologs.  
 Although this work furnishes a greater understanding of the substrate specificity 
and catalytic mechanism of HCS, several important mechanistic questions regarding the 
binding of AcCoA remain. For example, we do not fully understand the conformational 
changes that take place in the lid motif to accommodate AcCoA binding, nor do we know 
the interactions between AcCoA and the protein that occur to orient the substrates for 
catalysis. Solving a ternary complex of SpHCS would provide invaluable information 
towards answering these types of questions. We were unable to obtain a structure of a 
ternary complex using WT SpHCS in the presence of 2-OG and either CoA or acetonyl-
CoA, a non-reactive analog of AcCoA, nor from the addition of 2-OG and AcCoA to the 
catalytically inactive E167Q SpHCS mutant (Chapter 2). However, future studies in 
which SpHCS is crystallized with non-hydrolysable homocitryl-CoA analogs may yield a 
ternary complex that can then be functionally characterized to determine the residues that 
are important for AcCoA binding and catalysis. Alternatively, perhaps another HCS 
homolog would be more amenable for crystallization in a ternary complex. Solving a 
binary complex of HCS with homocitryl-CoA analogs will not only provide further 
insights into the mechanism, but may also serve as a starting point for structure-based 
design of potent HCS-specific inhibitors that may be developed into antifungal 
modulators. 
 
Regulation of HCS by L-lysine 
Another distinctive finding that arose from our structural and biochemical work 
on SpHCS is the discovery that the substrate 2-OG and the feedback inhibitor L-lysine 
bind competitively in the same ( / )8 TIM barrel active site (Chapter 3). Although 
feedback inhibition can be kinetically competitive, in most of these cases the inhibitor 
binds to an alternative binding site which causes an allosteric change in the protein which 
no longer allows the substrate to bind (9). This is not surprising considering the structural 
differences between the inhibiting intermediate or end product in the pathway and 
enzyme’s substrate. In fact, competitive binding of a feedback inhibition to the same site 
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as the substrate appears to be quite rare. However it does occur in some enzymes 
including glutamate synthase, with structural and biochemical studies demonstrating that 
the L-serine, L-alanine and glycine are competitive inhibitors with the enzyme’s substrate 
L-glutamate (10). In HCS, differential recognition of the substrate and inhibitor is 
achieved via a switch position within the active site of the enzyme that can distinguish 
between the C5 carboxylate group of 2-OG and the -ammonium group of L-lysine. 
Mutagenesis of the residues in the switch region that form hydrogen bonds to the -
ammonium moiety of L-lysine completely abolish feedback inhibition in vitro and in 
vivo, indicating their importance in the regulation of HCS. Recently, the structure of a 
TtHCS/L-lysine complex was also reported. This enzyme has an inhibitor-binding mode 
that is essentially identical to that of SpHCS, illustrating conservation of the feedback 
regulatory mechanism of HCS (Figure 5.1C and 5.1D).  
Our structural and biochemical results indicate that L-lysine is a competitive 
inhibitor toward 2-OG. However, in agreement with finding in ScHCS (11), two 
mutations in the C-terminal domain of SpHCS also decrease the enzymes sensitive to 
inhibition. These mutations are too far away from the active site to have a direct effect on 
L-lysine binding, but may change the enzyme’s conformational dynamics to favor 
substrate binding. Alternatively, the enzyme may exhibit half-site reactivity, where 
binding of L-lysine to inhibit one monomer transmits a conformational change that 
inhibits the other monomer, with these C-terminal residues being part of the network that 
relays this allosteric signal. Similar to work reported on prostaglandin endoperoxide H 
synthase (12), future studies are needed to investigate the function a heterodimer of WT 
SpHCS and the L-lysine insensitive D123N mutation to determine if HCS exhibits 
allosteric feedback inhibition through half-site reactivity.  
 
Identification of small molecule inhibitors of HCS 
Although the enzymes in the AAA pathway have long been considered targets for 
antifungal drug design (13), Chapter 4 is the first reported study to identify inhibitors of 
HCS, the first enzyme in this pathway. In this work, we developed an HTS protocol to 
identify small molecule inhibitors of HCS by modifying the fluorescent assay used for 
the biochemical characterization of HCS presented in Chapters 2 and 3. This assay was 
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used to screen the CCG’s library of 53,906 compounds that resulted in the preliminary 
identification of 341 compounds that inhibit SpHCS. These compounds may represent 
novel classes of HCS inhibitors, however further studies are needed to finalize the 
characterization of these molecules. To complete these studies, we plan to first screen 
these compounds in vivo for their ability to inhibit growth in the lys4+ transformed 
S. cerevisiae lys20  lys21  deletion strain (Chapter 2) containing an additional PDR5 
gene deletion. The PDR5 gene encodes a major pleiotropic ABC drug transporter, which 
causes the efflux of many drugs resulting in acquired drug resistance (14). This deletion 
strain will provide a convenient model strain that will negate the effects of multidrug 
transport while assaying SpHCS inhibitor compounds for in vivo potency and cell 
permeability. To identify compounds that are not specific to SpHCS in vivo, we will also 
perform a counter screen in which the cells are grown in media supplemented with 
L-lysine to identify generally cytotoxic compounds. The potency of the inhibitors 
confirmed in the in vivo screen will then be tested in vitro and in vivo by performing dose 
response curves in triplicate. We are optimistic that these additional screens will identify 
potent small molecule inhibitors to SpHCS, which can be used as lead compounds for 
antifungal therapies and to serve as molecular probes to further characterize HCS’s 
function in vivo. 
The results from this HTS assay not only demonstrate the feasibility of this 
approach but also provide a foundation for discovering inhibitors of HCS from fungal 
pathogens including C. albicans, C. neoformans and A. fumigatus. Indeed, C. albicans 
(CaHCS) Lys212 gene was obtained from the Pillus lab, cloned into a bacterial 
expression vector and purified using Co(II) IMAC and size exclusion chromatography as 
reported for SpHCS as described in Appendix B (Figure B.1). The steady state kinetic 
parameters of CaHCS Lys212 were also determined and found to be similar to the values 
for Co(II)-SpHCS (Appendix B and Table A.2). These preliminary studies on CaHCS 
Lys212 indicated that this enzyme is amenable to HTS using the CCG’s expanded 
150,000 compound library. It will be interesting to see if the inhibitors to SpHCS and 
CaHCS are similar or species specific.  
Additionally, inhibitors identified through HTS may also serve as a probe to 
further investigate the function of HCS in vitro and in vivo. Solving HCS/inhibitor 
 134 
complexes would provide insights into the mechanism of regulation by these inhibitors. 
These structural studies in conjunction with functional studies to determine the kinetic 
mechanism of regulation by these HCS inhibitors, will allow for the structure based 
design and synthesis of additional lead compounds that could be used to develop novel 
antifungal modulators. Not only will these antifungals have the potential to treat human 
fungal infections, but they could also be used to fight fungi such as the Aspergillus that 
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APPENDIX A 
DIVALENT METAL ION SPECIFICITY FOR THE ACTIVITY AND 
FEEDBACK INHIBITION OF HOMOCITRATE SYNTHASE
 
 HCS belongs to a group of enzymes that includes citrate synthase (1-3), malate 
synthase  (4, 5) and -IPMS (6, 7) that catalyze similar Claisen condensations reactions 
utilizing AcCoA as a carboxlymethyl donor to a 2-oxo acid substrate. Although these 
enzymes catalyze similar reactions, their structures and divalent metal specificities are 
different. The active site of citrate synthase does not contain a divalent metal (3), whereas 
the 2-oxo acid substrates of malate synthase and -IPMS coordinate to an active site 
metal with the proposed metal being Mg(II) in malate synthase and Zn(II) in -IPMS 
based on structural studies (5, 7). However, a recent biochemical study on the effects of 
divalent metals on -IPMS activity indicates that the enzyme has a broad specificity with 
Mg(II) and Mn(II) causing the highest activation (8). 
 Analogous to malate synthase and -IPMS, HCS possesses a divalent metal that 
is coordinated by to two histidines, a glutamate residue and a water molecule within the 
TIM barrel active site of the enzyme. Upon 2-OG binding, the C1 carboxylate and 2-oxo 
moiety of the substrate also coordinate the active site metal, whereas the -amine and 
carboxylate groups of L-lysine coordinate to the metal in feedback inhibition (Figure 3.2) 
(Chapter 2 and 3). Although this metal is essential for catalysis and L-lysine feedback 
inhibition, few studies have looked at the metal specificity of HCS. ICP-HRMS analysis 
of ScHCS determined that the enzyme is most likely Zn(II)-dependent. However, ScHCS 
treated with a metal chelator can be reactivated with the addition of Mn(II) or Zn(II) (9). 
Additionally, recent crystal structures of TtHCS have been reported with Mg(II), Cu(II) 
and Co(II) bound in the active site. Furthermore, the addition of Mg(II), and Mn(II) to 
EDTA treated TtHCS results in the highest activity of in vitro, suggesting one of these 
may be biologically relevant (10). Collectively, these results suggest a diverse divalent 
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metal specificity for HCS, yet the biologically relevant metal for this enzyme remains 
unresolved. 
 Here we characterize the activity and L-lysine feedback regulation of SpHCS 
containing a variety of divalent metals. SpHCS purified on IMAC columns charged with 
Zn(II), Co(II) and Ni(II) incorporated each metal into its active site, whereas SpHCS 
could only be partially reconstituted with Cu(II). In vitro kinetic analysis of these metal-
bound forms of the enzymes reveal that both activity and feedback inhibition are metal-
dependent, with Zn(II)-SpHCS exhibiting the highest activity and lowest Ki for L-lysine.  
Additionally, we found that Zn(II) was the dominant metal incorporated in vivo in 
SpHCS recombinantly expressed in E. coli, although at 9-18% abundance Together these 
results suggest that HCS has a broad metal specificity, but in vivo HCS may function 
predominantly as a Zn(II) dependent enzyme. 
  
MATERIALS AND METHODS 
    
Materials 
 Primers used for the exchange of the 6xHis tag for the Strep-tag II sequence were 
purchased from Integrated DNA technologies. The divalent metal ions (manganese 
chloride and copper chloride, zinc sulfate and magnesium chloride) used in the 
reconstitution of SpHCS and metal inhibition studies were purchased from Sigma. 
Reagents used in the kinetic studies were prepared as described in Chapters 2 and 3. 
 
Generation of a Strep-tag II SpHCS/pHIS2 Expression Vector 
The site-directed, ligase-independent mutagenesis (SLIM) technique (11) was 
used to remove the 6xHIS tag from SpHCS/pHIS2 and simultaneously insert a Strep-tag 
II sequence (WSHPQFEK). A set of four primers were designed consisting of: two 
forward primers that contain the 3’ end sequence after the 6xHIS tag with one primer 
containing a 5’ Strep-tag II sequence to replace the 6xHIS tag and two reverse 
compliment primers of the 5’ end before the 6xHIS tag with one primer containing the 
Strep-tag II sequence (Table A.1). PCR amplification reactions (50 μL) were mixed 






















































 (Invitrogen), 1x Pfx Amplification buffer, 1x PCRx Enhancer solution, and 
3.75 U Platinum  Pfx DNA Polymerase (Invitrogen). PCR reactions were denatured for 
2 minutes at 95 oC followed by 18 rounds of 30 seconds at 95 oC, 30 seconds at 50 oC, 
and 11 minutes at 65 oC in a thermocycler. Amplification reactions were digested in 1X 
buffer 4 (1X concentration = 20 mM Tris, pH 7.4, 5 mM MgCl2, 50 mM KCl) with 20 U 
Dpn 1 (Invitrogen) for 1 hour at 37 oC. The reaction was quenched with an equal volume 
of 2X SLIM buffer (50 mM Tris pH 8.8, 300 mM NaCl, 20 mM EDTA) and PCR 
products were denatured and hybridized by denaturing at 95 oC for 2 minutes followed by 
cooling to 25 oC at a rate of 0.2 oC/s. Hybridized PCR products were transformed into E. 
coli DH5  cells, plated on LB agar plates containing 100 μg/mL AMP and grown 
overnight at 37 oC. DNA from the resulting colonies was isolated utilizing a QIAprep 
Spin Miniprep kit (Qiagen) and dideoxynucleotide sequencing was performed 
(University of Michigan DNA Sequencing Core) to verify the sequence exchange. 
 
Expression and Purification of Strep-tag II SpHCS 
Expression of Strep-tag II SpHCS was preformed as described for SpHCS/pHIS2 
in Chapter 2, with the exception that in one case, 100 μM Zn acetate (ZnAc) was added 
to the cells during growth. Cell pellets were thawed and lysed with the addition of 5 mg 
lysozyme and rocking at room temperature for 1 hour, followed by either sonication in a 
glass beaker (Prep 1 and 2) or by three freeze cycles with homogenization (Prep 3 and 
ZnAc prep). After the addition of 30 ml of 50 mM sodium phosphate, pH 7.0, and 5 mM 
me; and the insoluble material was separated form the soluble enzyme by centrifugation 
at 15,000 rpm for 20 minutes in a Sorvall SS-34 rotor. The soluble enzyme was loaded 
onto a Strep•Tactin  superflow  Agarose column (Novagen) that had been regenerated 
with 1X regeneration buffer (100 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 
and 1 mM hydroxy-azophenyl-benzoic acid (HABA)) and pre-equilibrated with 50 mM 
sodium phosphate, pH 7.0, 250 mM NaCl, and 5 mM me. Strep-tag II SpHCS was 
eluted with a step gradient of 50 mM sodium phosphate pH 7.0, 250 mM NaCl, 2.5 mM 
desthiobiotin, and 5 mM me, and the peak fractions were pooled and the Strep tag II 
sequence was removed by TEV protease during dialysis overnight in 50 mM sodium 
phosphate pH 8.0, 150 mM NaCl and 5 mM -me. Cleaved SpHCS was further purified 
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by loading onto a Superdex 200 (Amersham Biosciences) gel filtration column and 
isocratically eluting with 25 mM Tris pH 9.0, 50 mM NaCl, and 1 mM TCEP. Peak 
fractions were judged to be essentially pure by SDS-PAGE and were concentrated to 
30-60 mg/mL. Concentrated SpHCS was flash frozen and stored at -80 oC.  
 
Incorporation of Divalent Metals into the Active Site of SpHCS 
To incorporate several different divalent cation metals, including Co(II), Ni(II), 
Zn(II), Mn(II) and Cu(II) into SpHCS we either purified SpHCS on different metal 
affinity columns or reconstituted apo-enzyme with the appropriate metal. The Talon 
(Clonetech) Co(II) resin, Ni(II) sepharose  high performance (GE Healthcare) resin and 
Zn(II) charged IMAC sepharose (GE Healthcare) resin columns were used to purify 
SpHCS to incorporate Co(II), Ni(II) and Zn(II), respectively. Because SpHCS could not 
be purified on Mn(II) or Cu(II) charged IMAC sepharose, we had to incorporate Mn(II) 
and Cu(II) into the active site of SpHCS after the first steps of purification. SpHCS was 
purified on either Talon Co(II) resin or Zn(II) IMAC resin followed TEV cleavage and 
removal of the 6xHIS tag via batch binding as previously described (Chapter 2). The 
enzyme was treated with 10 mM EDTA for 10 minutes followed by dialysis in 50 mM 
HEPES pH 8.0, 50 mM NaCl, 10 mM EDTA, 1 mM dipicilinic acid, and 0.05% (w/v) 
Chelex  100 resin (Bio-rad) for 2 hours at 4 oC to remove any traces of metal. The 
enzyme was then dialyzed two times in 4 L of re-equilibration buffer  (50 mM HEPES 
pH 8.0 and 50 mM NaCl) for 3 hours each at 4 oC to remove the metal chelating agents. 
SpHCS was then incubated with either 2 mM MnCl2 or CuCl2 for 15 minutes and 
concentrated to 2 mL using an 30k Amicon Ultra centrifugal Filter Device (Millipore). 
SpHCS reconstituted with each of the different divalent metals was further purified on a 
Superdex 200 (Amersham Biosciences) gel filtration column, concentrated to 30-60 
mg/ml, flash-frozen and stored as described in Chapter 2.  
 
Inductively Coupled Plasma-High Resolution Mass Spectroscopy  
WT SpHCS purified on Zn(II), Co(II) (Talon) and Ni(II) charged IMAC 
sepharose resin, SpHCS reconstituted with Mn(II) or Cu(II) and SpHCS purified on 
Strep•Tactin  superflow  Agarose were diluted to 20 μM in 50 mM HEPES, pH 7.5. 
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Metal content was analyzed using ICP-HRMS (University of Michigan, Department of 
Geology,) with the protein buffer used as a control as described in Chapter 2.  
 
Kinetic Studies 
 Steady state kinetic parameters were determined for WT Strep-tag II purified 
SpHCS and SpHCS incorporated with the various divalent metal ions as described using 
a fluorescent HCS assay for the Zn(II)-purified WT SpHCS (Chapter 2). Briefly, HCS 
assays were carried out in triplicate at room temperature in 100mM HEPES, pH 7.5 using 
10-30 nM enzyme and variable concentrations of 2-OG and AcCoA, up to 5 mM and 200 
μM, respectively. The equilibrium inhibition constant (Ki) values for SpHCS 
incorporated with Co(II), Ni(II) and Cu(II) versus the substrate 2-OG were calculated 
using that same fluorescent HCS assay as described in Chapter 3. Briefly, initial 
velocities were measured in triplicate at 2-OG concentrations of 0.66-2.0 mM at various 
fixed concentrations of L-lysine 0-150 μM for with AcCoA held constant at 100 μM. 
Using Prism (Graphpad Software), data was fit to the non-linear Michaelis-Menten 




Metal Content of SpHCS Incorporated with Different Divalent Metal Ions 
 During our structural studies, we discovered that SpHCS free enzyme crystallized 
with Co(II), which was presumably introduced during the Co(II) IMAC purification steps 
(Chapter 2). To the metal specificity of this enzyme, SpHCS containing a 6xHIS tag was 
recombinantly expressed in E. coli and purified using three different IMAC columns 
charged with Zn(II), Co(II) or Ni(II). The metal content of the purified protein was then 
determined by ICP-HRMS. Analysis of this data illustrates that the Zn(II)-purified 
SpHCS contained 86% Zn(II) with trace amounts of Cu(II), Mn(II) and Fe(II), the 
Co(II)-purified SpHCS was incorporated with 84% Cu(II) and 5% Zn(II) and the 
Ni(II)-purified SpHCS possessed 72% Ni(II) and 4% Zn(II) (Table A.2). Because the 
Zn(II)-purified enzyme contained trace amounts of Mn(II) and Cu(II), we sought to 
incorporate SpHCS with these metals, but were unable to accomplish this addition using  
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Table A.2 In vitro metal content of IMAC purified and reconstituted SpHCS and in vivo metal content of Strep-tag II 
purified SpHCS expressed recombinantly in E. coli.  
 
a 100 μM Zn acetate was added to cells during growth. 
b Metal content is expressed as a percentage of mol metal/mol SpHCS monomer after subtracting trace amounts of metal in the buffer. 
c Errors were not reported if they were  <0.05%. 
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conventional IMAC columns. Therefore, Mn(II) and Cu(II) were incorporated into 
SpHCS after the first steps of  IMAC purification and removal of the metal bound during 
purification. ICP-HRMS analysis of SpHCS treated with chelating agents demonstrated 
that only a small amount of remaining metal remained (totaling 4.6%) indicating that this 
protocol effectively eliminates the metal incorporated during IMAC purification (Table 
A.2). SpHCS reconstituted with Cu(II) contained 54% Cu(II) with a trace amount of 
Co(II), whereas SpHCS was unable to bind Mn(II) according to our ICP-HRMS results. 
Consistent with our structural data (Chapter 2 and 3), which illustrates one active site 
divalent metal per SpHCS monomer, incorporation of divalent metals into SpHCS during 
IMAC purification resulted in approximately the same 1:1 ratio for the Zn(II), Ni(II) and 
Cu(II) purified enzymes. However, full reconstitution of SpHCS with Cu(II) could not be 
achieved, which may indicate that the metal binding site has a low affinity that cannot be 
fully incorporated during non-column reconstitution. In summary, our results reveal that 
SpHCS has the ability to bind several different divalent metals in vitro.  
 
Kinetic Analysis of SpHCS Incorporated with Various Divalent Metals 
We next tested the effect different divalent metals have on the steady state 
kinetics parameters and equilibrium inhibition constant (Ki) for the each of the metal-
SpHCS complexes. SpHCS reconstituted with Zn(II), Co(II), Ni(II) and Cu(II) exhibited 
similar KM values for both 2-OG and AcCoA which ranged from 120-209 mM and  
5.0-10.7 μM, respectively (Figure A.1A, A.1B and Table A.3). However, the turnover 
rate of SpHCS appears to be dependent on the metal content with the observed trend in 
kcat values as follows: Zn(II) > Cu(II) >Co(II) > Ni(II). Although the kcat value for Co(II) 
was modestly higher than the kcat value for Cu(II), we predict that a larger incorporation 
of Cu(II) into the reconstituted enzyme would result in an increased turnover rate. 
Additionally, the incorporation of Ni(II) into SpHCS was modestly lower than that of 
Zn(II) and Cu(II) indicating that it may also have a higher expected kcat value. 
Alternatively, Ni(II)-SpHCS may actually be inactive as this enzyme retained 4.3% 
Zn(II) and exhibited similar activity to metal free SpHCS, which contains 4.6% metal 



















Figure A.1 In vitro activity of the metal-SpHCS complexes. (A and B) Michaelis-
Menten plot of the initial velocity versus 2-OG concentration (A) and AcCoA 
concentration (B) for the formation of homocitrate catalyzed by metal-SpHCS 
complexes. Data points are the average of triplicate measurements, and the error bars 

































Table A.3 Kinetic analysis of Strep-II tag purified and metal substituted HCS. 
 
 KM  2-OG 
 




  L-lysine vs. 
2-OG 
 mM μM min-1 μM 
Zn(II)b 159 ± 15 10.7 ± 0.6 303 ± 4 3.6 ± 0.7 
Co(II) 155 ± 18 9.2 ± 1.0 107 ± 2 62.7 ± 7.1 
Ni(II) 120 ± 2.4 5.0  ± 0.5 30.2 ± 0.8 14.3 ± 1.5 
Cu(II) 209 ± 31 6.0 ± 0.5 98.0 ± 2.2 6.0 ± 0.5 
Metal Free N.D N.D 33.1 ± 1.8c N.D 
Strep 1 486 ± 112 7.0 ± 0.7 180 ± 6 N.D 
Strep 2 173 ± 17 11.0 ± 1.0 95.0  ± 2 N.D 
Strep 3 366 ± 53 7.8 ± 0.67 111 ± 3 N.D 
Strep ZnAc 385 ± 52 8.8 ± 1.0 115 ± 3 N.D 
a Average of the individual kcat values determined for each substrate. 
b Steady state kinetic parameters and inhibition constant are previously reported (Chapters 2 and 3). 
c Estimated form initial velocity  using 100 nM SpHCs and saturating substrate concentrations. 
















To examine whether the different metals affect L-lysine feedback inhibition, we 
determined Ki values for the Zn(II), Co(II), Ni(II) and Cu(II) incorporated forms of 
SpHCS by measuring the initial velocity of the reactions for L-lysine inhibition versus 
2-OG. As expected, the double reciprocal plots of velocity versus substrate concentration 
illustrate that L-lysine is a competitive inhibitor versus 2-OG for each metal complex 
(Chapter 3) (Figure A.2). L-lysine completely inhibited each Me(II)-SpHCS complex 
with measured Ki values corresponded to the following trend: Zn(II)- and Cu(II)-SpHCS 
bound with the highest affinities (3.6 ± 0.7 μM and 6.0 ± 0.5 μM, respectively), followed 
by Ni(II)-SpHCS (14.3 ± 1.5) and Co(II)-SpHCS (62.7 ± 7.1) (Table A.3). The Ki value 
for Co(II)-SpHCS is >17-fold higher that that of Zn(II)-SpHCS, indicating a difference in 
the active site environment or unfavorable coordination of L-lysine to Co(II).  
  
Identification and Functional Analysis of the in vivo Metal Content of SpHCS  
 Our in vitro results suggest that SpHCS may bind and utilize different divalent 
metal ions in vivo during catalysis. To investigate this possibility, we determined the 
metal content of SpHCS expressed recombinantly in E. coli, using a Strep-tag II/SpHCS 
vector that was engineered to avoid incorporation of metals during purification of a 6xHis 
tagged SpHCS construct during the IMAC purification steps. ICP-HRMS analysis of four 
different Strep-tag II SpHCS purifications revealed that in vivo metal content varied 
between purifications and consisted of a heterogeneous mixture of transition state metals, 
including Zn(II), Cu(II), Ni(II) and trace amounts of Co(II), Mn(II) and Fe(II) (Table 
A.2). In all four purifications, Zn(II) was the most abundant metal followed by Cu(II). 
Additionally, the inclusion of Zn(II) acetate during cell growth did not increase the Zn(II) 
content in the purified SpHCS. This result is not surprising considering that the balance 
between Zn(II) uptake and efflux has a small tolerance range in E. coli (12), suggesting 
that no pool of free zinc exists in the cytosol under normal growth conditions. In contrast 
to the relatively high percentage of metal incorporation into SpHCS in vitro, the 
percentage of metal bound to the Strep-tag II SpHCS monomer ranged form 9-18% 
(Table A.2). Lower incorporation levels may be caused by the high level of expression of 
the recombinant SpHCS in E. coli, in conjunction with a high metal binding constant and 
















Figure A.2 L-lysine inhibition of SpHCS metal complexes. Double reciprocal plots of 
initial velocity versus 2-OG concentration at different concentrations of L-lysine and a 
fixed saturating concentration of AcCoA for Zn(II)-SpHCS (A), Cu(II)-SpHCS (B), 
Ni(II)-SpHCS (C) and Co(II)-SpHCS (D). Data points are the average of triplicate 





























Figure A.3 In vitro activity of Strep-tag II purified SpHCS. (A and B) Michaelis-
Menten plot of the initial velocity versus 2-OG concentration (A) and AcCoA 
concentration (B) for the formation of homocitrate catalyzed by Strep-II tag purified 
enzyme. Data points are the average of triplicate measurements, and the error bars 


















After determining the in vivo metal content of SpHCS expressed in E. coli, we 
next investigated the activity of the enzyme by measuring the steady state parameters of 
each Strep-II tag purification (Figure A.2A and A.2B). The KM values for 2-OG and 
AcCoA form these purifications ranged from 173-528 mM and 6.9-11.0 μM, 
respectively, and are similar to the SpHCS reconstituted with different divalent metals 
(Table A.3). In addition, the kcat values for the four Strep-II tag SpHCS purifications 
ranged from 95-184 min-1 with the rates being proportional to the total metal content of 
the enzyme (Table 4.1 and Table 4.3). Interestingly, the Strep-II tag SpHCS exhibited a 
disproportionately high turnover rate (kcat =184 min
-1 for 18.2% metal incorporation) 
compared to the almost fully incorporated Zn(II)-IMAC purified enzyme (kcat =303 min
-1 
for 86% metal incorporation) (Table A.1and A.3). This discrepancy might be explained 
by the different purification protocols where exposure of SpHCS to the IMAC column 
may alter the enzyme’s activity. Further studies are needed to determine if this is the 
case. In summary, SpHCS expressed recombinantly in E. coli contains a variety of 
metals, the majority of which is Zn(II), with the turnover rate of the enzyme being 




Divalent Metal Specificity on the Activity and Regulation of SpHCS 
Although HCS has been shown to be a metalloenzyme through biochemical and 
crystallographic studies (9, 10), little is known about the metal ion requirement for HCS 
activity. Additionally, no detailed studies have looked at the in vivo metal content or the 
dependence of HCS regulation in relation to bound divalent metal. In this work, our 
biochemical studies indicate that SpHCS can bind and utilize a variety of divalent metal 
ions, with Zn(II)-SpHCS displaying the highest turnover rate followed by Cu(II), Co(II) 
and Ni(II) (Table A.3), indicating that Zn(II) may be the biologically relevant metal 
cofactor. This result is in agreement with the assignment of Zn(II) in ScHCS (9), but 
contrast with the results found for the TtHCS enzyme (10). Okada et al found that the 
addition of Mg(II) and Mn(II) to TtHCS caused the greatest activation of this enzyme 
with reported specific activities of 41.5 and 39.5 mU/mg protein. However, when 
 150 
converted to kcat values, these specific activities correspond to only ~4 % of the kcat of 
TtHCS purified on a Ni(II)-IMAC column, suggesting the metals tested may not have 
been fully incorporated during the assays. We also observed this phenomenon when 
assaying metal free SpHCS in the addition of divalent metals (data not shown), but were 
able to circumvent this problem by nearly fully incorporating each divalent metal during 
IMAC purification. Our findings also show that Zn(II)-SpHCS exhibited the highest 
affinity towards the feedback inhibitor L-lysine closely followed by Cu(II) and Ni(II). 
The Ki value for Co(II)-SpHCS was moderately higher that those for the other metals. 
However, the variation in the Ki values among the different metal-bound enzymes is 
relatively modest when compared to the substantial increase in Ki values and insensitivity 
to AEC seen for SpHCS L-lysine interacting mutants, particularly for the D123N mutant 
(Chapter 3). This suggests that in vivo, the active site divalent metal identity may only 
have a small effect on the regulation of the metabolic flux through the AAA pathway. 
 
In vivo metal content of SpHCS expressed in E. coli 
 An analysis of the metal content and catalytic activity of Strep-tag II purified 
SpHCS which was recombinantly overexpressed in E. coli provides insights into the 
metal dependence of SpHCS in vivo. Consistent with our in vitro results, Zn(II) was the 
dominant metal bound to SpHCS, suggesting that this may be the biologically relevant 
metal that this ion. However, because the overall incorporation of metal was quite low it 
may also be possible that this enzyme binds and utilizes another metal ion such as Fe(II). 
Many Fe(II) dependent enzymes, including peptide deformylase (13), -carbonic 
anhydrase (14), S-Ribosylhomocysteinase LuxS (15) and the histone deacetylase HDAC8 
(16) were originally characterized as Zn(II) metalloenzymes because of the oxidation of 
Fe(II) to Fe(III) and metal exchange during  aerobic purification. Future studies are 
needed to determine if HCS can also bind and utilize Fe(II). 
  
Comparison of the Divalent Metal Specificity of HCS to -IPMS and Malate 
Synthase 
 Although the active sites of HCS and -IPMS are structurally similar and have 
nearly identical metal binding configurations (Chapter 2 see Figure 2.4), the divalent 
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metal specificities of these two enzymes appear to be different. These differences are in 
part due to the identity of the active site ligands that coordinate the metal ion.  Based on 
size and charges, metal are classified as “hard”, “soft” or “borderline” (17) (Table A.4). 
Additionally, metals considered “hard” or “soft” tend to strongly prefer “hard” or “soft” 
ligands respectively, with borderline metals coordinating to both classes of ligands (18, 
19) (Table A.4). For example, the catalytic core of malate synthase contains all “hard” 
ligands including the carboxylate oxygen of an aspartate and a glutamate, two water 
molecules and the C1 and 2-oxo group of its substrate glyoxylate that forms an octahedral 
coordination to a “hard” Mg(II) ion (Figure 1.3B) (5). Similar to malate synthase, 
biochemical studies on metal free -IPMS free indicate that addition a “hard” metal, 
either Mg(II) and Mn(II) ion the produce the highest activation of the enzyme in vitro (8). 
This result is somewhat surprising considering that two of the coordinating ligands in 
-IPMS are “soft” nitrogen atoms in the imidazole rings of a histidine residues (Figure 
2.4B) that do not tend to coordinate the “hard” Mg(II) and Mn(II) ions. Although, in 
certain cases Mn(II) has been reported to bind the nitrogen atoms of histidine imidazole 
groups (20), and thus this may be the biologically relevant metal in -IPMS. In contrast 
with these findings, we were unable to reconstitute SpHCS, with the “hard” metal Mn(II), 
but found that the enzyme readily incorporated with the “borderline” metals, Co(II), 
Cu(II), Ni(II) and Zn(II). These metals tend to coordinate to both hard and soft ligands. In 
addition, assignment of a “borderline” metal to the active site of HCS is consistent with 
the finding that the substrate 2-OG and inhibitor L-lysine both coordinate to the metal, 
despite the differences in their coordination groups (Figure 3.2). In summary, although 
HCS, -IPMS and malate synthase catalyze analogous Claisen condensation reactions, 
the divergence in their structures and metal dependence provide insights into the 
evolution of catalysis and regulation of these enzymes.  
 
Importance of the Metal in Identifying Antifungal Inhibitors to HCS 
 HCS has been proposed as an antifungal target because it is absent in humans and 
is an important part of the AAA pathway as the committed step in the pathway and is   
highly regulated through L-lysine feedback inhibition. Our characterization of the 



















Table A.4 Classification of hard and soft metals and ligands. 
METALS
a 
Hard Borderline Soft 
Ca(II) Co(II) Cd(II) 
Mg(II) Cu(II) Pt(II) 
Mn(II) Fe(II)  
 Ni(II)  




Aspartate carboxylate oxygen Histidine imidazole nitrogen 
Glutamate carboxylate oxygen Cysteine sulfur 
Asparagine carboxamide oxygen  
Glutamine carboxamide oxygen  
Solvent  
aFrom reference 17. 













of metals, and that the identity of the metal can contribute to the affinity of inhibitor 
binding, with L-lysine binding more weakly to Co(II)-SpHCS. Knowledge of the divalent 
metal that is bound to HCS in vivo may allow for a more accurate prediction of the 
potency of small molecule inhibitors which inactivate SpHCS through interaction with 




Although informative, the metal specificity studies in Chapter 4 only begin to 
elucidate the metal requirements of HCS. Our studies indicate that Zn(II) might be the 
biological divalent metal, however it is also possible that HCS is a Fe(II) dependent 
enzyme. ICP-HRMS analysis of Strep-tag II SpHCS purified anaerobically is needed to 
determine if Fe(II) is also bound to SpHCS in vivo. Additionally, it proved difficult to 
reconstitute metal free SpHCS with divalent metals before assaying for activity, 
indicating that SpHCS may have a low affinity for metal binding. To examine this 
possibility, metal binding studies are needed to determine the affinity of SpHCS for 
different divalent metal ions. Furthermore, while designing a secondary HTS to eliminate 
small metal chelators (Chapter 4), we found that excess Mn(II) inhibits SpHCS activity. 
Based on the crystal structure of the free enzyme, where a Mg(II) ion is coordinated to a 
glutamate residue and five water molecules (Figure 3.1C), we can speculate that the 
mechanism of metal inhibition may occur through this binding position. However future 
studies are still needed to determine if other divalent metals inhibit SpHCS, and if this is 
the mechanism of inhibition. Finally, experiments are still needed to establish the metal 
content of HCS from yeast under normal and stressed growing conditions. Not only will 
these experiment allow for the determination of the true biological metal, but they may 
also provide insights into whether HCS undergoes metal switching in vivo, similar to the 
proposed mechanism of HDAC8 and LpxC (16, 21). If metal switching does occur in 
HCS, this mechanism may further regulate the enzymes function and thus the metabolic 
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PURIFICATION OF CANDIDA ALBICANS HCS LYS212 
 
 Candida albicans HCS (CaHCS) was cloned, overexpressed and purified on a 
Co(II) Talon IMAC column as described for SpHCS (Chapter 2) (Figure B.1). We also 
determined the steady state kinetic parameters of CaHCS Lys212 (Km(2-OG) = 99 ± 19 μM, 
Km(AcCoA) = 3.6 ± 0.5 μM and kcat =124 ± 2.8) and found them to be similar to 







Figure 6.2 Gel filtration purification of CaHCS Lys212. A chromatogram depicting 
the elution profile of the enzyme on a Superdex 200 gel filtration column with molecular 
weight standards shown above the chromatogram. The inset panel illustrates the 
Coomassie staining of an SDS-PAGE gel of the peak fractions from this purification. 
 
 
 
 
 
 
 
